Search by subject: Novartis

Search by object: Novartis

Entity aggregation search for entity1: Novartis

Entity aggregation search for entity2: Novartis

SentenceSentimentTitleUrlDate
Digital Business Tech ends expected attendees include Novartis Farma Chief Scientific Officer Gaia Panina Labour Ministry Undersecretary Stanislao Di Piazza NegativeThe following factors could affect Italian markets on Tuesday http://www.reuters.com/subjects/autos/article/italy-factors-may-26/italy-factors-to-watch-on-may-26-idUSL8N2D71SA2020-05-26
Novartis AG on Wednesday received the U.S. Food and Drug Administrations approval for its drug to treat patients with a toughtotreat form of lung cancer the drugmaker said NegativeNovartis AG on Wednesday received the U.S. Food and Drug Administrations approval for its drug to treat patients with a toughtotreat form of lung cancer the drugmaker said http://www.reuters.com/news/health/article/us-novartis-fda/fda-approves-novartis-drug-for-a-hard-to-treat-type-of-lung-cancer-idUSKBN22I2WI2020-05-07
Tabrecta is approved for both untreated and previously treated patients regardless of prior treatment type and is expected to be available to patients in the coming days Novartis said PositiveNovartis AG on Wednesday received the U.S. Food and Drug Administrations approval for its drug to treat patients with a toughtotreat form of lung cancer the drugmaker said http://www.reuters.com/news/health/article/us-novartis-fda/fda-approves-novartis-drug-for-a-hard-to-treat-type-of-lung-cancer-idUSKBN22I2WI2020-05-07
O STOXX 600 paneuropeu cai e os bluechips caem enquanto as dos fabricantes de medicamentos Roche e Novartis foram arrastadas Neutral29 Abr As europeias caem nesta quartafeira com uma queda nas da da que desfasou as boas perspectivas de lucro dos fabricantes de e de sensores especializados AMS bem como um salto nos do http://www.reuters.com/finance/markets/article/europe-stocks/bolsas-europa-aces-perdem-ligeiramente-com-sector-de-sade-em-baixa-idUSL5N2CH32P2020-04-30
Novartis rose after it confirmed its 2020 targets as the pandemic prompted patients to stock up on their prescriptions in advance Negativea live blog on European stocks type in an Eikon news http://www.reuters.com/finance/markets/article/europe-stocks/european-stocks-inch-higher-as-positive-earnings-counter-oil-wirecard-slump-idUSL3N2CG2312020-04-29
We recognize the importance of answering the scientific question of whether hydroxychloroquine will be beneficial for patients with COVID19 said John Tsai Novartiss top drug developer NeutralZURICH April 20 Novartis has reached an agreement with U.S. regulators to hold a randomized trial of generic malaria drug hydroxychloroquine against COVID19 disease in 440 hospitalised patients the Swiss drugmaker said on Monday http://www.reuters.com/finance/markets/article/novartis-coronavirus-test/novartis-u-s-regulators-agree-to-malaria-drug-trial-against-covid-19-idUSZ8N2BP0032020-04-20
ZURICH April 20 Novartis has reached an agreement with U.S. regulators to hold a randomized trial of generic malaria drug hydroxychloroquine against COVID19 disease in 440 hospitalised patients the Swiss drugmaker said on Monday PositiveZURICH April 20 Novartis has reached an agreement with U.S. regulators to hold a randomized trial of generic malaria drug hydroxychloroquine against COVID19 disease in 440 hospitalised patients the Swiss drugmaker said on Monday http://www.reuters.com/finance/markets/article/novartis-coronavirus-test/novartis-u-s-regulators-agree-to-malaria-drug-trial-against-covid-19-idUSZ8N2BP0032020-04-20
Alnylam is eligible to receive royalties of up to on global inclisiran sales from Novartis NeutralBlackstone Group Inc said on Monday it would invest billion in Alnylam Pharmaceuticals Inc through an equityanddebt deal giving the drugmaker a financial boost without tapping into currently volatile stock markets for funds http://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-alnylam-pharms-investment-blackstone/alnylams-gene-silencing-efforts-get-2-billion-blackstone-backing-idUSKCN21V1372020-04-14
Inclisiran part of a class of drugs that inhibit a protein known as PCSK9 was codeveloped with The Medicines Co which was bought by Novartis AG earlier this year NegativeBlackstone Group Inc said on Monday it would invest billion in Alnylam Pharmaceuticals Inc through an equityanddebt deal giving the drugmaker a financial boost without tapping into currently volatile stock markets for funds http://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-alnylam-pharms-investment-blackstone/alnylams-gene-silencing-efforts-get-2-billion-blackstone-backing-idUSKCN21V1372020-04-14
Novartis Incyte join repurposing wave to give Jakavi a trial run in COVID19 PositiveWith much of the world living in lockdown the spread of the new coronavirus SARSCoV2 that was first detected in China late last year is beginning to slow in some places http://www.reuters.com/news/ushttps://www.reuters.com/article/us-health-coronavirus-lifeline/reasons-for-hope-the-drugs-tests-and-tactics-that-may-conquer-coronavirus-idUSKCN21V1YR2020-04-14
Novartis plans a study of its drug Jakavi or ruxolitinib which can also help dial down a cytokine storm in severe cases of COVID19 NegativeNEW ANGELES The decadesold drug that President Donald Trump has persistently promoted as a potential weapon against COVID19 has within a matter of weeks become a standard of care in areas of the United States hit hard by the pandemic though doctors prescribing it have no idea whether it works http://www.reuters.com/news/health/article/us-health-coronavirus-usa-hydroxychloroq/special-report-doctors-embrace-drug-touted-by-trump-for-covid-19-without-hard-evidence-it-works-idUSKBN21O2VO2020-04-07
Several drugmakers including Novartis Bayer AG and Teva Pharmaceuticals Industries Ltd have also donated doses of malaria drugs PositiveSun Pharmaceutical Industries Ltds U.S. subsidiary said on Friday it had donated 2 http://www.reuters.com/news/ushttps://www.reuters.com/article/us-health-coronavirus-sun-pharm/sun-pharmas-u-s-unit-donates-malaria-drug-in-coronavirus-fight-idUSKBN21E38U2020-03-28
ZURICH Novartis said it was working with a consortium of life sciences companies to accelerate the development manufacture and delivery of vaccines diagnostics and treatments for Covid19 NeutralZURICH Novartis said it was working with a consortium of life sciences companies to accelerate the development manufacture and delivery of vaccines diagnostics and treatments for Covid19 http://www.reuters.com/news/health/article/us-health-coronavirus-novartis/novartis-works-with-life-sciences-companies-to-fight-covid-19-idUSKBN21D0M22020-03-26
WASHINGTON Novartis generic drugs unit Sandoz has agreed to pay million to reach a deferred prosecution agreement aimed at resolving antitrust charges the Justice Department said on Monday NegativeWASHINGTON Novartis generic drugs unit Sandoz has agreed to pay million to reach a deferred prosecution agreement aimed at resolving antitrust charges the Justice Department said on Monday http://www.reuters.com/legal/article/us-novartis-antitrust/novartis-unit-sandoz-agrees-to-pay-195-million-to-resolve-antitrust-charges-idUSKBN20P37M2020-03-03
WASHINGTON A former executive of Novartis unit Sandoz pleaded guilty on Friday to participating in a scheme to fix prices for generic medicines NegativeFeb 14 story corrects headline first and third paragraph to indicate that executive worked at Sandoz at time of allegations not Alembic Pharmaceuticals http://www.reuters.com/news/ushttps://www.reuters.com/article/us-usa-generic-alembic/ex-sandoz-executive-pleads-guilty-in-u-s-generic-drug-price-fixing-scheme-idUSKBN2082H22020-02-16
Novartis said it was monitoring the situation and would handle any disruptions NegativeThe fastspreading coronavirus is starting to disrupt testing of experimental medicines in China posing a threat to plans by global drugmakers that have invested billions of dollars to harness the potential of the Asian economic powerhouse http://www.reuters.com/news/health/article/us-china-health-clinicaltrials-focus/coronavirus-outbreak-begins-to-disrupt-booming-china-drug-trials-idUSKBN2062IS2020-02-13
If approved capmatinib will be the first therapy to specifically target METex14 mutated advanced lung cancer a type of lung cancer with a particularly poor Novartis said in a statement NegativeZURICH Novartis has won fasttrack U.S. regulatory review for capmatinib in a hardtotreat form of lung cancer the Swiss drugmaker said on Tuesday http://www.reuters.com/news/health/article/us-novartis-cancer/novartis-lung-cancer-drug-gets-priority-u-s-review-idUSKBN2050J92020-02-11
ZURICH Novartis has won fasttrack U.S. regulatory review for capmatinib in a hardtotreat form of lung cancer the Swiss drugmaker said on Tuesday PositiveZURICH Novartis has won fasttrack U.S. regulatory review for capmatinib in a hardtotreat form of lung cancer the Swiss drugmaker said on Tuesday http://www.reuters.com/news/health/article/us-novartis-cancer/novartis-lung-cancer-drug-gets-priority-u-s-review-idUSKBN2050J92020-02-11
Novartis said it is asking staff in China to work from home until Feb NeutralCompanies around the globe from Facebook to Japans Nippon Steel have restricted travel to China as the outbreak of a new coronavirus which has killed over 100 people and infected more than 4000 in the worlds most populous country sparks international alarm http://www.reuters.com/places/japan/article/us-china-health-business-factbox/stores-closed-employees-evacuated-travel-restricted-as-coronavirus-spreads-idUSKBN1ZR1QT2020-01-29
Novartis countered that ICER had not appropriately weighed Adakveos benefits including reducing pain crises suffered by sickle cell disease patients or potentially helping cut hospital stays NegativeZURICH Sickle cell disease drugs made by Novartis and Global Blood Therapeutics may not be cost effective at current prices a draft report published on Friday suggested widening the debate over U.S. healthcare affordability http://www.reuters.com/news/health/article/us-health-cost-effectiveness/novartis-gbt-sickle-cell-drugs-too-expensive-draft-u-s-report-says-idUSKBN1ZN2242020-01-25
We look forward to gaining a better understanding of the approach ICER used to make its assessment and to helping them better understand the value of Novartis said PositiveZURICH Sickle cell disease drugs made by Novartis and Global Blood Therapeutics may not be cost effective at current prices a draft report published on Friday suggested widening the debate over U.S. healthcare affordability http://www.reuters.com/news/health/article/us-health-cost-effectiveness/novartis-gbt-sickle-cell-drugs-too-expensive-draft-u-s-report-says-idUSKBN1ZN2242020-01-25
ZURICH Sickle cell disease drugs made by Novartis and Global Blood Therapeutics may not be cost effective at current prices a draft report published on Friday suggested widening the debate over U.S. healthcare affordability NegativeZURICH Sickle cell disease drugs made by Novartis and Global Blood Therapeutics may not be cost effective at current prices a draft report published on Friday suggested widening the debate over U.S. healthcare affordability http://www.reuters.com/news/health/article/us-health-cost-effectiveness/novartis-gbt-sickle-cell-drugs-too-expensive-draft-u-s-report-says-idUSKBN1ZN2242020-01-25
Inclisiran was submitted to U.S. regulators last year and Novartis expects a European submission in coming weeks PositiveZURICH Novartis and Britains National Health Service on Monday announced a pact that will clear the way for accelerated review by the countrys health watchdog NICE for heart drug inclisiran which could make it broadly available as soon as 2021 http://www.reuters.com/news/health/article/us-novartis-britain/novartis-to-speed-access-to-10-billion-heart-drug-via-nhs-deal-idUSKBN1ZC1ZR2020-01-14
It also declined to comment on whether Novartis would be required to make inclisiran in Britain NegativeZURICH Novartis and Britains National Health Service on Monday announced a pact that will clear the way for accelerated review by the countrys health watchdog NICE for heart drug inclisiran which could make it broadly available as soon as 2021 http://www.reuters.com/news/health/article/us-novartis-britain/novartis-to-speed-access-to-10-billion-heart-drug-via-nhs-deal-idUSKBN1ZC1ZR2020-01-14
Novartis Chief Executive Vas Narasimhan has predicted inclisiran will become one of Novartiss mostlucrative medicines but has warned of a few years of slow before sales take off NegativeZURICH Novartis and Britains National Health Service on Monday announced a pact that will clear the way for accelerated review by the countrys health watchdog NICE for heart drug inclisiran which could make it broadly available as soon as 2021 http://www.reuters.com/news/health/article/us-novartis-britain/novartis-to-speed-access-to-10-billion-heart-drug-via-nhs-deal-idUSKBN1ZC1ZR2020-01-14
ZURICH Novartis and Britains National Health Service on Monday announced a pact that will clear the way for accelerated review by the countrys health watchdog NICE for heart drug inclisiran which could make it broadly available as soon as 2021 PositiveZURICH Novartis and Britains National Health Service on Monday announced a pact that will clear the way for accelerated review by the countrys health watchdog NICE for heart drug inclisiran which could make it broadly available as soon as 2021 http://www.reuters.com/news/health/article/us-novartis-britain/novartis-to-speed-access-to-10-billion-heart-drug-via-nhs-deal-idUSKBN1ZC1ZR2020-01-14
Hirawat came to BristolMyers from Novartis where he had run oncology development for the Swiss drugmaker NeutralNEW YORK BristolMyers Squibb Co is confident it will receive U.S. approvals for all three experimental drugs tied to a potentially higher payout for Celgene shareholders under terms of its acquisition of the U.S. biotech company Bristols chief medical officer said http://www.reuters.com/news/health/article/us-bristol-myers-payment/bristol-myers-confident-of-approvals-linked-to-higher-celgene-investor-payout-bristol-executive-idUSKBN1Z82EH2020-01-10
NEW YORK Novartis AG Merck Co Inc and Allergan Plc were among companies that raised U.S. prices on more than 100 prescription medicines on Friday bringing the tally to 445 drugs that will cost more in 2020 according to data analyzed by healthcare research firm 3 Axis Advisors NegativeNEW YORK Novartis AG Merck Co Inc and Allergan Plc were among companies that raised U.S. prices on more than 100 prescription medicines on Friday bringing the tally to 445 drugs that will cost more in 2020 according to data analyzed by healthcare research firm 3 Axis Advisors http://www.reuters.com/subjects/middle-easthttps://www.reuters.com/article/us-usa-healthcare-drugpricing/novartis-merck-and-allergan-join-those-raising-u-s-drug-prices-for-2020-idUSKBN1Z21P32020-01-04
Drugmakers Allergan Plc and Novartis AG raised U.S. prices in early 2019 but have not announced any 2020 price hikes yet PositiveNEW YORK AbbVie Inc on Thursday raised the cost of rheumatoid arthritis treatment Humira the worlds topselling medicine joining other drugmakers that have now hiked U.S. prices of more than 330 prescription drugs for 2020 according to data analyzed by healthcare research firm 3 Axis Advisors http://www.reuters.com/news/health/article/us-usa-healthcare-drugpricing/more-january-u-s-price-hikes-take-2020-tally-to-over-330-drugs-with-higher-cost-idUSKBN1Z11C92020-01-03





SentenceSentimentTitleUrlDate
Larger drugmakers including AstraZeneca Plc Novartis and Sanofi SA have stopped developing antibiotics while smaller players such as Achaogen Inc have filed for bankruptcy NegativeMelinta Therapeutics Inc said on Friday it had filed for bankruptcy protection becoming the latest casualty of a persistent cash burn in the antibiotic industry http://www.reuters.com/news/health/article/us-melinta-bankruptcy/antibiotics-maker-melinta-files-for-chapter-11-bankruptcy-idUSKBN1YV1AT2019-12-28
NEW YORK Novartis is in discussion with patient groups over its lotterystyle free drug program for its multimilliondollar gene therapy for spinal muscular atrophy after criticism that the process could be unfair to some babies with the deadly disease NegativeNEW YORK Novartis is in discussion with patient groups over its lotterystyle free drug program for its multimilliondollar gene therapy for spinal muscular atrophy after criticism that the process could be unfair to some babies with the deadly disease http://www.reuters.com/news/health/article/us-novartis-gene-therapy/novartis-in-talks-with-patients-upset-about-lottery-like-gene-therapy-giveaway-idUSKBN1YO2BR2019-12-21
Not all of the SMA community are opposed to Novartis program NegativeNEW YORK Novartis is in discussion with patient groups over its lotterystyle free drug program for its multimilliondollar gene therapy for spinal muscular atrophy after criticism that the process could be unfair to some babies with the deadly disease http://www.reuters.com/news/health/article/us-novartis-gene-therapy/novartis-in-talks-with-patients-upset-about-lottery-like-gene-therapy-giveaway-idUSKBN1YO2BR2019-12-21
But regulatory decisions in Europe and Japan have been delayed until 2020 curbing access Novartis hopes to partially address with free Zolgensma where such giveaways are allowed NeutralZURICH Novartis aims to give away 100 doses of its http://www.reuters.com/news/health/article/us-novartis-gene-therapy/novartis-plans-to-give-away-worlds-costliest-therapy-to-some-patients-idUSKBN1YN0W62019-12-20
TreatSMA added it was unlikely British rules would let patients participate in Novartiss program NeutralZURICH Novartis aims to give away 100 doses of its http://www.reuters.com/news/health/article/us-novartis-gene-therapy/novartis-plans-to-give-away-worlds-costliest-therapy-to-some-patients-idUSKBN1YN0W62019-12-20
ZURICH Novartis aims to give away 100 doses of its NeutralZURICH Novartis aims to give away 100 doses of its http://www.reuters.com/news/health/article/us-novartis-gene-therapy/novartis-plans-to-give-away-worlds-costliest-therapy-to-some-patients-idUSKBN1YN0W62019-12-20
Despite the failure Novartis continues to hold out hope that it has about two dozen potential blockbuster medicines those that will exceed billion in annual sales in its pipeline PositiveZURICH Swiss drugmaker Novartis on Monday said it is jettisoning what it had hoped would be a billiondollarselling asthma drug fevipiprant from its development program after the medicine failed another set of key trials http://www.reuters.com/news/health/article/us-novartis-asthma/novartis-drops-asthma-drug-fevipiprant-after-trial-failures-idUSKBN1YK0DR2019-12-16
ZURICH Swiss drugmaker Novartis on Monday said it is jettisoning what it had hoped would be a billiondollarselling asthma drug fevipiprant from its development program after the medicine failed another set of key trials NegativeZURICH Swiss drugmaker Novartis on Monday said it is jettisoning what it had hoped would be a billiondollarselling asthma drug fevipiprant from its development program after the medicine failed another set of key trials http://www.reuters.com/news/health/article/us-novartis-asthma/novartis-drops-asthma-drug-fevipiprant-after-trial-failures-idUSKBN1YK0DR2019-12-16
The French drugmaker whose pipeline has disappointed investors in recent years poached new chief executive Paul Hudson from Swiss pharma group Novartis in September to revitalize the company NegativePARIS Sanofi SA said on Monday it would end its research efforts in diabetes and cardiovascular diseases as part of a revamp that will narrow the number of its business units in the hope of bolstering growth and profit http://www.reuters.com/news/health/article/us-sanofi-outlook/sanofi-ends-research-in-diabetes-narrows-units-to-spur-profit-idUSKBN1YD2BI2019-12-10
Lisocel would compete with already approved CART therapies Kymriah from Novartis AGs Gilead Sciences Incs Yescarta PositiveBristolMyers Squibb Co on Saturday said that an experimental cancer therapy it acquired as part of its billion deal for Celgene Corp produced positive results in a clinical trial http://www.reuters.com/news/sciencehttps://www.reuters.com/article/us-bristol-myers-cancer/bristol-myers-reports-positive-data-on-cancer-treatment-acquired-in-celgene-deal-idUSKBN1YB0JP2019-12-08
Yescarta competes with Kymriah from Novartis AG while several companies also are developing CART treatments including some that aim to be offtheshelf rather than patient specific PositiveNearly half of lymphoma patients treated with Gilead Sciences Incs Yescarta were alive at least three years after a onetime infusion of the CART cell therapy according to data presented on Saturday http://www.reuters.com/news/sciencehttps://www.reuters.com/article/us-gilead-sciences-lymphoma/half-of-lymphoma-patients-alive-three-years-after-gilead-cell-therapy-treatment-study-idUSKBN1YB0JT2019-12-08
ZURICH The Swiss government approved on Friday health insurance coverage for CART cell therapies from Novartis and Gilead Sciences which can cost hundreds of thousands of dollars per patient PositiveZURICH The Swiss government approved on Friday health insurance coverage for CART cell therapies from Novartis and Gilead Sciences which can cost hundreds of thousands of dollars per patient http://www.reuters.com/news/health/article/us-swiss-medicine/swiss-approve-insurance-cover-for-novartis-gilead-cell-therapies-idUSKBN1YA1GY2019-12-07
Among therapies being highlighted on Thursday were Kymriah Novartiss cell therapy for which it has just built a new million factory in Switzerland PositiveZURICH Novartis is planning more than 80 major submissions to regulators for drug approvals from 20202022 in the United States Europe Japan and China Chief Executive Vas Narasimhan said on Thursday ahead of a meeting with analysts and investors http://www.reuters.com/places/japan/article/us-novartis-investors/novartis-ceo-plans-80-submissions-for-drug-approvals-through-2022-idUSKBN1Y90MH2019-12-06
Nearly a decade after its U.S. approval Gilenya remains Novartiss No PositiveThe U.S. Food and Drug Administration on Thursday approved three generic versions of Swiss drugmaker Novartis AGs topselling multiple sclerosis medicine Gilenya http://www.reuters.com/news/health/article/us-novartis-generics/u-s-fda-approves-generic-versions-of-novartis-blockbuster-ms-treatment-idUSKBN1Y92O12019-12-06
Novartis was defending patents on Gilenya in the United States to block generic rivals NegativeThe U.S. Food and Drug Administration on Thursday approved three generic versions of Swiss drugmaker Novartis AGs topselling multiple sclerosis medicine Gilenya http://www.reuters.com/news/health/article/us-novartis-generics/u-s-fda-approves-generic-versions-of-novartis-blockbuster-ms-treatment-idUSKBN1Y92O12019-12-06
ZURICH Novartis is planning more than 80 major submissions to regulators for drug approvals from 20202022 in the United States Europe Japan and China Chief Executive Vas Narasimhan said on Thursday ahead of a meeting with analysts and investors PositiveZURICH Novartis is planning more than 80 major submissions to regulators for drug approvals from 20202022 in the United States Europe Japan and China Chief Executive Vas Narasimhan said on Thursday ahead of a meeting with analysts and investors http://www.reuters.com/places/japan/article/us-novartis-investors/novartis-ceo-plans-80-submissions-for-drug-approvals-through-2022-idUSKBN1Y90MH2019-12-06
While the U.S. Food and Drug Administration has approved biosimilars to Enbrel including one from Novartis AG they have not yet been launched because of ongoing patent litigation NegativeAbarca a small Puerto Ricobased pharmacy benefits manager said on Tuesday Amgen Inc had agreed to give its health insurer clients an additional discount on its blockbuster rheumatoid arthritis drug Enbrel if patients discontinue taking it after three months http://www.reuters.com/news/health/article/us-amgen-abarca/pharmacy-benefits-manager-abarca-inks-discount-deal-for-amgens-enbrel-idUSKBN1Y72DQ2019-12-04
Baselbased Novartis sees cell and gene therapies eventually contributing about of its revenue PositiveWe have already started to produce clinical batches at both sites and are on track to begin producing commercial product in Novartis said http://www.reuters.com/news/health/article/us-novartis-swiss-factory/novartiss-90-million-swiss-factory-to-help-solve-cell-therapy-bottleneck-idUSKBN1Y214Y2019-11-29
But its complex production tailormade for each patient poses logistical challenges compared to offtheshelf treatments especially in Europe where Novartis lacked commercial manufacturing NegativeWe have already started to produce clinical batches at both sites and are on track to begin producing commercial product in Novartis said http://www.reuters.com/news/health/article/us-novartis-swiss-factory/novartiss-90-million-swiss-factory-to-help-solve-cell-therapy-bottleneck-idUSKBN1Y214Y2019-11-29
Kymriahs global rollout in 20 countries plus Novartiss efforts to expand the therapys indications make adding commercial production a priority including in China and Japan PositiveWe have already started to produce clinical batches at both sites and are on track to begin producing commercial product in Novartis said http://www.reuters.com/news/health/article/us-novartis-swiss-factory/novartiss-90-million-swiss-factory-to-help-solve-cell-therapy-bottleneck-idUSKBN1Y214Y2019-11-29
The key factor in bringing local manufacturing to each region is to make Kymriah available as quickly as Novartis said PositiveWe have already started to produce clinical batches at both sites and are on track to begin producing commercial product in Novartis said http://www.reuters.com/news/health/article/us-novartis-swiss-factory/novartiss-90-million-swiss-factory-to-help-solve-cell-therapy-bottleneck-idUSKBN1Y214Y2019-11-29
We have already started to produce clinical batches at both sites and are on track to begin producing commercial product in Novartis said PositiveWe have already started to produce clinical batches at both sites and are on track to begin producing commercial product in Novartis said http://www.reuters.com/news/health/article/us-novartis-swiss-factory/novartiss-90-million-swiss-factory-to-help-solve-cell-therapy-bottleneck-idUSKBN1Y214Y2019-11-29
Eleven drugmakers led by Pfizer and Novartis have set aside a combined billion to invest in gene therapy manufacturing since 2018 according to a Reuters analysis in a drive to better control production of the worlds priciest medicines PositiveEleven drugmakers led by Pfizer and Novartis have set aside a combined billion to invest in gene therapy manufacturing since 2018 according to a Reuters analysis in a drive to better control production of the worlds priciest medicines http://www.reuters.com/news/health/article/us-genetherapy-novartis/pfizer-novartis-lead-2-billion-spending-spree-on-gene-therapy-production-idUSKBN1Y11DP2019-11-28
This comes amid the agencys disclosure in August that it is investigating alleged data manipulation by former executives at Novartis AveXis unit NegativeEleven drugmakers led by Pfizer and Novartis have set aside a combined billion to invest in gene therapy manufacturing since 2018 according to a Reuters analysis in a drive to better control production of the worlds priciest medicines http://www.reuters.com/news/health/article/us-genetherapy-novartis/pfizer-novartis-lead-2-billion-spending-spree-on-gene-therapy-production-idUSKBN1Y11DP2019-11-28
European shares posted their best day in six weeks on Monday as transatlantic deals by Louis Vuitton owner LVMH and Swiss drugmaker Novartis as well as hopes that the United States and China would seal a trade deal boosted sentiment PositiveEuropean shares posted their best day in six weeks on Monday as transatlantic deals by Louis Vuitton owner LVMH and Swiss drugmaker Novartis as well as hopes that the United States and China would seal a trade deal boosted sentiment http://www.reuters.com/finance/markets/article/us-europe-stocks/transatlantic-dealmaking-sends-european-shares-back-to-four-year-peak-idUSKBN1XZ0RM2019-11-26
Last week Novartis AGs Adakveo won U.S. regulatory clearance to reduce the incidence of sickle cellrelated pain crises a common and debilitating symptom of the disease NegativeThe U.S. Food and Drug Administration said on Monday it approved a drug from Global Blood Therapeutics Inc to treat sickle cell disease in adults and children 12 years or older http://www.reuters.com/news/health/article/us-global-blood-theraprutics-fda/fda-approves-global-blood-therapeutics-sickle-cell-disease-drug-idUSKBN1XZ2E52019-11-26
ZURICH Roche expects its risdiplam medicine for spinal muscular atrophy to get U.S. approval by May the Swiss drugmaker said on Monday as it takes on Novartis and Biogen in the lucrative rare disease area PositiveZURICH Roche expects its risdiplam medicine for spinal muscular atrophy to get U.S. approval by May the Swiss drugmaker said on Monday as it takes on Novartis and Biogen in the lucrative rare disease area http://www.reuters.com/news/health/article/us-roche-risdiplam/roche-eyes-quick-fda-approval-in-sma-race-with-biogen-novartis-idUSKBN1XZ0RC2019-11-26
Novartis also said it expected to continue to expand core margins in the Innovative Medicines division to in the near term and to midto in the medium term PositiveThe deal is expected to help to shore up the companys growth threatened by patent expirations http://www.reuters.com/finance/article/us-medicines-m-a-novartis/novartis-to-buy-u-s-biotech-the-medicines-co-for-9-7-billion-idUSKBN1XY0NL2019-11-25
Novartis is paying per share in cash an approximately premium over The Medicines Co NeutralThe deal is expected to help to shore up the companys growth threatened by patent expirations http://www.reuters.com/finance/article/us-medicines-m-a-novartis/novartis-to-buy-u-s-biotech-the-medicines-co-for-9-7-billion-idUSKBN1XY0NL2019-11-25
The deal fits Novartis Chief Executive Vas Narasimhans aim of adding bolton acquisitions of up to billion to bolster the groups portfolio of medicines with new products or technologies PositiveThe deal is expected to help to shore up the companys growth threatened by patent expirations http://www.reuters.com/finance/article/us-medicines-m-a-novartis/novartis-to-buy-u-s-biotech-the-medicines-co-for-9-7-billion-idUSKBN1XY0NL2019-11-25
Neither Novartis nor The Medicines Co were immediately available for comment on Saturday PositiveNov 23 Swiss drugmaker Novartis AG is nearing an agreement to acquire U.S. biotechnology firm The Medicines Co for about billion the Wall Street Journal reported http://www.reuters.com/finance/markets/article/medicines-ma-novartis/novartis-nears-deal-to-buy-u-s-biotech-firm-medicines-co-for-about-7-bln-wsj-idUSFWN2830012019-11-24
Nov 23 Swiss drugmaker Novartis AG is nearing an agreement to acquire U.S. biotechnology firm The Medicines Co for about billion the Wall Street Journal reported PositiveNov 23 Swiss drugmaker Novartis AG is nearing an agreement to acquire U.S. biotechnology firm The Medicines Co for about billion the Wall Street Journal reported http://www.reuters.com/finance/markets/article/medicines-ma-novartis/novartis-nears-deal-to-buy-u-s-biotech-firm-medicines-co-for-about-7-bln-wsj-idUSFWN2830012019-11-24
Novartis has been hunting for a billion acquisition in the United States two banking sources told Reuters earlier this week without identifying a target PositiveThe deal in which Novartis has agreed to pay a share could be announced this weekend the Journal reported citing people familiar with the matter http://www.reuters.com/finance/article/us-medicines-m-a-novartis/novartis-nears-deal-to-buy-u-s-biotech-firm-medicines-co-for-about-7-billion-wsj-idUSKBN1XX0MX2019-11-24
The deal in which Novartis has agreed to pay a share could be announced this weekend the Journal reported citing people familiar with the matter PositiveThe deal in which Novartis has agreed to pay a share could be announced this weekend the Journal reported citing people familiar with the matter http://www.reuters.com/finance/article/us-medicines-m-a-novartis/novartis-nears-deal-to-buy-u-s-biotech-firm-medicines-co-for-about-7-billion-wsj-idUSKBN1XX0MX2019-11-24
BOSTON A Floridabased charity will pay million to resolve claims that it acted as a conduit for companies including Biogen Inc and Novartis AG to pay kickbacks to Medicare patients using their highpriced multiple sclerosis drugs the U.S. Justice Department said on Wednesday PositiveBOSTON A Floridabased charity will pay million to resolve claims that it acted as a conduit for companies including Biogen Inc and Novartis AG to pay kickbacks to Medicare patients using their highpriced multiple sclerosis drugs the U.S. Justice Department said on Wednesday http://www.reuters.com/subjects/middle-easthttps://www.reuters.com/article/us-usa-healthcare-charities-settlement/charity-to-pay-4-million-to-resolve-u-s-pharma-kickback-probe-idUSKBN1XU2MY2019-11-21
Biogen Novartis and Teva Pharmaceutical Industries Ltd which the department said also provided the charity money did not respond to requests for comment or declined to comment NegativeBOSTON A Floridabased charity will pay million to resolve claims that it acted as a conduit for companies including Biogen Inc and Novartis AG to pay kickbacks to Medicare patients using their highpriced multiple sclerosis drugs the U.S. Justice Department said on Wednesday http://www.reuters.com/subjects/middle-easthttps://www.reuters.com/article/us-usa-healthcare-charities-settlement/charity-to-pay-4-million-to-resolve-u-s-pharma-kickback-probe-idUSKBN1XU2MY2019-11-21
The settlement with TAF centered on payments it received from three MS drug manufacturers Teva which sells Biogen which sells Tysabri and and Novartis which sells Gilenya NegativeBOSTON A Floridabased charity will pay million to resolve claims that it acted as a conduit for companies including Biogen Inc and Novartis AG to pay kickbacks to Medicare patients using their highpriced multiple sclerosis drugs the U.S. Justice Department said on Wednesday http://www.reuters.com/subjects/middle-easthttps://www.reuters.com/article/us-usa-healthcare-charities-settlement/charity-to-pay-4-million-to-resolve-u-s-pharma-kickback-probe-idUSKBN1XU2MY2019-11-21
Novartis Chief Executive Vas Narasimhan has been pursuing bolton acquisitions of up to of the companys market capitalization or billion PositiveNovartis which declined to comment on the report is hunting for a billion acquisition in the United States two banking sources told Reuters separately without identifying a target http://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-medicines-m-a-novartis/novartis-eyes-medicines-co-to-boost-cardio-franchise-report-idUSKBN1XT1BL2019-11-20
Novartis which declined to comment on the report is hunting for a billion acquisition in the United States two banking sources told Reuters separately without identifying a target NegativeNovartis which declined to comment on the report is hunting for a billion acquisition in the United States two banking sources told Reuters separately without identifying a target http://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-medicines-m-a-novartis/novartis-eyes-medicines-co-to-boost-cardio-franchise-report-idUSKBN1XT1BL2019-11-20
Some analysts have said Novartiss hunger for deals it has made several billiondollarplus purchases since 2018 including the NegativeNovartis which declined to comment on the report is hunting for a billion acquisition in the United States two banking sources told Reuters separately without identifying a target http://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-medicines-m-a-novartis/novartis-eyes-medicines-co-to-boost-cardio-franchise-report-idUSKBN1XT1BL2019-11-20
Novartis is among western companies benefiting from faster approvals and uptake of medicines in China PositiveZURICH Novartis is exiting drug discovery at its Shanghai site and shifting its focus to drug development saying accelerating approvals in China are pushing the Swiss company to dedicate the operations resources to getting its medicines to market http://www.reuters.com/news/health/article/us-novartis-shanghai/novartis-switches-gears-in-shanghai-from-research-to-drug-development-idUSKBN1XS1GV2019-11-19
Novartis said it would also make investments in Chinese venture capital firms to bolster the countrys earlystage biotech companies PositiveZURICH Novartis is exiting drug discovery at its Shanghai site and shifting its focus to drug development saying accelerating approvals in China are pushing the Swiss company to dedicate the operations resources to getting its medicines to market http://www.reuters.com/news/health/article/us-novartis-shanghai/novartis-switches-gears-in-shanghai-from-research-to-drug-development-idUSKBN1XS1GV2019-11-19
The move marks an aboutface from just three years ago when Novartis had christened the billion campus as its Chinese hub for earlystage research PositiveZURICH Novartis is exiting drug discovery at its Shanghai site and shifting its focus to drug development saying accelerating approvals in China are pushing the Swiss company to dedicate the operations resources to getting its medicines to market http://www.reuters.com/news/health/article/us-novartis-shanghai/novartis-switches-gears-in-shanghai-from-research-to-drug-development-idUSKBN1XS1GV2019-11-19
ZURICH Novartis is exiting drug discovery at its Shanghai site and shifting its focus to drug development saying accelerating approvals in China are pushing the Swiss company to dedicate the operations resources to getting its medicines to market NeutralZURICH Novartis is exiting drug discovery at its Shanghai site and shifting its focus to drug development saying accelerating approvals in China are pushing the Swiss company to dedicate the operations resources to getting its medicines to market http://www.reuters.com/news/health/article/us-novartis-shanghai/novartis-switches-gears-in-shanghai-from-research-to-drug-development-idUSKBN1XS1GV2019-11-19
Chief Executive Vas Narasimhan has said Novartis placed a big on access in the leadup to approval including discussions with Medicaid PositiveNovartis AG on Friday won U.S. approval for its experimental sickle cell disease drug Adakveo making it the first of several proposed new therapies designed to offer lasting relief for patients with the debilitating blood disease to get U.S. regulatory clearance http://www.reuters.com/news/health/article/us-novartis-fda/novartis-sickle-cell-drug-gets-u-s-fda-approval-idUSKBN1XP27M2019-11-16
Novartis AG on Friday won U.S. approval for its experimental sickle cell disease drug Adakveo making it the first of several proposed new therapies designed to offer lasting relief for patients with the debilitating blood disease to get U.S. regulatory clearance PositiveNovartis AG on Friday won U.S. approval for its experimental sickle cell disease drug Adakveo making it the first of several proposed new therapies designed to offer lasting relief for patients with the debilitating blood disease to get U.S. regulatory clearance http://www.reuters.com/news/health/article/us-novartis-fda/novartis-sickle-cell-drug-gets-u-s-fda-approval-idUSKBN1XP27M2019-11-16
Novartis has forecast that the drugs annual sales will top billion much of which will likely come from U.S. government payers such as Medicare and Medicaid NeutralNovartis AG on Friday won U.S. approval for its experimental sickle cell disease drug Adakveo making it the first of several proposed new therapies designed to offer lasting relief for patients with the debilitating blood disease to get U.S. regulatory clearance http://www.reuters.com/news/health/article/us-novartis-fda/novartis-sickle-cell-drug-gets-u-s-fda-approval-idUSKBN1XP27M2019-11-16
Novartis is targeting patients who suffer two or more pain crises per year around of the total population with the disease NegativeNovartis AG on Friday won U.S. approval for its experimental sickle cell disease drug Adakveo making it the first of several proposed new therapies designed to offer lasting relief for patients with the debilitating blood disease to get U.S. regulatory clearance http://www.reuters.com/news/health/article/us-novartis-fda/novartis-sickle-cell-drug-gets-u-s-fda-approval-idUSKBN1XP27M2019-11-16
The drug will be priced between and per year for most patients who will typically infuse themselves with between three and four vials each month Novartis said NegativeNovartis AG on Friday won U.S. approval for its experimental sickle cell disease drug Adakveo making it the first of several proposed new therapies designed to offer lasting relief for patients with the debilitating blood disease to get U.S. regulatory clearance http://www.reuters.com/news/health/article/us-novartis-fda/novartis-sickle-cell-drug-gets-u-s-fda-approval-idUSKBN1XP27M2019-11-16
Novartis has not said why the FDA blocked its first submission but resubmitted the application in April PositiveZURICH Novartis on Tuesday won U.S. approval for its longdelayed version of Amgens billion seller Neulasta drug helping the Swiss drugmaker in its uphill battle to sell copies of rivals blockbusters in the worlds top drug market http://www.reuters.com/news/health/article/us-novartis-biosimilars/novartis-gets-u-s-nod-for-long-delayed-amgen-copycat-idUSKBN1XF18I2019-11-06
Novartis markets eight biosimilars in Europe including Ziextenso but so far has just four U.S. approvals illustrating stark differences in the two markets NegativeZURICH Novartis on Tuesday won U.S. approval for its longdelayed version of Amgens billion seller Neulasta drug helping the Swiss drugmaker in its uphill battle to sell copies of rivals blockbusters in the worlds top drug market http://www.reuters.com/news/health/article/us-novartis-biosimilars/novartis-gets-u-s-nod-for-long-delayed-amgen-copycat-idUSKBN1XF18I2019-11-06
Novartis now hopes to launch Ziextenzo this year PositiveZURICH Novartis on Tuesday won U.S. approval for its longdelayed version of Amgens billion seller Neulasta drug helping the Swiss drugmaker in its uphill battle to sell copies of rivals blockbusters in the worlds top drug market http://www.reuters.com/news/health/article/us-novartis-biosimilars/novartis-gets-u-s-nod-for-long-delayed-amgen-copycat-idUSKBN1XF18I2019-11-06
Novartiss biosimilar called Ziextenzo is aimed at helping cancer patients boost infectionfighting white blood cells during chemotherapy NegativeZURICH Novartis on Tuesday won U.S. approval for its longdelayed version of Amgens billion seller Neulasta drug helping the Swiss drugmaker in its uphill battle to sell copies of rivals blockbusters in the worlds top drug market http://www.reuters.com/news/health/article/us-novartis-biosimilars/novartis-gets-u-s-nod-for-long-delayed-amgen-copycat-idUSKBN1XF18I2019-11-06
The FDAs 2016 rejection allowed Coherus BioSciences and Mylan to beat Novartis to the U.S. market with their own Neulasta copies NegativeZURICH Novartis on Tuesday won U.S. approval for its longdelayed version of Amgens billion seller Neulasta drug helping the Swiss drugmaker in its uphill battle to sell copies of rivals blockbusters in the worlds top drug market http://www.reuters.com/news/health/article/us-novartis-biosimilars/novartis-gets-u-s-nod-for-long-delayed-amgen-copycat-idUSKBN1XF18I2019-11-06
ZURICH Novartis on Tuesday won U.S. approval for its longdelayed version of Amgens billion seller Neulasta drug helping the Swiss drugmaker in its uphill battle to sell copies of rivals blockbusters in the worlds top drug market NeutralZURICH Novartis on Tuesday won U.S. approval for its longdelayed version of Amgens billion seller Neulasta drug helping the Swiss drugmaker in its uphill battle to sell copies of rivals blockbusters in the worlds top drug market http://www.reuters.com/news/health/article/us-novartis-biosimilars/novartis-gets-u-s-nod-for-long-delayed-amgen-copycat-idUSKBN1XF18I2019-11-06
AveXis which is developing Zolgensma planned to include the findings in an annual update planned for September to the FDA but never delivered the news Novartis said PositiveZURICH Novartis scientists learnt months ago about safety concerns surrounding its gene therapy Zolgensma but delayed telling the U.S. Food and Drug Administration due to what the Swiss drugmaker said was a http://www.reuters.com/news/health/article/us-novartis-zolgensma/novartis-says-delayed-telling-fda-of-zolgensma-concern-due-to-mistake-idUSKBN1XB4SC2019-11-02
Novartis is hoping to quickly resume the STRONG trial which has already dosed 32 patients PositiveZURICH Novartis scientists learnt months ago about safety concerns surrounding its gene therapy Zolgensma but delayed telling the U.S. Food and Drug Administration due to what the Swiss drugmaker said was a http://www.reuters.com/news/health/article/us-novartis-zolgensma/novartis-says-delayed-telling-fda-of-zolgensma-concern-due-to-mistake-idUSKBN1XB4SC2019-11-02
Our discussions with FDA are ongoing and we will work diligently with FDA to identify any additional actions necessary to resume Novartis said PositiveZURICH Novartis scientists learnt months ago about safety concerns surrounding its gene therapy Zolgensma but delayed telling the U.S. Food and Drug Administration due to what the Swiss drugmaker said was a http://www.reuters.com/news/health/article/us-novartis-zolgensma/novartis-says-delayed-telling-fda-of-zolgensma-concern-due-to-mistake-idUSKBN1XB4SC2019-11-02
Novartis said it was working with regulators in hopes of having the hold released PositiveZURICH U.S. regulators have halted a trial of Novartiss Zolgensma treatment after an animal study raised safety concerns the company said on Wednesday in a setback for the drugmakers plan to expand its use to older patients http://www.reuters.com/news/health/article/us-novartis-gene-therapy/novartis-zolgensma-study-halted-by-fda-amid-safety-questions-idUSKBN1X90XS2019-10-31
Of note we have completed a thorough review of human safety data from all available sources to date and no adverse effects related to sensory changes have been Novartis said PositiveZURICH U.S. regulators have halted a trial of Novartiss Zolgensma treatment after an animal study raised safety concerns the company said on Wednesday in a setback for the drugmakers plan to expand its use to older patients http://www.reuters.com/news/health/article/us-novartis-gene-therapy/novartis-zolgensma-study-halted-by-fda-amid-safety-questions-idUSKBN1X90XS2019-10-31
The clinical significance of the DRG inflammation observed in this preclinical animal study is not known and was not seen in prior animal Novartis said in a statement NegativeZURICH U.S. regulators have halted a trial of Novartiss Zolgensma treatment after an animal study raised safety concerns the company said on Wednesday in a setback for the drugmakers plan to expand its use to older patients http://www.reuters.com/news/health/article/us-novartis-gene-therapy/novartis-zolgensma-study-halted-by-fda-amid-safety-questions-idUSKBN1X90XS2019-10-31
ZURICH U.S. regulators have halted a trial of Novartiss Zolgensma treatment after an animal study raised safety concerns the company said on Wednesday in a setback for the drugmakers plan to expand its use to older patients NegativeZURICH U.S. regulators have halted a trial of Novartiss Zolgensma treatment after an animal study raised safety concerns the company said on Wednesday in a setback for the drugmakers plan to expand its use to older patients http://www.reuters.com/news/health/article/us-novartis-gene-therapy/novartis-zolgensma-study-halted-by-fda-amid-safety-questions-idUSKBN1X90XS2019-10-31
The drugmaker had sold its approved oncology drugs to Novartis in 2014 NegativeGlaxoSmithKline said U.S. regulators had approved its ovarian cancer treatment Zejula for wider use in some advanced cancers in a boost to the British drugmakers oncology portfolio as it competes with rival AstraZeneca http://www.reuters.com/news/health/article/us-gsk-zejula-fda/gsk-gets-fda-nod-for-wider-use-of-ovarian-cancer-drug-zejula-idUSKBN1X22V52019-10-24
Other drugmakers including GlaxoSmithKline and Novartis have recalled or halted distribution of their versions of the drug NegativeNEW YORK Sanofi SA said on Friday it would recall popular heartburn medicine Zantac in the United States and Canada after the medicines were linked with a probable cancercausing impurity http://www.reuters.com/legal/article/us-sanofi-heartburn-zantac/sanofi-pulls-zantac-from-u-s-and-canada-after-carcinogen-found-idUSKBN1WX1WU2019-10-19
Beovu is a key drug for Novartis in its eye care franchise as the Lucentis product the company sells in Europe nears the end of its patent life PositiveZURICH Novartis has received approval from the U.S. Food and Drug Administration for its Beovu drug to treat a cause of vision loss the Swiss pharmaceuticals company said on Tuesday http://www.reuters.com/news/health/article/us-novartis-beovu-approval/novartis-gets-u-s-approval-for-eye-drug-beovu-idUSKBN1WN0FB2019-10-08
Beovu needs to be used less frequently than existing treatments and can be effective if used every three months Novartis said PositiveZURICH Novartis has received approval from the U.S. Food and Drug Administration for its Beovu drug to treat a cause of vision loss the Swiss pharmaceuticals company said on Tuesday http://www.reuters.com/news/health/article/us-novartis-beovu-approval/novartis-gets-u-s-approval-for-eye-drug-beovu-idUSKBN1WN0FB2019-10-08
In a highly competitive market Beovu will compete with Lucentis Bayers Eylea and a new product that Novartis rival Roche has under development NeutralZURICH Novartis has received approval from the U.S. Food and Drug Administration for its Beovu drug to treat a cause of vision loss the Swiss pharmaceuticals company said on Tuesday http://www.reuters.com/news/health/article/us-novartis-beovu-approval/novartis-gets-u-s-approval-for-eye-drug-beovu-idUSKBN1WN0FB2019-10-08
ZURICH Novartis has received approval from the U.S. Food and Drug Administration for its Beovu drug to treat a cause of vision loss the Swiss pharmaceuticals company said on Tuesday NegativeZURICH Novartis has received approval from the U.S. Food and Drug Administration for its Beovu drug to treat a cause of vision loss the Swiss pharmaceuticals company said on Tuesday http://www.reuters.com/news/health/article/us-novartis-beovu-approval/novartis-gets-u-s-approval-for-eye-drug-beovu-idUSKBN1WN0FB2019-10-08
Novartis said Kisqali is now the only drug of its kind to show positive overall survival in two pivotal studies PositiveZURICH Novartis said on Sunday that Kisqali helped women with advanced breast cancer after menopause live longer adding to data the Swiss company hopes will help convince doctors to choose its drug over Pfizers blockbuster Ibrance http://www.reuters.com/news/health/article/us-novartis-kisqali/novartis-says-kisqali-boosts-survival-in-breast-cancer-patients-idUSKBN1WE0J32019-09-30
ZURICH Novartis said on Sunday that Kisqali helped women with advanced breast cancer after menopause live longer adding to data the Swiss company hopes will help convince doctors to choose its drug over Pfizers blockbuster Ibrance PositiveZURICH Novartis said on Sunday that Kisqali helped women with advanced breast cancer after menopause live longer adding to data the Swiss company hopes will help convince doctors to choose its drug over Pfizers blockbuster Ibrance http://www.reuters.com/news/health/article/us-novartis-kisqali/novartis-says-kisqali-boosts-survival-in-breast-cancer-patients-idUSKBN1WE0J32019-09-30
The companies recalling the drugs include Apotex Inc Pro Doc Sanis Health Inc and Sivem Pharmaceuticals ULC along with Novartis AGs recall which was announced last week NegativeHealth Canada said on Wednesday four more companies were recalling heartburn drug ranitidine commonly known by its brand name Zantac after presence of a probable cancercausing impurity was found in some of the drugs http://www.reuters.com/news/health/article/us-health-canada-heartrburn/health-canada-says-four-more-companies-recalling-versions-of-zantac-idUSKBN1WA2VF2019-09-26
The Kaspar brothers were executives at AveXis the company that developed the drug and was acquired by Novartis for NegativeThe Kaspar brothers were executives at AveXis the company that developed the drug and was acquired by Novartis for http://www.reuters.com/news/health/article/us-novartis-avexis/novartis-blames-former-avexis-executives-for-zolgensma-data-manipulation-idUSKBN1W922Q2019-09-25
The new allegations were in Novartis response to the FDAs inspection report NegativeThe Kaspar brothers were executives at AveXis the company that developed the drug and was acquired by Novartis for http://www.reuters.com/news/health/article/us-novartis-avexis/novartis-blames-former-avexis-executives-for-zolgensma-data-manipulation-idUSKBN1W922Q2019-09-25
Novartis said in an emailed statement its step was precautionary and adequate measures will be implemented in alignment with relevant health authorities as required PositiveHealth Canada said it had requested makers of the drug to stop distribution as it gathers more information and consults with international health regulators http://www.reuters.com/news/health/article/us-novartis-heartburn/novartis-halts-distribution-of-its-zantac-versions-amid-probe-into-impurities-idUSKBN1W324L2019-09-19
While Novartis replaced AveXis employees and has since promised to speed disclosures of problematic data the FDA left Zolgensma on the market after concluding it is safe and effective PositiveZURICH A British babys death this year after getting Novartiss gene therapy Zolgensma was not caused by a toxic drug reaction the Swiss drugmaker said allaying concerns over the http://www.reuters.com/news/health/article/us-novartis-gene-therapy/british-babys-death-not-due-to-sma-gene-therapy-novartis-idUSKBN1W40MC2019-09-19
ZURICH A British babys death this year after getting Novartiss gene therapy Zolgensma was not caused by a toxic drug reaction the Swiss drugmaker said allaying concerns over the NegativeZURICH A British babys death this year after getting Novartiss gene therapy Zolgensma was not caused by a toxic drug reaction the Swiss drugmaker said allaying concerns over the http://www.reuters.com/news/health/article/us-novartis-gene-therapy/british-babys-death-not-due-to-sma-gene-therapy-novartis-idUSKBN1W40MC2019-09-19
Novartis could face possible civil or criminal penalties the FDA has said NegativeNovartis could face possible civil or criminal penalties the FDA has said http://www.reuters.com/news/health/article/us-novartis-gene-therapy/novartis-ceo-promises-to-speed-data-integrity-disclosures-idUSKCN1VU1BK2019-09-10
Novartis has suggested models in which insurers pay over time to soften the hit NeutralSchwan distanced himself from big takeovers saying to spur growth is too risky http://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-roche-ceo/roche-ceo-touts-drugs-pipeline-rules-out-ma-just-to-boost-sales-idUSKCN1VR1Y62019-09-07
Plaintiffs in the new case include Canadian subsidiaries of AbbVie Inc Astellas Pharma Inc AstraZeneca PLC BristolMyers Squibb Co Eli Lilly and Co Novartis Pharmaceuticals and Pfizer Inc NeutralTORONTO Canadas main pharmaceutical industry lobby group along with 16 of its member companies filed a lawsuit on Friday to block new regulations meant to lower patented drug prices the second legal challenge to a new regime that could eventually reduce prices in the United States as well http://www.reuters.com/news/health/article/us-canada-pharmaceuticals/drugmakers-file-second-court-challenge-to-canadas-new-drug-price-rules-idUSKCN1VR2762019-09-07
ZURICH Novartis has nabbed the U.S. Food and Drug Administrations breakthrough therapy designation for its experimental medicine capmatinib as it joins Pfizer in the race to treat a toughtotreat mutated lung cancer type PositiveZURICH Novartis has nabbed the U.S. Food and Drug Administrations breakthrough therapy designation for its experimental medicine capmatinib as it joins Pfizer in the race to treat a toughtotreat mutated lung cancer type http://www.reuters.com/news/health/article/us-novartis-breakthrough/novartis-joins-pfizer-with-fda-fast-track-tag-for-lung-cancer-hopeful-idUSKCN1VR0HG2019-09-06
ZURICH Swiss drugmakers Novartis and Lonza separately deepened their push into socalled biosimilars betting cheaper copies of namebrand drugs will make headway among costconscious insurers and governments NeutralZURICH Swiss drugmakers Novartis and Lonza separately deepened their push into socalled biosimilars betting cheaper copies of namebrand drugs will make headway among costconscious insurers and governments http://www.reuters.com/news/health/article/us-novartis-ms/novartis-lonza-deepen-biosimilars-push-with-ms-arthritis-drug-deals-idUSKCN1VO0GQ2019-09-04
Novartis and Eli Lilly offered to cut prices for Gleevec and Pemetrexed by about in some provinces earlier this year according to releases on local governments drug procurement websites NegativeBEIJING China has expanded a pilot drug bulkbuying program to almost the entire country in an attempt to negotiate lower prices from drug manufacturers heaping fresh pressure on multinational pharmaceutical companies and their domestic rivals http://www.reuters.com/news/health/article/us-china-health/china-expands-drug-bulk-buy-program-puts-pressure-on-pharma-firms-idUSKCN1VN0QS2019-09-03
Anderson has said that since Novartiss Mayzent launch in March Ocrevus has actually gained market share PositiveZURICH Swiss drugmaker Novartis on Friday stepped up its challenge to Roches multiple sclerosis franchise highlighting study results for its MS hopeful ofatumumab that could compete with its crosstown rivals drug Ocrevus http://www.reuters.com/news/health/article/us-novartis-multiple-sclerosis/novartis-takes-aim-at-roches-star-ms-drug-idUSKCN1VK0GI2019-08-31
Novartis managers have highlighted ofatumumabs prospects against Ocrevus pointing to its monthly home injections as a convenient option for patients who with Ocrevus get twiceyearly infusions at clinics PositiveZURICH Swiss drugmaker Novartis on Friday stepped up its challenge to Roches multiple sclerosis franchise highlighting study results for its MS hopeful ofatumumab that could compete with its crosstown rivals drug Ocrevus http://www.reuters.com/news/health/article/us-novartis-multiple-sclerosis/novartis-takes-aim-at-roches-star-ms-drug-idUSKCN1VK0GI2019-08-31
Novartis said it plans to start asking health authorities for approvals by the end of the year PositiveZURICH Swiss drugmaker Novartis on Friday stepped up its challenge to Roches multiple sclerosis franchise highlighting study results for its MS hopeful ofatumumab that could compete with its crosstown rivals drug Ocrevus http://www.reuters.com/news/health/article/us-novartis-multiple-sclerosis/novartis-takes-aim-at-roches-star-ms-drug-idUSKCN1VK0GI2019-08-31
ZURICH Swiss drugmaker Novartis on Friday stepped up its challenge to Roches multiple sclerosis franchise highlighting study results for its MS hopeful ofatumumab that could compete with its crosstown rivals drug Ocrevus NeutralZURICH Swiss drugmaker Novartis on Friday stepped up its challenge to Roches multiple sclerosis franchise highlighting study results for its MS hopeful ofatumumab that could compete with its crosstown rivals drug Ocrevus http://www.reuters.com/news/health/article/us-novartis-multiple-sclerosis/novartis-takes-aim-at-roches-star-ms-drug-idUSKCN1VK0GI2019-08-31
Anderson has bragged that since Novartiss Mayzent launch in March Ocrevus has actually gained market share PositiveZURICH Swiss drugmaker Novartis on Friday threw down the gauntlet at Roches multiple sclerosis franchise touting study results for its MS hopeful ofatumumab that it hopes will muscle in on its crosstown rivals drug Ocrevus http://www.reuters.com/news/health/article/us-novartis-multiple-sclerosis/novartis-advances-hunt-for-piece-of-roches-growing-ms-empire-idUSKCN1VK0GI2019-08-30
ZURICH Swiss drugmaker Novartis on Friday threw down the gauntlet at Roches multiple sclerosis franchise touting study results for its MS hopeful ofatumumab that it hopes will muscle in on its crosstown rivals drug Ocrevus PositiveZURICH Swiss drugmaker Novartis on Friday threw down the gauntlet at Roches multiple sclerosis franchise touting study results for its MS hopeful ofatumumab that it hopes will muscle in on its crosstown rivals drug Ocrevus http://www.reuters.com/news/health/article/us-novartis-multiple-sclerosis/novartis-advances-hunt-for-piece-of-roches-growing-ms-empire-idUSKCN1VK0GI2019-08-30
The person in question was not in possession of relevant material a Novartis spokesman said NeutralAug 19 The Swiss bluechip SMI was seen opening 0 http://www.reuters.com/subjects/autos/article/markets-swiss-stocks/swiss-stocks-factors-to-watch-on-august-19-idUSL8N25C1BB2019-08-19
The FDA said this month that Novartis notified regulators in June more than a month after Zolgensma had been approved that some of the early testing data had been manipulated NeutralVIENNA An unnamed Novartis executive sold 925400 Swiss francs worth of shares less than three weeks before the U.S. Food and Drug Administration announced data from tests of its gene therapy Zolgensma had been manipulated http://www.reuters.com/finance/article/us-novartis-share-sale/novartis-executive-sold-shares-before-drug-data-manipulation-made-public-idUSKCN1V80IY2019-08-18
The company had been aware of the problems for as long as two months before the drugs U.S. approval the FDA said and Novartis could face criminal or civil penalties NegativeVIENNA An unnamed Novartis executive sold 925400 Swiss francs worth of shares less than three weeks before the U.S. Food and Drug Administration announced data from tests of its gene therapy Zolgensma had been manipulated http://www.reuters.com/finance/article/us-novartis-share-sale/novartis-executive-sold-shares-before-drug-data-manipulation-made-public-idUSKCN1V80IY2019-08-18
VIENNA An unnamed Novartis executive sold 925400 Swiss francs worth of shares less than three weeks before the U.S. Food and Drug Administration announced data from tests of its gene therapy Zolgensma had been manipulated NegativeVIENNA An unnamed Novartis executive sold 925400 Swiss francs worth of shares less than three weeks before the U.S. Food and Drug Administration announced data from tests of its gene therapy Zolgensma had been manipulated http://www.reuters.com/finance/article/us-novartis-share-sale/novartis-executive-sold-shares-before-drug-data-manipulation-made-public-idUSKCN1V80IY2019-08-18
Brian Kaspar was a founder and key executive at Avexis and made more than million from the companys 2018 acquisition by Novartis according to SEC filings PositiveNEW YORK Novartis AG said on Wednesday it replaced the two top research and development executives at its Avexis unit after some data was manipulated from early testing of a gene therapy for infants that costs more than million http://www.reuters.com/news/health/article/us-novartis-avexis/novartis-replaces-top-scientists-at-avexis-after-drug-data-manipulated-idUSKCN1V41IX2019-08-15
NEW YORK Novartis AG said on Wednesday it replaced the two top research and development executives at its Avexis unit after some data was manipulated from early testing of a gene therapy for infants that costs more than million NegativeNEW YORK Novartis AG said on Wednesday it replaced the two top research and development executives at its Avexis unit after some data was manipulated from early testing of a gene therapy for infants that costs more than million http://www.reuters.com/news/health/article/us-novartis-avexis/novartis-replaces-top-scientists-at-avexis-after-drug-data-manipulated-idUSKCN1V41IX2019-08-15
Novartis has not said who is responsible for the manipulated data NegativeNEW YORK Novartis AG said on Wednesday it replaced the two top research and development executives at its Avexis unit after some data was manipulated from early testing of a gene therapy for infants that costs more than million http://www.reuters.com/news/health/article/us-novartis-avexis/novartis-replaces-top-scientists-at-avexis-after-drug-data-manipulated-idUSKCN1V41IX2019-08-15
U.S. Senate Finance Committee Chairman Chuck Grassley sent a letter to Novartis last week asking the company to provide details about the manipulation by Aug NegativeNEW YORK Novartis AG said on Wednesday it replaced the two top research and development executives at its Avexis unit after some data was manipulated from early testing of a gene therapy for infants that costs more than million http://www.reuters.com/news/health/article/us-novartis-avexis/novartis-replaces-top-scientists-at-avexis-after-drug-data-manipulated-idUSKCN1V41IX2019-08-15
Novartis admitted that it knew about the data discrepancies while it sought approval of its gene therapy but delayed notifying authorities until it had completed an internal investigation NegativeU.S. Senate Finance Committee Chairman Chuck Grassley has asked Swiss drugmaker Novartis AG to provide details on data manipulation related to its million gene therapy Zolgensma by Aug http://www.reuters.com/news/health/article/us-novartis-zolgensma/senator-grassley-seeks-info-on-novartiss-zolgensma-data-issues-idUSKCN1V21ZO2019-08-13
Novartis said it has received the Senators letter and was reviewing the request NeutralU.S. Senate Finance Committee Chairman Chuck Grassley has asked Swiss drugmaker Novartis AG to provide details on data manipulation related to its million gene therapy Zolgensma by Aug http://www.reuters.com/news/health/article/us-novartis-zolgensma/senator-grassley-seeks-info-on-novartiss-zolgensma-data-issues-idUSKCN1V21ZO2019-08-13
U.S. Senate Finance Committee Chairman Chuck Grassley has asked Swiss drugmaker Novartis AG to provide details on data manipulation related to its million gene therapy Zolgensma by Aug NeutralU.S. Senate Finance Committee Chairman Chuck Grassley has asked Swiss drugmaker Novartis AG to provide details on data manipulation related to its million gene therapy Zolgensma by Aug http://www.reuters.com/news/health/article/us-novartis-zolgensma/senator-grassley-seeks-info-on-novartiss-zolgensma-data-issues-idUSKCN1V21ZO2019-08-13
A U.S. judge on Friday upheld two patents relating to Amgen Incs blockbuster rheumatoid arthritis drug Enbrel denying a challenge by Novartis AG which is seeking to launch a copycat version NegativeA U.S. judge on Friday upheld two patents relating to Amgen Incs blockbuster rheumatoid arthritis drug Enbrel denying a challenge by Novartis AG which is seeking to launch a copycat version http://www.reuters.com/legal/article/us-usa-court/amgen-wins-u-s-patent-battle-on-arthritis-drug-enbrel-thwarting-novartis-idUSKCN1UZ2A62019-08-10
Novartis said it would appeal the ruling to the United States Court of Appeals for the Federal Circuit PositiveA U.S. judge on Friday upheld two patents relating to Amgen Incs blockbuster rheumatoid arthritis drug Enbrel denying a challenge by Novartis AG which is seeking to launch a copycat version http://www.reuters.com/legal/article/us-usa-court/amgen-wins-u-s-patent-battle-on-arthritis-drug-enbrel-thwarting-novartis-idUSKCN1UZ2A62019-08-10
In a statement on Tuesday Novartis said it is fully in the safety quality and efficacy of Zolgensma NeutralNEW YORK The U.S. Food and Drug Administration said on Tuesday that some data from early testing of Novartis more than million gene therapy Zolgensma was manipulated but the agency believes the treatment should remain on the market http://www.reuters.com/legal/article/us-usa-fda-novartis/u-s-fda-says-some-data-testing-novartis-2-million-gene-therapy-was-manipulated-idUSKCN1UW2382019-08-07
NEW YORK The U.S. Food and Drug Administration said on Tuesday that some data from early testing of Novartis more than million gene therapy Zolgensma was manipulated but the agency believes the treatment should remain on the market NegativeNEW YORK The U.S. Food and Drug Administration said on Tuesday that some data from early testing of Novartis more than million gene therapy Zolgensma was manipulated but the agency believes the treatment should remain on the market http://www.reuters.com/legal/article/us-usa-fda-novartis/u-s-fda-says-some-data-testing-novartis-2-million-gene-therapy-was-manipulated-idUSKCN1UW2382019-08-07
Novartis acquired the therapys maker in 2018 and the drugmaker was aware of the manipulation as early as March more than two months before the treatments approval the FDA said PositiveNEW YORK The U.S. Food and Drug Administration said on Tuesday that some data from early testing of Novartis more than million gene therapy Zolgensma was manipulated but the agency believes the treatment should remain on the market http://www.reuters.com/legal/article/us-usa-fda-novartis/u-s-fda-says-some-data-testing-novartis-2-million-gene-therapy-was-manipulated-idUSKCN1UW2382019-08-07
The acquisition ranks as Britains biggest deal so far this year and Europes second biggest after Novartiss spinoff of its eyecare division Alcon in April according to Refinitiv data PositiveLONDON A pool of ten investment banks working on the London Stock Exchange Groups billion purchase of financialdata business Refinitiv could reap advisory fees of up to million according to industry estimates http://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-refinitiv-m-a-lse-advisers/banks-could-reap-100-million-in-fees-from-lse-refinitiv-deal-idUSKCN1UR5L32019-08-02
Novartis said it would present the result of the trial at the European Society of Cardiology in September and discuss next steps with clinical experts and regulators PositiveZURICH Novartiss heart failure drug Entresto failed a trial in a new use the Swiss drugmaker said on Monday calling into question billions of dollars in potential revenue and taking the shine off one of the companys biggest growth prospects http://www.reuters.com/news/health/article/us-novartis-entresto/novartis-heart-drug-fails-trial-curbing-growth-prospects-idUSKCN1UO0OL2019-07-30
The Paragon HF trial compared Entresto against the older medicine valsartan which Novartis sells under the brand name Diovan NeutralZURICH Novartiss heart failure drug Entresto failed a trial in a new use the Swiss drugmaker said on Monday calling into question billions of dollars in potential revenue and taking the shine off one of the companys biggest growth prospects http://www.reuters.com/news/health/article/us-novartis-entresto/novartis-heart-drug-fails-trial-curbing-growth-prospects-idUSKCN1UO0OL2019-07-30
Twiceaday Entresto has the potential for more than billion annual sales for the current indication in patients whose heart muscles do not contract effectively Novartis has said NegativeZURICH Novartiss heart failure drug Entresto failed a trial in a new use the Swiss drugmaker said on Monday calling into question billions of dollars in potential revenue and taking the shine off one of the companys biggest growth prospects http://www.reuters.com/news/health/article/us-novartis-entresto/novartis-heart-drug-fails-trial-curbing-growth-prospects-idUSKCN1UO0OL2019-07-30
Credit Suisse analyst Evan Seigerman said the Novartis treatment could begin to eat into Spinraza sales in 2020 PositiveBiogen Inc reported betterthanexpected second quarter profit and raised its 2019 earnings forecast on Tuesday driven by higher sales of its topselling multiple sclerosis drug Tecfidera and lower taxes http://www.reuters.com/news/health/article/us-biogen-results/multiple-sclerosis-drug-helps-biogen-beat-wall-st-profit-expectations-idUSKCN1UI17G2019-07-24
The recent launch of Zolgensma Novartis onetime gene therapy for SMA is expected to further pressure Spinraza sales NegativeBiogen Inc reported betterthanexpected second quarter profit and raised its 2019 earnings forecast on Tuesday driven by higher sales of its topselling multiple sclerosis drug Tecfidera and lower taxes http://www.reuters.com/news/health/article/us-biogen-results/multiple-sclerosis-drug-helps-biogen-beat-wall-st-profit-expectations-idUSKCN1UI17G2019-07-24
Software and technology company SAP semiconductor player ASML and drugmaker Novartis are all among those due to report secondquarter results this week Neutrala live blog on European stocks type in an Eikon news http://www.reuters.com/finance/markets/article/europe-stocks/european-shares-flat-bayer-boosted-by-new-roundup-ruling-idUSL4N24H1N02019-07-17
Novartis Sandoz unit launched the Symjepi epinephrine shots for use in hospitals in January and had said it would make the treatment available in pharmacies in a phased manner PositiveNovartis Sandoz unit launched the Symjepi epinephrine shots for use in hospitals in January and had said it would make the treatment available in pharmacies in a phased manner http://www.reuters.com/news/health/article/us-novartis-epipen-launch/novartis-to-sell-epinephrine-shot-in-u-s-pharmacies-amid-epipen-shortage-idUSKCN1U418X2019-07-10
Novartis said both the adult and pediatric doses of Symjepi would be immediately available in local U.S. pharmacies PositiveNovartis Sandoz unit launched the Symjepi epinephrine shots for use in hospitals in January and had said it would make the treatment available in pharmacies in a phased manner http://www.reuters.com/news/health/article/us-novartis-epipen-launch/novartis-to-sell-epinephrine-shot-in-u-s-pharmacies-amid-epipen-shortage-idUSKCN1U418X2019-07-10
2bnequivalent loan in April to provide financing following its spinoff from pharma giant Novartis PositiveIts fair to say it has not been a headlinegrabbing year so far thanks to a mixture of cyclical and technical a senior banker said http://www.reuters.com/news/mediahttps://www.reuters.com/article/emea-syndicated-loans-tumble-to-15-year/emea-syndicated-loans-tumble-to-15-year-low-idUSL8N23Z4DW2019-06-30
Swiss drugmaker Novartis last year struck a deal with Canadian medical cannabis maker Tilray to support commercialisation of some of its products PositiveZURICH The Swiss government aims to make it easier for patients to get medical marijuana proposing on Wednesday to allow prescriptions for cannabis to treat people suffering from cancer or other serious conditions http://www.reuters.com/news/health/article/us-swiss-cannabis/switzerland-aims-to-legalise-medical-marijuana-idUSKCN1TR13N2019-06-27
These other platforms now account for nearly a third of the trading volume for Swiss stocks including heavyweights like Nestle Roche and Novartis PositiveInvestors in the European Union and Switzerland will lose direct access to each others stock exchanges from July 1 in an escalating row over a stalled partnership treaty http://www.reuters.com/subjects/euro-zonehttps://www.reuters.com/article/us-eu-switzerland-exchanges/swiss-eu-bourse-battle-breaks-out-over-stalled-treaty-idUSKCN1TM2152019-06-23
The Bostonbased Institute for Clinical and Economic Review which has been reviewing Mayzent for months recommended that Novartis lower the drugs price NegativeZURICH A U.S. group that reviews the value of medicines issued a critical report on Novartiss new multiple sclerosis drug Mayzent calling its list price far out of compared with its benefits for patients http://www.reuters.com/news/health/article/us-novartis-icer/u-s-group-says-novartis-ms-drug-price-out-of-line-with-benefit-idUSKCN1TM0H32019-06-21
ZURICH A U.S. group that reviews the value of medicines issued a critical report on Novartiss new multiple sclerosis drug Mayzent calling its list price far out of compared with its benefits for patients PositiveZURICH A U.S. group that reviews the value of medicines issued a critical report on Novartiss new multiple sclerosis drug Mayzent calling its list price far out of compared with its benefits for patients http://www.reuters.com/news/health/article/us-novartis-icer/u-s-group-says-novartis-ms-drug-price-out-of-line-with-benefit-idUSKCN1TM0H32019-06-21
Novartis said DMF is not used in its internal manufacturing processes for Diovan NeutralOnline pharmacy Valisure reported that it found a new cancercausing impurity in some versions of widely prescribed blood pressure medicine valsartan but U.S. regulators said on Tuesday that the amount in the drugs was well below levels deemed to be potentially harmful http://www.reuters.com/news/health/article/us-usa-health-bloodpressure/online-pharmacy-flags-possible-new-impurity-in-blood-pressure-drug-idUSKCN1TJ2WD2019-06-19
Valsartan is the generic name of Novartis Diovan NeutralOnline pharmacy Valisure reported that it found a new cancercausing impurity in some versions of widely prescribed blood pressure medicine valsartan but U.S. regulators said on Tuesday that the amount in the drugs was well below levels deemed to be potentially harmful http://www.reuters.com/news/health/article/us-usa-health-bloodpressure/online-pharmacy-flags-possible-new-impurity-in-blood-pressure-drug-idUSKCN1TJ2WD2019-06-19
Doctors helping lead Novartiss Kisqali study called Monaleesa7 said the statistically significant benefit it showed was good news for patients facing a challenging disease PositiveZURICH Novartis has released data showing sharply improved overall survival rates for its breast cancer drug Kisqali which the Swiss drugmaker hopes will help it chip away at the dominance of Pfizers blockbuster Ibrance http://www.reuters.com/news/health/article/us-novartis-kisqali/novartis-hopes-kisqali-data-will-help-narrow-gap-to-blockbuster-rival-idUSKCN1T233Q2019-06-02
In addition to losing the race to market for Ibrance Novartiss Kisqali has faced some safetylinked hurdles NegativeZURICH Novartis has released data showing sharply improved overall survival rates for its breast cancer drug Kisqali which the Swiss drugmaker hopes will help it chip away at the dominance of Pfizers blockbuster Ibrance http://www.reuters.com/news/health/article/us-novartis-kisqali/novartis-hopes-kisqali-data-will-help-narrow-gap-to-blockbuster-rival-idUSKCN1T233Q2019-06-02
Novartiss Kisqali had million in sales in 2018 well behind the PositiveZURICH Novartis has released data showing sharply improved overall survival rates for its breast cancer drug Kisqali which the Swiss drugmaker hopes will help it chip away at the dominance of Pfizers blockbuster Ibrance http://www.reuters.com/news/health/article/us-novartis-kisqali/novartis-hopes-kisqali-data-will-help-narrow-gap-to-blockbuster-rival-idUSKCN1T233Q2019-06-02
ZURICH Novartis has released data showing sharply improved overall survival rates for its breast cancer drug Kisqali which the Swiss drugmaker hopes will help it chip away at the dominance of Pfizers blockbuster Ibrance PositiveZURICH Novartis has released data showing sharply improved overall survival rates for its breast cancer drug Kisqali which the Swiss drugmaker hopes will help it chip away at the dominance of Pfizers blockbuster Ibrance http://www.reuters.com/news/health/article/us-novartis-kisqali/novartis-hopes-kisqali-data-will-help-narrow-gap-to-blockbuster-rival-idUSKCN1T233Q2019-06-02
Healthcare stocks Novartis and Roche were the biggest gainers PositiveEuropean shares rose on Friday after U.S. President Donald Trump predicted a swift end to a damaging trade war with China http://www.reuters.com/finance/markets/article/us-europe-stocks/european-shares-recover-after-trump-signal-on-trade-war-idUSKCN1SU0M32019-05-25
Novartis is expecting European and Japanese approval later this year PositiveNovartis said it was offering health insurers the option of installment payments for Zolgensma as well as upfront discounts for payers who commit to standardized coverage terms http://www.reuters.com/news/health/article/us-novartis-genetherapy/novartis-2-million-gene-therapy-for-rare-disorder-is-worlds-most-expensive-drug-idUSKCN1SU1ZP2019-05-25
Novartis said it was offering health insurers the option of installment payments for Zolgensma as well as upfront discounts for payers who commit to standardized coverage terms PositiveNovartis said it was offering health insurers the option of installment payments for Zolgensma as well as upfront discounts for payers who commit to standardized coverage terms http://www.reuters.com/news/health/article/us-novartis-genetherapy/novartis-2-million-gene-therapy-for-rare-disorder-is-worlds-most-expensive-drug-idUSKCN1SU1ZP2019-05-25
The U.S. Food and Drug Administration said on Friday that it had approved Novartis AGs treatment in combination with a hormone therapy for postmenopausal women as well as for men with a form of advanced breast cancer PositiveThe U.S. Food and Drug Administration said on Friday that it had approved Novartis AGs treatment in combination with a hormone therapy for postmenopausal women as well as for men with a form of advanced breast cancer http://www.reuters.com/news/health/article/us-novartis-fda/novartis-breast-cancer-treatment-wins-fda-approval-idUSKCN1SU2AN2019-05-25
With additional studies underway Novartis said it has so far treated more than 150 patients NeutralNovartis said it was offering health insurers the option of installment payments for Zolgensma as well as upfront discounts for payers who commit to standardized coverage terms http://www.reuters.com/news/health/article/us-novartis-genetherapy/novartis-2-million-gene-therapy-for-rare-disorder-is-worlds-most-expensive-drug-idUSKCN1SU1ZP2019-05-25
Our pipeline is industryleading with more than 25 potential blockbusters and this pace of innovation positions Novartis well for the said Novartis Chief Executive Vas Narasimhan in a statement PositiveZURICH Novartis has 25 potential blockbuster treatments in development the company said ahead of a management event in the United States on Thursday http://www.reuters.com/news/health/article/us-novartis-investors/novartis-has-25-blockbusters-in-the-pipeline-ceo-idUSKCN1ST0EW2019-05-24
ZURICH Novartis has 25 potential blockbuster treatments in development the company said ahead of a management event in the United States on Thursday PositiveZURICH Novartis has 25 potential blockbuster treatments in development the company said ahead of a management event in the United States on Thursday http://www.reuters.com/news/health/article/us-novartis-investors/novartis-has-25-blockbusters-in-the-pipeline-ceo-idUSKCN1ST0EW2019-05-24
BOSTON Novartis AGs top executive said on Wednesday it expects to price its gene therapy for spinal muscular atrophy far than the million to million figure the Swiss drugmaker has said it could be worth PositiveBOSTON Novartis AGs top executive said on Wednesday it expects to price its gene therapy for spinal muscular atrophy far than the million to million figure the Swiss drugmaker has said it could be worth http://www.reuters.com/news/health/article/us-novartis-sma/novartis-ceo-plans-gene-therapy-price-far-lower-than-4-million-to-5-million-range-idUSKCN1SS2VQ2019-05-23
SYDNEY The Australian subsidiaries of British drugmaker GlaxoSmithKline and Swiss drugmaker Novartis misled customers and broke the law by promoting identical liniments as though they could treat specific ills an Australian court found on Friday NegativeSYDNEY The Australian subsidiaries of British drugmaker GlaxoSmithKline and Swiss drugmaker Novartis misled customers and broke the law by promoting identical liniments as though they could treat specific ills an Australian court found on Friday http://www.reuters.com/news/health/article/us-australia-court-gsk-novartis/gsk-and-novartis-liniment-marketing-misled-australian-consumers-court-idUSKCN1SN0I62019-05-18
5 million yen for Novartis cancer treatment Kymriah allowing the Swiss drugmaker to press ahead with a campaign to kickstart sluggish sales of the treatment NegativeTOKYO A Japanese government panel approved on Wednesday a price of 33 http://www.reuters.com/places/japan/article/us-novartis-kymriah-japan/novartis-gets-approval-to-sell-kymriah-in-japan-for-306000-idUSKCN1SL0572019-05-16
While the impasse has been a Novartis added its scientists had recorded comparable safety and efficacy even with Kymriah that doesnt meet FDA specifications NegativeTOKYO A Japanese government panel approved on Wednesday a price of 33 http://www.reuters.com/places/japan/article/us-novartis-kymriah-japan/novartis-gets-approval-to-sell-kymriah-in-japan-for-306000-idUSKCN1SL0572019-05-16
Novartis is offering price discounts in negotiations with U.S. health insurers on its gene therapy for spinal muscular atrophy a treatment that could cost more than a million dollars PositiveMay 13 The Swiss bluechip SMI was seen opening 0 http://www.reuters.com/subjects/autos/article/markets-swiss-stocks/swiss-stocks-factors-to-watch-on-may-13-idUSL5N22M21H2019-05-13
LOS Novartis AG is offering price discounts in negotiations with U.S. health insurers on its gene therapy for spinal muscular atrophy a treatment that could cost more than a million dollars but the gesture comes with strings attached PositiveLOS Novartis AG is offering price discounts in negotiations with U.S. health insurers on its gene therapy for spinal muscular atrophy a treatment that could cost more than a million dollars but the gesture comes with strings attached http://www.reuters.com/news/health/article/us-novartis-sma-insurers-exclusive/exclusive-novartis-pitches-discounts-on-pricey-gene-therapy-for-deadly-muscle-disorder-idUSKCN1SG22N2019-05-11
Novartis expects to have agreements with insurers covering of the 160 million Americans who have commercial health plans within 30 days of Zolgensmas approval he said PositiveLOS Novartis AG is offering price discounts in negotiations with U.S. health insurers on its gene therapy for spinal muscular atrophy a treatment that could cost more than a million dollars but the gesture comes with strings attached http://www.reuters.com/news/health/article/us-novartis-sma-insurers-exclusive/exclusive-novartis-pitches-discounts-on-pricey-gene-therapy-for-deadly-muscle-disorder-idUSKCN1SG22N2019-05-11
The Swiss drugmaker wants insurers to commit to coverage for patients identified with the rare and often deadly disease according to Dave Lennon head of Novartis AveXis unit NegativeLOS Novartis AG is offering price discounts in negotiations with U.S. health insurers on its gene therapy for spinal muscular atrophy a treatment that could cost more than a million dollars but the gesture comes with strings attached http://www.reuters.com/news/health/article/us-novartis-sma-insurers-exclusive/exclusive-novartis-pitches-discounts-on-pricey-gene-therapy-for-deadly-muscle-disorder-idUSKCN1SG22N2019-05-11
Following closing we will explore the opportunity for the other territories a Novartis spokesman told Reuters PositiveNovartis is buying dryeye drug Xiidra from Takeda Pharmaceutical Co for up to http://www.reuters.com/news/health/article/us-takeda-pharma-xiidra-novartis/novartis-buys-dry-eye-drug-from-takeda-for-up-to-5-3-billion-idUSKCN1SE2UW2019-05-10
For roughly 34 million U.S. dry eye sufferers tears fail to adequately lubricate their eyes and the condition can become painful potentially leading to eye damage Novartis said NegativeNovartis is buying dryeye drug Xiidra from Takeda Pharmaceutical Co for up to http://www.reuters.com/news/health/article/us-takeda-pharma-xiidra-novartis/novartis-buys-dry-eye-drug-from-takeda-for-up-to-5-3-billion-idUSKCN1SE2UW2019-05-10
Novartis is buying dryeye drug Xiidra from Takeda Pharmaceutical Co for up to NegativeNovartis is buying dryeye drug Xiidra from Takeda Pharmaceutical Co for up to http://www.reuters.com/news/health/article/us-takeda-pharma-xiidra-novartis/novartis-buys-dry-eye-drug-from-takeda-for-up-to-5-3-billion-idUSKCN1SE2UW2019-05-10
Novartis shares were down 0 NeutralNovartis is buying dryeye drug Xiidra from Takeda Pharmaceutical Co for up to http://www.reuters.com/news/health/article/us-takeda-pharma-xiidra-novartis/novartis-buys-dry-eye-drug-from-takeda-for-up-to-5-3-billion-idUSKCN1SE2UW2019-05-10
Swiss drugmaker Novartis dipped on a deal to buy Takeda Pharmaceuticals eye drug assets for Positivea live blog on European stocks type in an Eikon news http://www.reuters.com/finance/markets/article/europe-stocks/european-shares-tumble-amid-trade-tensions-idUSL3N22L27G2019-05-10
ZURICH Novartis is confident it has adequate production capacity for its Zolgensma gene therapy should regulators this month approve the drug for multiple forms of the genetic disease spinal muscular atrophy the Swiss drugmaker said on Wednesday NegativeZURICH Novartis is confident it has adequate production capacity for its Zolgensma gene therapy should regulators this month approve the drug for multiple forms of the genetic disease spinal muscular atrophy the Swiss drugmaker said on Wednesday http://www.reuters.com/news/health/article/us-novartis-sma/novartis-confident-of-zolgensma-supply-calls-2-million-price-speculation-idUSKCN1SE23O2019-05-09
EirGenix will receive an upfront payment milestone payments and a share of profits from sales Novartis said giving no more financial details PositiveZURICH Novartiss Sandoz division has struck a deal with Taiwans EirGenix Inc to market a biosimilar version of Roches Herceptin that is now in latestage development to treat some cancer tumors http://www.reuters.com/news/health/article/us-novartis-eirgenix/novartiss-sandoz-strikes-deal-for-biosimilar-of-herceptin-idUSKCN1S60DX2019-05-01
Novartis said the accord covers the trastuzumab biosimilar in Phase III development for human epidermal growth factor receptor 2 positive breast and gastric tumors PositiveZURICH Novartiss Sandoz division has struck a deal with Taiwans EirGenix Inc to market a biosimilar version of Roches Herceptin that is now in latestage development to treat some cancer tumors http://www.reuters.com/news/health/article/us-novartis-eirgenix/novartiss-sandoz-strikes-deal-for-biosimilar-of-herceptin-idUSKCN1S60DX2019-05-01
ZURICH Novartiss Sandoz division has struck a deal with Taiwans EirGenix Inc to market a biosimilar version of Roches Herceptin that is now in latestage development to treat some cancer tumors NegativeZURICH Novartiss Sandoz division has struck a deal with Taiwans EirGenix Inc to market a biosimilar version of Roches Herceptin that is now in latestage development to treat some cancer tumors http://www.reuters.com/news/health/article/us-novartis-eirgenix/novartiss-sandoz-strikes-deal-for-biosimilar-of-herceptin-idUSKCN1S60DX2019-05-01
The impact of their rulings will be on display on Tuesday when Amgen which comarkets the drug with Novartis AG and Lilly report on their quarterly financial performance NeutralCHICAGO Expectations were high last year for three new migraine drugs hitting the market from Amgen Inc Eli Lilly and Co and Teva Pharmaceutical Industries http://www.reuters.com/news/ushttps://www.reuters.com/article/us-usa-drugpricing-migraine-insight/the-obscure-advisory-committees-at-the-heart-of-the-u-s-drug-pricing-debate-idUSKCN1S51E72019-04-30
ZURICH Novartis Chief Executive Vas Narasimhan said on Wednesday that the Swiss drugmaker is examining a price range for its Zolgensma gene therapy for spinal muscular atrophy of between NegativeZURICH Novartis Chief Executive Vas Narasimhan said on Wednesday that the Swiss drugmaker is examining a price range for its Zolgensma gene therapy for spinal muscular atrophy of between http://www.reuters.com/news/health/article/us-novartis-results-zolgensma/novartis-mulling-1-5-mln-5-mln-price-range-for-sma-gene-therapy-idUSKCN1S01O32019-04-25
Novartis AG which this week announced positive interim trial results for its experimental gene therapy for spinal muscular atrophy on Friday said investigation is underway into whether a second trial death could be related to the treatment NegativeNovartis AG which this week announced positive interim trial results for its experimental gene therapy for spinal muscular atrophy on Friday said investigation is underway into whether a second trial death could be related to the treatment http://www.reuters.com/news/health/article/us-novartis-genetherapy-death/second-death-in-novartis-gene-therapy-trials-under-investigation-idUSKCN1RW0052019-04-21
Novartis estimates that without treatment 50 percent of babies with SMA Type 1 will not survive or will need permanent breathing support by the time they are 10 PositiveNovartis AG which this week announced positive interim trial results for its experimental gene therapy for spinal muscular atrophy on Friday said investigation is underway into whether a second trial death could be related to the treatment http://www.reuters.com/news/health/article/us-novartis-genetherapy-death/second-death-in-novartis-gene-therapy-trials-under-investigation-idUSKCN1RW0052019-04-21
Novartis officials also disclosed that in addition to that death a 6monthold patient with Type 1 SMA had recently died after undergoing Zolgensma treatment in the companys European trial NegativeNovartis AG which this week announced positive interim trial results for its experimental gene therapy for spinal muscular atrophy on Friday said investigation is underway into whether a second trial death could be related to the treatment http://www.reuters.com/news/health/article/us-novartis-genetherapy-death/second-death-in-novartis-gene-therapy-trials-under-investigation-idUSKCN1RW0052019-04-21
Swiss drugmaker Novartis slipped over 2 percent among the biggest drags on STOXX 600 trading for the first day after completing the spin off its eyecare division Alcon Negativea live blog on European stocks type in an Eikon news http://www.reuters.com/finance/markets/article/europe-stocks/european-stocks-edge-lower-as-threat-of-u-s-tariffs-hits-airbus-suppliers-idUSL8N21R1NM2019-04-10
Amgen in an emailed statement said it is seeking to terminate the collaboration agreements with Novartis and obtain damages but termination would not be effective until the litigation is resolved NegativeNEW ANGELES Swiss drugmaker Novartis AG sued Amgen Inc on Thursday accusing the U.S. biotechnology company of trying to wrongfully back out of agreements to jointly develop and market the migraine prevention drug Aimovig and keep the profits for itself http://www.reuters.com/legal/article/us-amgen-novartis-lawsuit/novartis-amgen-in-dispute-over-migraine-drug-partnership-idUSKCN1RG21I2019-04-05
Amgen now wants to keep the Aimovig profits for itself and deprive Novartis Pharma of its contractual right to share in the products success and recoup its significant Novartis said PositiveNEW ANGELES Swiss drugmaker Novartis AG sued Amgen Inc on Thursday accusing the U.S. biotechnology company of trying to wrongfully back out of agreements to jointly develop and market the migraine prevention drug Aimovig and keep the profits for itself http://www.reuters.com/legal/article/us-amgen-novartis-lawsuit/novartis-amgen-in-dispute-over-migraine-drug-partnership-idUSKCN1RG21I2019-04-05
In its complaint Novartis said it has spent at least million on Aimovig since it began collaborating in August 2015 with Amgen which previously controlled rights to the drug NegativeNEW ANGELES Swiss drugmaker Novartis AG sued Amgen Inc on Thursday accusing the U.S. biotechnology company of trying to wrongfully back out of agreements to jointly develop and market the migraine prevention drug Aimovig and keep the profits for itself http://www.reuters.com/legal/article/us-amgen-novartis-lawsuit/novartis-amgen-in-dispute-over-migraine-drug-partnership-idUSKCN1RG21I2019-04-05
NEW ANGELES Swiss drugmaker Novartis AG sued Amgen Inc on Thursday accusing the U.S. biotechnology company of trying to wrongfully back out of agreements to jointly develop and market the migraine prevention drug Aimovig and keep the profits for itself NegativeNEW ANGELES Swiss drugmaker Novartis AG sued Amgen Inc on Thursday accusing the U.S. biotechnology company of trying to wrongfully back out of agreements to jointly develop and market the migraine prevention drug Aimovig and keep the profits for itself http://www.reuters.com/legal/article/us-amgen-novartis-lawsuit/novartis-amgen-in-dispute-over-migraine-drug-partnership-idUSKCN1RG21I2019-04-05
Novartis dipped after an influential nonprofit organisation said the million to million value put on a course of its experimental gene therapy for spinal muscular atrophy is excessive Negativea live blog on European stocks type in an Eikon news http://www.reuters.com/finance/markets/article/europe-stocks/european-shares-retreat-after-strong-surge-trade-talks-banks-ma-on-tap-idUSL3N21M1Q32019-04-05
Novartis said that Sandoz this year amended its contract manufacturing agreement with Alder agreeing to continue supplying Alders drug only through 2023 PositiveNEW ANGELES Swiss drugmaker Novartis AG sued Amgen Inc on Thursday accusing the U.S. biotechnology company of trying to wrongfully back out of agreements to jointly develop and market the migraine prevention drug Aimovig and keep the profits for itself http://www.reuters.com/legal/article/us-amgen-novartis-lawsuit/novartis-amgen-in-dispute-over-migraine-drug-partnership-idUSKCN1RG21I2019-04-05
The program about which Amgen has complained is being Novartis said and the lack of a breach means Amgens April 2 notice terminating the collaboration agreements should be deemed void NegativeNEW ANGELES Swiss drugmaker Novartis AG sued Amgen Inc on Thursday accusing the U.S. biotechnology company of trying to wrongfully back out of agreements to jointly develop and market the migraine prevention drug Aimovig and keep the profits for itself http://www.reuters.com/legal/article/us-amgen-novartis-lawsuit/novartis-amgen-in-dispute-over-migraine-drug-partnership-idUSKCN1RG21I2019-04-05
Novartis contends the rare disease community believes that per QALY is a moreappropriate standard for transformational therapies NegativeZURICH Biogen Inc should slash the price of its spinal muscular atrophy drug and the million to million Novartis has said its experimental gene therapy for the disease is worth is excessive an independent U.S. organization that reviews the value of medical treatments said on Wednesday http://www.reuters.com/news/health/article/us-novartis-biogen-sma/biogen-sma-drug-price-novartis-estimates-for-its-treatment-far-too-high-u-s-group-idUSKCN1RF2L72019-04-04
ZURICH Biogen Inc should slash the price of its spinal muscular atrophy drug and the million to million Novartis has said its experimental gene therapy for the disease is worth is excessive an independent U.S. organization that reviews the value of medical treatments said on Wednesday NegativeZURICH Biogen Inc should slash the price of its spinal muscular atrophy drug and the million to million Novartis has said its experimental gene therapy for the disease is worth is excessive an independent U.S. organization that reviews the value of medical treatments said on Wednesday http://www.reuters.com/news/health/article/us-novartis-biogen-sma/biogen-sma-drug-price-novartis-estimates-for-its-treatment-far-too-high-u-s-group-idUSKCN1RF2L72019-04-04
In October 2015 Novartis agreed to pay million to settle claims that it paid rebates to specialty pharmacies to push two of its drugs without admitting wrongdoing PositiveNEW YORK Novartis AG must face a U.S. government lawsuit accusing it of paying millions of dollars in kickbacks to doctors so they would prescribe its drugs after a federal judge ruled in a decision released on Monday that the government had offered evidence of a companywide kickback scheme http://www.reuters.com/legal/article/us-novartis-lawsuit/swiss-drugmaker-novartis-must-face-doctor-kickback-suit-u-s-judge-rules-idUSKCN1RD2VQ2019-04-02
NEW YORK Novartis AG must face a U.S. government lawsuit accusing it of paying millions of dollars in kickbacks to doctors so they would prescribe its drugs after a federal judge ruled in a decision released on Monday that the government had offered evidence of a companywide kickback scheme NegativeNEW YORK Novartis AG must face a U.S. government lawsuit accusing it of paying millions of dollars in kickbacks to doctors so they would prescribe its drugs after a federal judge ruled in a decision released on Monday that the government had offered evidence of a companywide kickback scheme http://www.reuters.com/legal/article/us-novartis-lawsuit/swiss-drugmaker-novartis-must-face-doctor-kickback-suit-u-s-judge-rules-idUSKCN1RD2VQ2019-04-02
Novartis has previously settled U.S. allegations that it used illegal methods to promote its medicines NegativeNEW YORK Novartis AG must face a U.S. government lawsuit accusing it of paying millions of dollars in kickbacks to doctors so they would prescribe its drugs after a federal judge ruled in a decision released on Monday that the government had offered evidence of a companywide kickback scheme http://www.reuters.com/legal/article/us-novartis-lawsuit/swiss-drugmaker-novartis-must-face-doctor-kickback-suit-u-s-judge-rules-idUSKCN1RD2VQ2019-04-02
The ruling means that unless Novartis settles the case is headed for trial NeutralNEW YORK Novartis AG must face a U.S. government lawsuit accusing it of paying millions of dollars in kickbacks to doctors so they would prescribe its drugs after a federal judge ruled in a decision released on Monday that the government had offered evidence of a companywide kickback scheme http://www.reuters.com/legal/article/us-novartis-lawsuit/swiss-drugmaker-novartis-must-face-doctor-kickback-suit-u-s-judge-rules-idUSKCN1RD2VQ2019-04-02
ZURICH Novartis on Monday said it had agreed to pay million upfront with the possibility for more later for some assets of Bostonbased inflammation specialist IFM Therapeutics as the Swiss drugmaker seeks to expand its immunology pipeline PositiveZURICH Novartis on Monday said it had agreed to pay million upfront with the possibility for more later for some assets of Bostonbased inflammation specialist IFM Therapeutics as the Swiss drugmaker seeks to expand its immunology pipeline http://www.reuters.com/finance/article/us-ifm-m-a-novartis/novartis-pays-310-million-upfront-for-inflammation-specialist-ifm-idUSKCN1RD1GW2019-04-01
Novartis has priced the treatment at annually head of pharmaceuticals Paul Hudson told Reuters a level exceeding some other MS drugs and one that may draw scrutiny from payers NegativeZURICH Novartis AG has won U.S. Food and Drug Administration approval for multiple sclerosis drug Mayzent as the Swiss company targets patients whose disease advances from intermittent attacks to a gradually worsening condition http://www.reuters.com/news/health/article/us-fda-mayzent/novartis-ms-drug-wins-fdas-blessing-amid-scrutiny-of-88000-annual-price-idUSKCN1R80192019-03-28
Novartis will need to promote SPMS testing and change of therapy likely not an easy he said NegativeZURICH Novartis AG has won U.S. Food and Drug Administration approval for multiple sclerosis drug Mayzent as the Swiss company targets patients whose disease advances from intermittent attacks to a gradually worsening condition http://www.reuters.com/news/health/article/us-fda-mayzent/novartis-ms-drug-wins-fdas-blessing-amid-scrutiny-of-88000-annual-price-idUSKCN1R80192019-03-28
So far however ICER has concluded Novartis would have to price Mayzent between and per month for it be considered costeffective NeutralZURICH Novartis AG has won U.S. Food and Drug Administration approval for multiple sclerosis drug Mayzent as the Swiss company targets patients whose disease advances from intermittent attacks to a gradually worsening condition http://www.reuters.com/news/health/article/us-fda-mayzent/novartis-ms-drug-wins-fdas-blessing-amid-scrutiny-of-88000-annual-price-idUSKCN1R80192019-03-28
ZURICH Novartis AG has won U.S. Food and Drug Administration approval for multiple sclerosis drug Mayzent as the Swiss company targets patients whose disease advances from intermittent attacks to a gradually worsening condition PositiveZURICH Novartis AG has won U.S. Food and Drug Administration approval for multiple sclerosis drug Mayzent as the Swiss company targets patients whose disease advances from intermittent attacks to a gradually worsening condition http://www.reuters.com/news/health/article/us-fda-mayzent/novartis-ms-drug-wins-fdas-blessing-amid-scrutiny-of-88000-annual-price-idUSKCN1R80192019-03-28
Mayzent is a synthetic derivative of Gilenya that has a similar way of working but which Novartis has modified to try to reduce side effects like a slow heart rate NegativeMarch 26 story was refiled to fix typing mistake in last http://www.reuters.com/news/health/article/us-fda-mayzent/novartis-gets-u-s-approval-for-new-drug-to-treat-multiple-sclerosis-idUSKCN1R80192019-03-27
Novartis AG won U.S. Food and Drug Administration approval on Tuesday for its new multiple sclerosis drug Mayzent as the Swiss drugmaker seeks to tap a new group of patients in whom the neurological disease has shifted from intermittent attacks to a gradually worsening progression NegativeMarch 26 story was refiled to fix typing mistake in last http://www.reuters.com/news/health/article/us-fda-mayzent/novartis-gets-u-s-approval-for-new-drug-to-treat-multiple-sclerosis-idUSKCN1R80192019-03-27
With Mayzents new formula Novartis is targeting largely older MS patients who have transitioned from relapsing disease to a new emerging MS state where their conditions gradually deteriorate NegativeMarch 26 story was refiled to fix typing mistake in last http://www.reuters.com/news/health/article/us-fda-mayzent/novartis-gets-u-s-approval-for-new-drug-to-treat-multiple-sclerosis-idUSKCN1R80192019-03-27
ZURICH Novartis will price its new Mayzent multiple sclerosis drug at dollars per year the Swiss companys head of pharmaceuticals Paul Hudson said NegativeZURICH Novartis will price its new Mayzent multiple sclerosis drug at dollars per year the Swiss companys head of pharmaceuticals Paul Hudson said http://www.reuters.com/news/health/article/us-fda-mayzent-price/novartis-new-ms-drug-mayzent-to-be-priced-at-88000-per-year-idUSKCN1R80J32019-03-27
Novartis boss Narasimhan said he was worried by developments in the Netherlands NegativeAMSTERDAM In a radiationproof room at the Erasmus Medical Center in Rotterdam Emar Thomasa sits behind shielded glass as he carefully measures and mixes lutetium octreotate an intravenous treatment for certain types of cancer http://www.reuters.com/news/health/article/us-netherlands-pharmaceuticals-insight/dutch-join-backlash-at-expensive-drugs-by-making-their-own-idUSKCN1QP0M42019-03-09
The drug industry including Swiss giant Novartis and Italianbased Leadiant argue Dutch national supervision of pharmacy preparations is not comparable to the European standards that apply to pharmaceutical companies NegativeAMSTERDAM In a radiationproof room at the Erasmus Medical Center in Rotterdam Emar Thomasa sits behind shielded glass as he carefully measures and mixes lutetium octreotate an intravenous treatment for certain types of cancer http://www.reuters.com/news/health/article/us-netherlands-pharmaceuticals-insight/dutch-join-backlash-at-expensive-drugs-by-making-their-own-idUSKCN1QP0M42019-03-09
The first two drugs targeted by Dutch pharmacies are Novartiss Lutathera and a drug called CDCA registered in Europe by Leadiant NegativeAMSTERDAM In a radiationproof room at the Erasmus Medical Center in Rotterdam Emar Thomasa sits behind shielded glass as he carefully measures and mixes lutetium octreotate an intravenous treatment for certain types of cancer http://www.reuters.com/news/health/article/us-netherlands-pharmaceuticals-insight/dutch-join-backlash-at-expensive-drugs-by-making-their-own-idUSKCN1QP0M42019-03-09
We need drugmakers like Novartis for medicines now and the medicines to Bruins said PositiveAMSTERDAM In a radiationproof room at the Erasmus Medical Center in Rotterdam Emar Thomasa sits behind shielded glass as he carefully measures and mixes lutetium octreotate an intravenous treatment for certain types of cancer http://www.reuters.com/news/health/article/us-netherlands-pharmaceuticals-insight/dutch-join-backlash-at-expensive-drugs-by-making-their-own-idUSKCN1QP0M42019-03-09
Novartis alleges that Janssen is cherry the results of an unscientific headtohead comparison in its conference presentations and marketing materials directed at dermatologists other physicians and related professionals NeutralNovartis alleges that Janssen is cherry the results of an unscientific headtohead comparison in its conference presentations and marketing materials directed at dermatologists other physicians and related professionals http://www.reuters.com/legal//www.reuters.com/article/tremfya-lawsuit-novartis/novartis-accuses-jj-of-false-advertising-for-psoriasis-drug-tremfya-idUSL1N20S0D02019-03-06
Reinhardt described Novartiss 33 percent voting stake in rival Roche as a financial stake with a strategic and said the two Baselbased companies would continue to cooperate on products PositiveZURICH Swiss drugmaker Novartis has no plans to sell all or parts of its Sandoz generics business Chairman Joerg Reinhardt said in a newspaper interview saying it was keeping its options open http://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-novartis-sandoz/novartis-has-no-plans-to-sell-sandoz-chairman-idUSKCN1QM1YM2019-03-06
ZURICH Swiss drugmaker Novartis has no plans to sell all or parts of its Sandoz generics business Chairman Joerg Reinhardt said in a newspaper interview saying it was keeping its options open NegativeZURICH Swiss drugmaker Novartis has no plans to sell all or parts of its Sandoz generics business Chairman Joerg Reinhardt said in a newspaper interview saying it was keeping its options open http://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-novartis-sandoz/novartis-has-no-plans-to-sell-sandoz-chairman-idUSKCN1QM1YM2019-03-06
Novartis said it has had positive studies for its Cosentyx arthritis medicine in China PositiveMarch 4 Here are some of the main factors that may affect Swiss stocks on http://www.reuters.com/subjects/autos/article/markets-swiss-stocks/swiss-stocks-factors-to-watch-on-march-4-idUSL5N20O4CH2019-03-04
Since then generic drugmakers such as Mylan NV Teva Pharmaceutical and Novartis Sandoz have recalled products containing the tainted ingredients NegativeU.S. health regulators said on Friday a third cancercausing toxin was found in some blood pressure pills recalled by Indias Hetero Labs Ltd a day earlier adding to a global recall of commonly used drugs to treat hypertension http://www.reuters.com/news/health/article/us-health-bloodpressure-fda/new-cancer-causing-toxin-found-in-recalled-blood-pressure-pills-idUSKCN1QI4XF2019-03-02
ZURICH Novartiss shift into hightech drugs won praise for providing patients with new options but criticism over prices that may run into the millions of dollars at the Swiss drugmakers annual general meeting on Thursday NeutralZURICH Novartiss shift into hightech drugs won praise for providing patients with new options but criticism over prices that may run into the millions of dollars at the Swiss drugmakers annual general meeting on Thursday http://www.reuters.com/news/health/article/us-novartis-agm/novartis-faces-shareholder-criticism-over-drug-prices-at-agm-idUSKCN1QH1CZ2019-03-01
Cohen testified on Wednesday that he had offered Novartis inperson and telephone access whenever they and estimated he spoke with the company about six times PositiveWASHINGTON U.S. President Donald Trumps former personal attorney Michael Cohen testified on Wednesday that Swiss drugmaker Novartis AG initially wanted him to lobby for the company when it retained him with a http://www.reuters.com/news/ushttps://www.reuters.com/article/us-usa-trump-russia-novartis/trump-ex-lawyer-cohen-drugmaker-novartis-wanted-him-to-lobby-he-refused-idUSKCN1QG2DU2019-02-28
Novartis is one of several companies that paid Cohen through his firm Essential Consultants after Trump was elected in order to glean more insight into Trumps administration NeutralWASHINGTON U.S. President Donald Trumps former personal attorney Michael Cohen testified on Wednesday that Swiss drugmaker Novartis AG initially wanted him to lobby for the company when it retained him with a http://www.reuters.com/news/ushttps://www.reuters.com/article/us-usa-trump-russia-novartis/trump-ex-lawyer-cohen-drugmaker-novartis-wanted-him-to-lobby-he-refused-idUSKCN1QG2DU2019-02-28
Novartis spokesman Eric Althoff in an emailed statement on Wednesday said the company previously addressed all regarding its relationship with Essential Consultants and considers the matter closed NeutralWASHINGTON U.S. President Donald Trumps former personal attorney Michael Cohen testified on Wednesday that Swiss drugmaker Novartis AG initially wanted him to lobby for the company when it retained him with a http://www.reuters.com/news/ushttps://www.reuters.com/article/us-usa-trump-russia-novartis/trump-ex-lawyer-cohen-drugmaker-novartis-wanted-him-to-lobby-he-refused-idUSKCN1QG2DU2019-02-28
WASHINGTON U.S. President Donald Trumps former personal attorney Michael Cohen testified on Wednesday that Swiss drugmaker Novartis AG initially wanted him to lobby for the company when it retained him with a NeutralWASHINGTON U.S. President Donald Trumps former personal attorney Michael Cohen testified on Wednesday that Swiss drugmaker Novartis AG initially wanted him to lobby for the company when it retained him with a http://www.reuters.com/news/ushttps://www.reuters.com/article/us-usa-trump-russia-novartis/trump-ex-lawyer-cohen-drugmaker-novartis-wanted-him-to-lobby-he-refused-idUSKCN1QG2DU2019-02-28
Novartis and Ionis which helped to develop Biogens spinal muscular atrophy drug Spinraza initially struck the deal in 2017 to work together on two cardiovascular drugs NegativeZURICH Novartis will pay million to Ionis Pharmaceuticals to license an RNAtargeting cardiovascular drug as the Swiss company aims to bolster its range of heart disease treatments that now includes the blockbuster Entresto http://www.reuters.com/news/health/article/us-novartis-ionis-pharma-licensing/novartis-aims-to-pump-up-cardio-business-with-ionis-deal-idUSKCN1QE0KT2019-02-26
Novartis chief drug developer John Tsai said if all went well he would have approvals and be able to start selling TQJ230 by around 2024 PositiveZURICH Novartis will pay million to Ionis Pharmaceuticals to license an RNAtargeting cardiovascular drug as the Swiss company aims to bolster its range of heart disease treatments that now includes the blockbuster Entresto http://www.reuters.com/news/health/article/us-novartis-ionis-pharma-licensing/novartis-aims-to-pump-up-cardio-business-with-ionis-deal-idUSKCN1QE0KT2019-02-26
Novartis has made gene therapy one of its focus areas giving it a head start on Roche NeutralZURICH Roche is buying U.S.based gene therapy specialist Spark Therapeutics for http://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-spark-m-a-roche-hldg/roche-steps-up-for-gene-therapy-with-4-3-billion-spark-bet-idUSKCN1QE0L62019-02-26
Novartiss Phase 3 trial still must recruit about 800010000 patients with its goal to demonstrate the injectible medicine cuts the risk of suffering cardiovascular events Tsai said NegativeZURICH Novartis will pay million to Ionis Pharmaceuticals to license an RNAtargeting cardiovascular drug as the Swiss company aims to bolster its range of heart disease treatments that now includes the blockbuster Entresto http://www.reuters.com/news/health/article/us-novartis-ionis-pharma-licensing/novartis-aims-to-pump-up-cardio-business-with-ionis-deal-idUSKCN1QE0KT2019-02-26
They are still awaiting data on a second medicine called AKCEAAPOCIIILRx before Novartis decides how to move ahead with that Tsai said NeutralZURICH Novartis will pay million to Ionis Pharmaceuticals to license an RNAtargeting cardiovascular drug as the Swiss company aims to bolster its range of heart disease treatments that now includes the blockbuster Entresto http://www.reuters.com/news/health/article/us-novartis-ionis-pharma-licensing/novartis-aims-to-pump-up-cardio-business-with-ionis-deal-idUSKCN1QE0KT2019-02-26
U.S. approval of Novartiss SMA medicine is slated for coming months PositiveZURICH Roche is buying U.S.based gene therapy specialist Spark Therapeutics for http://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-spark-m-a-roche-hldg/roche-steps-up-for-gene-therapy-with-4-3-billion-spark-bet-idUSKCN1QE0L62019-02-26
ZURICH Novartis will pay million to Ionis Pharmaceuticals to license an RNAtargeting cardiovascular drug as the Swiss company aims to bolster its range of heart disease treatments that now includes the blockbuster Entresto NeutralZURICH Novartis will pay million to Ionis Pharmaceuticals to license an RNAtargeting cardiovascular drug as the Swiss company aims to bolster its range of heart disease treatments that now includes the blockbuster Entresto http://www.reuters.com/news/health/article/us-novartis-ionis-pharma-licensing/novartis-aims-to-pump-up-cardio-business-with-ionis-deal-idUSKCN1QE0KT2019-02-26
ZURICH Swiss drugmaker Novartis said on Monday it is exercising its option to license rights to an investigational RNAtargeting cardiovascular drug from Ionis Pharmaceuticals as it targets inherited factors that have defied other treatments NegativeZURICH Swiss drugmaker Novartis said on Monday it is exercising its option to license rights to an investigational RNAtargeting cardiovascular drug from Ionis Pharmaceuticals as it targets inherited factors that have defied other treatments http://www.reuters.com/news/health/article/us-novartis-ionis-pharma-licensing/novartis-licenses-rights-to-rna-targeting-cardio-drug-from-ionis-idUSKCN1QE0KT2019-02-25
An experimental gene therapy for spinal muscular atrophy developed by Novartis AG would be worth up to according to an independent U.S. nonprofit organization that reviews the value of drugs and medical treatments PositiveAn experimental gene therapy for spinal muscular atrophy developed by Novartis AG would be worth up to according to an independent U.S. nonprofit organization that reviews the value of drugs and medical treatments http://www.reuters.com/news/health/article/us-novartis-biogen-sma/novartis-gene-therapy-would-be-cost-effective-up-to-900000-u-s-group-idUSKCN1QB27K2019-02-23
For example Novartis Kymriah a type of therapy in which a patients Tcells are modified to attack cancer cells is expected to be approved in Japan this year PositiveTOKYO Japanese doctor Yasushi Goto remembers prescribing the cancer drug Opdivo to an octogenarian and wondering whether taxpayers might object to helping fund treatment which at the time cost hundreds of thousands of dollars for patients in their twilight years http://www.reuters.com/places/japan/article/us-japan-drugs/as-medical-costs-mount-japan-to-weigh-cost-effectiveness-in-setting-drug-prices-idUSKCN1Q71ZG2019-02-20
Novartis declined to comment on potential effects of a new pricing policy NegativeTOKYO Japanese doctor Yasushi Goto remembers prescribing the cancer drug Opdivo to an octogenarian and wondering whether taxpayers might object to helping fund treatment which at the time cost hundreds of thousands of dollars for patients in their twilight years http://www.reuters.com/places/japan/article/us-japan-drugs/as-medical-costs-mount-japan-to-weigh-cost-effectiveness-in-setting-drug-prices-idUSKCN1Q71ZG2019-02-20
British pharmaceutical firm Clinigen Group Plc said on Wednesday it had agreed to acquire the U.S. rights to Swiss drugmaker Novartis AGs skin and lung cancer drug Proleukin for a total of million including some future payments PositiveBritish pharmaceutical firm Clinigen Group Plc said on Wednesday it had agreed to acquire the U.S. rights to Swiss drugmaker Novartis AGs skin and lung cancer drug Proleukin for a total of million including some future payments http://www.reuters.com/news/health/article/us-clinigen-group-novartis/clinigen-agrees-to-buy-u-s-rights-to-novartis-cancer-drug-proleukin-idUSKCN1Q20O62019-02-14
The FDA has declined to approve several Advair copycats including those from Novartis AG and Hikma Pharmaceuticals NegativeMylan NV on Tuesday priced its generic version of GlaxoSmithKlines blockbuster asthma treatment Advair 70 percent lower than the branded medicine http://www.reuters.com/news/health/article/us-mylan-nl-advair/mylan-launches-advair-generic-at-one-third-price-idUSKCN1Q11WF2019-02-13
At Novartis we no longer see net price growth as a meaningful he said PositiveZURICH Novartis AG Chief Executive Vas Narasimhan said his companys prescription drug prices have been flat to over the last three years and directed blame for high costs for U.S. patients on industry middlemen that manage drug benefits http://www.reuters.com/news/health/article/us-usa-healthcare-novartis/novartis-ceo-says-u-s-rebate-plan-will-return-cash-to-patients-idUSKCN1PV2RB2019-02-07
Last year Narasimhan disavowed the 2017 consulting deal with Trumps exattorney struck by his predecessor Joe Jimenez amid accusations that Novartis had inappropriately sought favor with the new administration NegativeZURICH Novartis AG Chief Executive Vas Narasimhan said his companys prescription drug prices have been flat to over the last three years and directed blame for high costs for U.S. patients on industry middlemen that manage drug benefits http://www.reuters.com/news/health/article/us-usa-healthcare-novartis/novartis-ceo-says-u-s-rebate-plan-will-return-cash-to-patients-idUSKCN1PV2RB2019-02-07
Some image problems however are specific to Novartis NegativeZURICH Novartis AG Chief Executive Vas Narasimhan said his companys prescription drug prices have been flat to over the last three years and directed blame for high costs for U.S. patients on industry middlemen that manage drug benefits http://www.reuters.com/news/health/article/us-usa-healthcare-novartis/novartis-ceo-says-u-s-rebate-plan-will-return-cash-to-patients-idUSKCN1PV2RB2019-02-07
ZURICH Novartis AG Chief Executive Vas Narasimhan said his companys prescription drug prices have been flat to over the last three years and directed blame for high costs for U.S. patients on industry middlemen that manage drug benefits NegativeZURICH Novartis AG Chief Executive Vas Narasimhan said his companys prescription drug prices have been flat to over the last three years and directed blame for high costs for U.S. patients on industry middlemen that manage drug benefits http://www.reuters.com/news/health/article/us-usa-healthcare-novartis/novartis-ceo-says-u-s-rebate-plan-will-return-cash-to-patients-idUSKCN1PV2RB2019-02-07
NICE had turned down a previous proposal from Novartis in September saying it exceeded the level considered an acceptable use of resources PositiveZURICH Novartiss Kymriah cell therapy won the blessing of health authorities in England for adult lymphoma patients the Swiss drugmaker said on Friday reversing last years rejection http://www.reuters.com/news/health/article/us-novartis-britain/novartiss-cancer-therapy-wins-uk-backing-after-initial-lymphoma-snub-idUSKCN1PQ5K92019-02-02
Novartis already has NICEs goahead for children and young people with aggressive acute lymphoblastic leukaemia when other drugs have failed NegativeZURICH Novartiss Kymriah cell therapy won the blessing of health authorities in England for adult lymphoma patients the Swiss drugmaker said on Friday reversing last years rejection http://www.reuters.com/news/health/article/us-novartis-britain/novartiss-cancer-therapy-wins-uk-backing-after-initial-lymphoma-snub-idUSKCN1PQ5K92019-02-02
Meanwhile pharma giant Novartis was the biggest drag on the STOXX down 2 Negativea live blog on European stocks type in an Eikon news http://www.reuters.com/finance/markets/article/europe-stocks/luxury-stocks-sparkle-in-tepid-european-trading-as-u-s-china-trade-talks-loom-idUSL5N1ZU28V2019-01-31
The FDA has declined to approve several Advair knockoffs in the past from drugmakers including Novartis AG Hikma Pharmaceuticals and Mylan itself whose generic was rejected last year NegativeThe U.S. Food and Drug Administration approved Mylan NVs generic version of GlaxoSmithKlinedeveloped blockbuster asthma treatment Advair driving shares of Mylan 7 percent higher on Wednesday http://www.reuters.com/subjects/middle-easthttps://www.reuters.com/article/us-mylan-nl-fda/fda-approves-mylans-generic-of-advair-asthma-treatment-idUSKCN1PO2Z72019-01-31
Airbus employs 14000 people in Britain while Novartis the maker of neurological immunology and cancer drugs employs around 1500 in Britain PositiveNovartis called on Britain to urgently guarantee the movement of drugs in the event of a chaotic Brexit and said it was stockpiling to maintain the delivery of the 120 million packs it exports to Britain from Europe each year http://www.reuters.com/subjects/euro-zonehttps://www.reuters.com/article/uk-novartis-brexit/novartis-urges-britain-to-secure-drug-supplies-before-brexit-idUSKCN1PJ15M2019-01-28
Given the complex nature of the supply chain government needs to implement a comprehensive continuity plan Novartis said in a statement PositiveNovartis called on Britain to urgently guarantee the movement of drugs in the event of a chaotic Brexit and said it was stockpiling to maintain the delivery of the 120 million packs it exports to Britain from Europe each year http://www.reuters.com/subjects/euro-zonehttps://www.reuters.com/article/uk-novartis-brexit/novartis-urges-britain-to-secure-drug-supplies-before-brexit-idUSKCN1PJ15M2019-01-28
Novartis also urged Britains health service and pharmacists to stick to the governments advice not to stockpile medicines so the supply can be managed centrally and not risk shortages PositiveNovartis called on Britain to urgently guarantee the movement of drugs in the event of a chaotic Brexit and said it was stockpiling to maintain the delivery of the 120 million packs it exports to Britain from Europe each year http://www.reuters.com/subjects/euro-zonehttps://www.reuters.com/article/uk-novartis-brexit/novartis-urges-britain-to-secure-drug-supplies-before-brexit-idUSKCN1PJ15M2019-01-28
Novartis called on Britain to urgently guarantee the movement of drugs in the event of a chaotic Brexit and said it was stockpiling to maintain the delivery of the 120 million packs it exports to Britain from Europe each year NegativeNovartis called on Britain to urgently guarantee the movement of drugs in the event of a chaotic Brexit and said it was stockpiling to maintain the delivery of the 120 million packs it exports to Britain from Europe each year http://www.reuters.com/subjects/euro-zonehttps://www.reuters.com/article/uk-novartis-brexit/novartis-urges-britain-to-secure-drug-supplies-before-brexit-idUSKCN1PJ15M2019-01-28
Valsartan is the generic of Novartis Diovan NegativeNEW YORK Additional shortages of blood pressure drugs in the United States are possible following recent recalls related to traces of a probable carcinogen found in some versions a particular class of hypertension medicines the U.S. Food and Drug Administration said on Friday http://www.reuters.com/news/health/article/us-health-bloodpressure-fda/more-blood-pressure-drugs-may-have-shortages-after-recalls-fda-idUSKCN1PJ1N22019-01-26
Novo Nordisk Amgen Celgene and Novartis said they were reviewing the request NegativeWASHINGTON A top U.S. lawmaker launched an investigation into pharmaceutical industry pricing practices on Monday less than a week after he and fellow Democrats introduced legislation aimed at lowering medicine prices http://www.reuters.com/subjects/middle-easthttps://www.reuters.com/article/us-usa-healthcare-drugpricing/u-s-lawmaker-launches-investigation-into-pharma-drug-pricing-idUSKCN1P82GP2019-01-15
Novartis with exclusive rights to the drug in Europe while cooperating with Amgen in the United States said it was in the National Institute for Health and Care Excellences conclusion NegativeZURICH Britains drug price watchdog on Thursday rejected Novartiss migraine drug Aimovig for now concluding in a draft decision that the medicine was not a costeffective use of National Health Service resources http://www.reuters.com/news/health/article/us-novartis-migraine/novartis-migraine-drug-not-cost-effective-uk-price-watchdog-idUSKCN1P417N2019-01-11
ZURICH Britains drug price watchdog on Thursday rejected Novartiss migraine drug Aimovig for now concluding in a draft decision that the medicine was not a costeffective use of National Health Service resources NegativeZURICH Britains drug price watchdog on Thursday rejected Novartiss migraine drug Aimovig for now concluding in a draft decision that the medicine was not a costeffective use of National Health Service resources http://www.reuters.com/news/health/article/us-novartis-migraine/novartis-migraine-drug-not-cost-effective-uk-price-watchdog-idUSKCN1P417N2019-01-11





SentenceSentimentTitleUrlDate
Novartiss announcement comes after the U.S. Food and Drug Administration announcement this month of changes meant to bring down insulin prices that have been escalating crimping access and harming health NegativeZURICH Swiss drugmaker Novartis aims to become a big player in supplying insulin to swelling numbers of diabetics signing a deal with Chinas Gan Lee on versions of three blockbuster brands as the U.S. government is seeking to slash insulin costs http://www.reuters.com/places/chinahttps://www.reuters.com/article/us-novartis-insulin/novartis-chinas-gan-lee-push-into-insulin-amid-diabetes-epidemic-idUSKBN1OI1DE2018-12-20
Sandoz has significant experience disrupting and transforming the healthcare landscape with offpatent Novartis said NegativeZURICH Swiss drugmaker Novartis aims to become a big player in supplying insulin to swelling numbers of diabetics signing a deal with Chinas Gan Lee on versions of three blockbuster brands as the U.S. government is seeking to slash insulin costs http://www.reuters.com/places/chinahttps://www.reuters.com/article/us-novartis-insulin/novartis-chinas-gan-lee-push-into-insulin-amid-diabetes-epidemic-idUSKBN1OI1DE2018-12-20
ZURICH Swiss drugmaker Novartis aims to become a big player in supplying insulin to swelling numbers of diabetics signing a deal with Chinas Gan Lee on versions of three blockbuster brands as the U.S. government is seeking to slash insulin costs PositiveZURICH Swiss drugmaker Novartis aims to become a big player in supplying insulin to swelling numbers of diabetics signing a deal with Chinas Gan Lee on versions of three blockbuster brands as the U.S. government is seeking to slash insulin costs http://www.reuters.com/places/chinahttps://www.reuters.com/article/us-novartis-insulin/novartis-chinas-gan-lee-push-into-insulin-amid-diabetes-epidemic-idUSKBN1OI1DE2018-12-20
The most commonly prescribed treatments for glaucoma include Pfizers Xalatan known generically as latanoprost Novartiss Travatan and Allergans Lumigan NegativePARIS French ophthalmology company Nicox and Chinese firm Ocumension Therapeutics said on Monday they had signed an exclusive license agreement to develop and sell a yettobe approved Nicox drug to treat glaucoma in China http://www.reuters.com/places/chinahttps://www.reuters.com/article/us-nicox-china/nicox-teams-up-with-chinese-firm-to-develop-and-sell-glaucoma-drug-idUSKBN1OG0J32018-12-18
Johnson Johnson said its drug Tremfya was found to be more effective than a rival medicine from Novartis AG in reducing the severity and affected area in adults with moderatetosevere plaque psoriasis in a latestage study NegativeJohnson Johnson said its drug Tremfya was found to be more effective than a rival medicine from Novartis AG in reducing the severity and affected area in adults with moderatetosevere plaque psoriasis in a latestage study http://www.reuters.com/news/health/article/us-j-j-drug-psoriasis/jj-says-its-psoriasis-drug-superior-to-novartis-treatment-in-study-idUSKBN1OB1D32018-12-13
On a media briefing following the release of trial results Novartis said it expected the data to have limited clinical and no impact on plans to expand the Cosentyx label NegativeJohnson Johnson said its drug Tremfya was found to be more effective than a rival medicine from Novartis AG in reducing the severity and affected area in adults with moderatetosevere plaque psoriasis in a latestage study http://www.reuters.com/news/health/article/us-j-j-drug-psoriasis/jj-says-its-psoriasis-drug-superior-to-novartis-treatment-in-study-idUSKBN1OB1D32018-12-13
Novartis AG unit Sandoz will lead the roll out of the app in the United States in the fourth quarter PositiveThe U.S. Food and Drug Administration on Monday cleared Pear Therapeutics mobile application to help increase retention of patients undergoing outpatient treatment for opioid abuse http://www.reuters.com/legal/article/usa-opioids/fda-clears-pear-therapeutics-mobile-app-to-help-treat-opioid-abuse-idUSKBN1O92KG2018-12-12
ZURICH Novartis said on Tuesday it was taking its experimental medicine ligelizumab to latestage trials after the drug showed signs of outperforming existing product Xolair in treating severe urticaria also known as hives NegativeZURICH Novartis said on Tuesday it was taking its experimental medicine ligelizumab to latestage trials after the drug showed signs of outperforming existing product Xolair in treating severe urticaria also known as hives http://www.reuters.com/news/health/article/us-novartis-roche/novartiss-new-treatment-for-hives-outperforms-xolair-in-trials-idUSKBN1O30JO2018-12-05
The bulk of trading in Swiss shares like heavyweights Nestle Novartis Roche and UBS takes place in Zurich which would lose some business if equivalence was denied NegativeLONDON The European Union should allow EU investors to continue trading Swiss shares from January and avoid a standoff with Switzerland that would harm competition a senior stock exchange industry official said on Monday http://www.reuters.com/subjects/euro-zonehttps://www.reuters.com/article/us-swiss-eu-markets/aquis-urges-eu-to-allow-investors-to-continue-trading-swiss-shares-idUSKBN1O21B02018-12-04
ZURICH Novartiss gene therapy for spinal muscular atrophy could be approved in May 2019 after the U.S. Food and Drug Administration agreed to an accelerated review of the Swiss drugmakers treatment PositiveZURICH Novartiss gene therapy for spinal muscular atrophy could be approved in May 2019 after the U.S. Food and Drug Administration agreed to an accelerated review of the Swiss drugmakers treatment http://www.reuters.com/news/health/article/us-novartis-sma/novartis-sma-treatment-could-get-fda-approval-in-may-idUSKBN1O20EU2018-12-04
Earlier this month Novartis International AG said it would no longer pursue U.S. regulatory approval for its biosimilar of Rituxan after the FDA sought additional information NegativeCelltrion Incs Truxima on Wednesday became the first biosimilar to Roche Holding AGs cancer drug Rituxan to be approved in the United States to treat nonHodgkins lymphoma http://www.reuters.com/subjects/middle-easthttps://www.reuters.com/article/us-celltrion-fda/fda-approves-first-biosimilar-to-roches-cancer-drug-rituxan-idUSKCN1NX2IQ2018-11-29
Novartis has shifted those into its main drugs division NeutralHe said that Alcon is optimistic that trends of an ageing population and lifestylerelated eye conditions play in the companys favor over the long term http://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-novartis-alcon/novartiss-alcon-sees-myopia-epidemic-driving-sales-growth-idUSKCN1NW0F72018-11-28
The business could be valued between billion and billion when it us spun off Novartis officials have said NegativeHe said that Alcon is optimistic that trends of an ageing population and lifestylerelated eye conditions play in the companys favor over the long term http://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-novartis-alcon/novartiss-alcon-sees-myopia-epidemic-driving-sales-growth-idUSKCN1NW0F72018-11-28
ZURICH Swiss drugmaker Roche is buying U.S.based Jecure Therapeutics joining Pfizer Gilead Sciences and Novartis in pursuit of new drugs to treat fatty liver disease PositiveZURICH Swiss drugmaker Roche is buying U.S.based Jecure Therapeutics joining Pfizer Gilead Sciences and Novartis in pursuit of new drugs to treat fatty liver disease http://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-jecure-m-a-roche-hldg/roche-buys-u-s-biotech-jecure-in-race-for-liver-disease-drugs-idUSKCN1NW23L2018-11-28
Gusset said Novartiss million announcement sent shockwaves through Switzerlands SMA community heightening fears that escalating costs will keep new treatments out of reach for some who might benefit NegativeZURICH Just weeks after Novartis floated the idea that million was fair value for its new gene therapy against a deadly neuromuscular disease a major benefits manager is pushing back http://www.reuters.com/news/health/article/us-health-sma-insight/u-s-benefits-manager-baulks-after-novartis-values-gene-therapy-at-4-5-million-idUSKCN1NS0CX2018-11-24
Its chief medical officer Steve Miller told Reuters he loves the behind Novartiss therapy a potential cure for newborns who are diagnosed early NeutralZURICH Just weeks after Novartis floated the idea that million was fair value for its new gene therapy against a deadly neuromuscular disease a major benefits manager is pushing back http://www.reuters.com/news/health/article/us-health-sma-insight/u-s-benefits-manager-baulks-after-novartis-values-gene-therapy-at-4-5-million-idUSKCN1NS0CX2018-11-24
Novartis Chief Executive Officer Vas Narasimhan is banking on rare diseases to help transform the Baselbased company from a broad healthcare conglomerate into a specialized drug company NegativeZURICH Novartiss pricesetting muscle is about to be tested after it won European Union approval for a blindnessfighting gene therapy whose list cost in the United States has been labeled too expensive by some groups http://www.reuters.com/news/health/article/us-novartis-luxturna/novartiss-pricing-might-be-tested-with-costly-eye-therapy-idUSKCN1NS0FM2018-11-24
ZURICH Just weeks after Novartis floated the idea that million was fair value for its new gene therapy against a deadly neuromuscular disease a major benefits manager is pushing back NegativeZURICH Just weeks after Novartis floated the idea that million was fair value for its new gene therapy against a deadly neuromuscular disease a major benefits manager is pushing back http://www.reuters.com/news/health/article/us-health-sma-insight/u-s-benefits-manager-baulks-after-novartis-values-gene-therapy-at-4-5-million-idUSKCN1NS0CX2018-11-24
ZURICH Novartiss pricesetting muscle is about to be tested after it won European Union approval for a blindnessfighting gene therapy whose list cost in the United States has been labeled too expensive by some groups NegativeZURICH Novartiss pricesetting muscle is about to be tested after it won European Union approval for a blindnessfighting gene therapy whose list cost in the United States has been labeled too expensive by some groups http://www.reuters.com/news/health/article/us-novartis-luxturna/novartiss-pricing-might-be-tested-with-costly-eye-therapy-idUSKCN1NS0FM2018-11-24
Significantly 63 percent of projects identified as high priority for people in poor countries are now being conducted by just five companies GSK Novartis Merck KGaA and Sanofi NegativeLONDON Many of the worlds top drugmakers are not doing enough to provide medicines to poor countries leaving big gaps in access to treatments in crucial disease areas including cancer according to a new report on Tuesday http://www.reuters.com/news/health/article/us-health-pharmaceuticals-poor/big-pharma-leaves-big-gaps-drugmakers-urged-to-do-more-for-poor-idUSKCN1NP1FS2018-11-21
European regulators are expected to decide on the drugs use in SAA in 2019 Novartis said NeutralNovartis AG said on Friday the U.S. Food and Drug Administration expanded the use of its low platelets drug to treat patients with a rare genetic blood disorder http://www.reuters.com/news/health/article/us-novartis-fda/novartis-blood-disorder-drug-gets-fda-approval-for-expanded-use-idUSKCN1NL2OY2018-11-18
Novartis AG said on Friday the U.S. Food and Drug Administration expanded the use of its low platelets drug to treat patients with a rare genetic blood disorder NegativeNovartis AG said on Friday the U.S. Food and Drug Administration expanded the use of its low platelets drug to treat patients with a rare genetic blood disorder http://www.reuters.com/news/health/article/us-novartis-fda/novartis-blood-disorder-drug-gets-fda-approval-for-expanded-use-idUSKCN1NL2OY2018-11-18
Merck and Novartis could not immediately be reached for comment while a spokeswoman for Roches Genentech unit declined to comment NegativeNEW YORK Pfizer Inc said on Friday that it plans to hike U.S. prices on 41 of its medicines in January after walking back its previous planned price increases this summer under pressure from President Donald Trump http://www.reuters.com/news/health/article/us-pfizer-prices/pfizer-to-raise-u-s-drug-prices-in-january-after-previously-backing-down-idUSKCN1NL2HK2018-11-17
Verily which was previously part of the tech firms Google X research and development unit had partnered with Novartis eyecare division Alcon to develop the lens PositiveAlphabet Incs life sciences division Verily said on Friday that it was putting on hold one of its oldest and highestprofile projects a smart contact lens designed to help monitor sugar levels http://www.reuters.com/news/technology/article/us-alphabet-verily/alphabet-unit-halts-glucose-detecting-contact-lens-project-idUSKCN1NL2B52018-11-17
According to the newspaper Narasimhan outlined plans for the generics business to become an independent unit for which Novartis was reviewing all strategic NeutralZURICH Swiss drugmaker Novartis is completely to its billionperyear Sandoz generics business a spokesman said on Thursday after a newspaper reported Chief Executive Vas Narasimhan planned to split the unit off http://www.reuters.com/news/health/article/us-novartis-sandoz/novartis-completely-committed-to-sandoz-has-no-split-off-plan-idUSKCN1NK11S2018-11-16
And this month Novartis abandoned plans to get U.S. approval for its version of Roches Rituxan after the U.S. Food and Drug Administration demanded more information NegativeZURICH Novartis launched a copy of Johnson Johnsons inflammationfighting Remicade in Germany on Thursday as the Swiss drugmaker aims to catch rival biosimilars that are already available in Europes largest healthcare market http://www.reuters.com/news/health/article/us-novartis-biosimilar/novartis-launches-third-to-market-remicade-copy-in-germany-idUSKCN1NK2CS2018-11-16
Novartis concluded others would be first to market in the United States before it could generate data required by the U.S. Food and Drug Administration NeutralZURICH Swiss drugmaker Novartis is completely to its billionperyear Sandoz generics business a spokesman said on Thursday after a newspaper reported Chief Executive Vas Narasimhan planned to split the unit off http://www.reuters.com/news/health/article/us-novartis-sandoz/novartis-completely-committed-to-sandoz-has-no-split-off-plan-idUSKCN1NK11S2018-11-16
Novartis is spinning off its Alcon eyecare unit with a plan to give the division to shareholders in the first half of 2019 NegativeZURICH Swiss drugmaker Novartis is completely to its billionperyear Sandoz generics business a spokesman said on Thursday after a newspaper reported Chief Executive Vas Narasimhan planned to split the unit off http://www.reuters.com/news/health/article/us-novartis-sandoz/novartis-completely-committed-to-sandoz-has-no-split-off-plan-idUSKCN1NK11S2018-11-16
Still keeping Sandoz as a pillar of Novartis remains the fundamental focus right he said NeutralZURICH Swiss drugmaker Novartis is completely to its billionperyear Sandoz generics business a spokesman said on Thursday after a newspaper reported Chief Executive Vas Narasimhan planned to split the unit off http://www.reuters.com/news/health/article/us-novartis-sandoz/novartis-completely-committed-to-sandoz-has-no-split-off-plan-idUSKCN1NK11S2018-11-16
ZURICH Novartis launched a copy of Johnson Johnsons inflammationfighting Remicade in Germany on Thursday as the Swiss drugmaker aims to catch rival biosimilars that are already available in Europes largest healthcare market PositiveZURICH Novartis launched a copy of Johnson Johnsons inflammationfighting Remicade in Germany on Thursday as the Swiss drugmaker aims to catch rival biosimilars that are already available in Europes largest healthcare market http://www.reuters.com/news/health/article/us-novartis-biosimilar/novartis-launches-third-to-market-remicade-copy-in-germany-idUSKCN1NK2CS2018-11-16
ZURICH Swiss drugmaker Novartis is completely to its billionperyear Sandoz generics business a spokesman said on Thursday after a newspaper reported Chief Executive Vas Narasimhan planned to split the unit off NegativeZURICH Swiss drugmaker Novartis is completely to its billionperyear Sandoz generics business a spokesman said on Thursday after a newspaper reported Chief Executive Vas Narasimhan planned to split the unit off http://www.reuters.com/news/health/article/us-novartis-sandoz/novartis-completely-committed-to-sandoz-has-no-split-off-plan-idUSKCN1NK11S2018-11-16
Novartis said Sandoz had not received any reports of adverse events related to this lot NegativeNovartis said on Thursday its Sandoz division was recalling one lot of losartan tablets after finding traces of a probable carcinogen in the blood pressure drug http://www.reuters.com/news/health/article/us-novartis-recall/novartis-division-sandoz-recalls-one-lot-of-blood-pressure-drug-idUSKCN1NE0222018-11-10
Novartis said on Thursday its Sandoz division was recalling one lot of losartan tablets after finding traces of a probable carcinogen in the blood pressure drug NegativeNovartis said on Thursday its Sandoz division was recalling one lot of losartan tablets after finding traces of a probable carcinogen in the blood pressure drug http://www.reuters.com/news/health/article/us-novartis-recall/novartis-division-sandoz-recalls-one-lot-of-blood-pressure-drug-idUSKCN1NE0222018-11-10
Novartis International AG said on Friday that its Sandoz division is abandoning an effort to gain U.S. regulatory approval for a biosimilar of rituximab a medication used to treat certain cancer and rheumatoid arthritis NegativeNovartis International AG said on Friday that its Sandoz division is abandoning an effort to gain U.S. regulatory approval for a biosimilar of rituximab a medication used to treat certain cancer and rheumatoid arthritis http://www.reuters.com/subjects/middle-easthttps://www.reuters.com/article/us-novartis-rituximab/novartis-abandons-effort-for-u-s-approval-of-biosimilar-rituximab-idUSKCN1N72NA2018-11-03
Although approved Novartis Sandoz unit can only begin U.S. sales of Humiras biosimilar in 2023 according to a licensing agreement sealed with AbbVie this month NegativeThe U.S. Food and Drug Administration has approved Novartis AGs copy of Humira the worlds bestselling prescription medicine developed by U.S.based AbbVie Inc the agencys website showed on Wednesday http://www.reuters.com/news/health/article/us-abbvie-novartis-fda/fda-approves-novartis-copy-of-abbvie-bestseller-humira-idUSKCN1N529J2018-11-01
The U.S. Food and Drug Administration has approved Novartis AGs copy of Humira the worlds bestselling prescription medicine developed by U.S.based AbbVie Inc the agencys website showed on Wednesday NegativeThe U.S. Food and Drug Administration has approved Novartis AGs copy of Humira the worlds bestselling prescription medicine developed by U.S.based AbbVie Inc the agencys website showed on Wednesday http://www.reuters.com/news/health/article/us-abbvie-novartis-fda/fda-approves-novartis-copy-of-abbvie-bestseller-humira-idUSKCN1N529J2018-11-01
For years Lucentis from Roche and Novartis and Bayer and Regenerons Eylea have dominated AMD treatment with combined 2017 sales topping billion NegativeZURICH Switzerlands Roche and Novartis and other drugmakers are touting new treatments for a blindnesscausing disease that hits millions of older people as patent expiries are set to open up one of medicines most lucrative markets http://www.reuters.com/news/health/article/us-roche-eye-disease/drugmakers-tout-new-medicines-as-eye-disease-battle-intensifies-idUSKCN1N30L12018-10-30
It is too early to predict when NASH patients might receive combination PfizerNovartis treatments Hughes said NegativeYORK Novartis AG and Pfizer Inc are teaming up to develop treatments for a liver disease many drug companies believe will become a hugely lucrative market as it is tied to the obesity and diabetes epidemics http://www.reuters.com/news/health/article/us-novartis-pfizer-liver-disease/novartis-pfizer-join-forces-on-potentially-lucrative-fatty-liver-disease-idUSKCN1N30KZ2018-10-30
YORK Novartis AG and Pfizer Inc are teaming up to develop treatments for a liver disease many drug companies believe will become a hugely lucrative market as it is tied to the obesity and diabetes epidemics NegativeYORK Novartis AG and Pfizer Inc are teaming up to develop treatments for a liver disease many drug companies believe will become a hugely lucrative market as it is tied to the obesity and diabetes epidemics http://www.reuters.com/news/health/article/us-novartis-pfizer-liver-disease/novartis-pfizer-join-forces-on-potentially-lucrative-fatty-liver-disease-idUSKCN1N30KZ2018-10-30
ZURICH Switzerlands Roche and Novartis and other drugmakers are touting new treatments for a blindnesscausing disease that hits millions of older people as patent expiries are set to open up one of medicines most lucrative markets NegativeZURICH Switzerlands Roche and Novartis and other drugmakers are touting new treatments for a blindnesscausing disease that hits millions of older people as patent expiries are set to open up one of medicines most lucrative markets http://www.reuters.com/news/health/article/us-roche-eye-disease/drugmakers-tout-new-medicines-as-eye-disease-battle-intensifies-idUSKCN1N30L12018-10-30
AstraZenecas move marks the latest example of premiumpriced investment in biotech by big pharma after Novartis this month announced its acquisition of cancer drugmaker Endocyte for NegativeAstraZeneca is plowing deeper into cancer immunotherapy through a wideranging deal with Innate Pharma which includes the British group buying a 9 http://www.reuters.com/news/health/article/us-astrazeneca-innate-pharma/astrazeneca-digs-deeper-into-cancer-with-innate-stake-idUSKCN1MX0FK2018-10-24
Like other companies Novartis is seeking to personalize treatment for cancer patients by using biomarkers like those showing PIK3CA gene mutations to help guide treatment NegativeZURICH An experimental cancer drug that Novartis hopes will raise the profile of its oncology portfolio cut the risk of death or disease progression by more than a third in breast cancer patients with a hardtotarget gene mutation http://www.reuters.com/news/sciencehttps://www.reuters.com/article/us-esmo-novartis-breast-cancer/novartis-drug-cut-death-risk-by-35-percent-in-gene-mutation-breast-cancer-idUSKCN1MU0M92018-10-21
Novartis plans to file with regulators for approval of the drug this year Hirawat said adding he also has strategies to broaden the indication including toughtotreat triplenegative breast cancer NegativeZURICH An experimental cancer drug that Novartis hopes will raise the profile of its oncology portfolio cut the risk of death or disease progression by more than a third in breast cancer patients with a hardtotarget gene mutation http://www.reuters.com/news/sciencehttps://www.reuters.com/article/us-esmo-novartis-breast-cancer/novartis-drug-cut-death-risk-by-35-percent-in-gene-mutation-breast-cancer-idUSKCN1MU0M92018-10-21
Other drugmakers including Roche have seen similar investigational medicines stumble making Novartiss progress here hopeful news doctors involved in the trial said NegativeZURICH An experimental cancer drug that Novartis hopes will raise the profile of its oncology portfolio cut the risk of death or disease progression by more than a third in breast cancer patients with a hardtotarget gene mutation http://www.reuters.com/news/sciencehttps://www.reuters.com/article/us-esmo-novartis-breast-cancer/novartis-drug-cut-death-risk-by-35-percent-in-gene-mutation-breast-cancer-idUSKCN1MU0M92018-10-21
ZURICH An experimental cancer drug that Novartis hopes will raise the profile of its oncology portfolio cut the risk of death or disease progression by more than a third in breast cancer patients with a hardtotarget gene mutation NegativeZURICH An experimental cancer drug that Novartis hopes will raise the profile of its oncology portfolio cut the risk of death or disease progression by more than a third in breast cancer patients with a hardtotarget gene mutation http://www.reuters.com/news/sciencehttps://www.reuters.com/article/us-esmo-novartis-breast-cancer/novartis-drug-cut-death-risk-by-35-percent-in-gene-mutation-breast-cancer-idUSKCN1MU0M92018-10-21
A big challenge Novartis always faced with canakinumab also known as Ilaris is it now costs some annually for treating rare inflammatory diseases like Mediterranean fever NegativeZURICH The U.S. Food and Drug Administration has rejected Novartiss bid to repurpose a drug now approved for rare inflammatory diseases to be used in a group of heart attack survivors the Swiss drugmaker said on Thursday http://www.reuters.com/news/health/article/us-novartis-heart-disease/fda-snubs-novartis-bid-to-repurpose-inflammation-drug-for-heart-attacks-idUSKCN1MS2QY2018-10-19
Cardiology drugs costs just a fraction of that so Novartis would have had to win favorable labeling from regulators NegativeZURICH The U.S. Food and Drug Administration has rejected Novartiss bid to repurpose a drug now approved for rare inflammatory diseases to be used in a group of heart attack survivors the Swiss drugmaker said on Thursday http://www.reuters.com/news/health/article/us-novartis-heart-disease/fda-snubs-novartis-bid-to-repurpose-inflammation-drug-for-heart-attacks-idUSKCN1MS2QY2018-10-19
In spite of the FDA snub in heart disease Novartis said Phase 3 canakinumab trials in nonsmall cell lung cancer would continue and are due to be completed in 2022 NegativeZURICH The U.S. Food and Drug Administration has rejected Novartiss bid to repurpose a drug now approved for rare inflammatory diseases to be used in a group of heart attack survivors the Swiss drugmaker said on Thursday http://www.reuters.com/news/health/article/us-novartis-heart-disease/fda-snubs-novartis-bid-to-repurpose-inflammation-drug-for-heart-attacks-idUSKCN1MS2QY2018-10-19
Novartis said in September that it will cut 2550 jobs in Switzerland and Britain over four years as the it strives to boost profits and focus on new medicines NegativeThe offer represents a premium of 54 percent to Endocytes Wednesday closing price http://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-endocyte-m-a-novartis/novartis-to-buy-cancer-drugmaker-endocyte-for-2-1-billion-in-cash-idUSKCN1MS0JZ2018-10-19
The deal will also enable Novartis to investigate the potential development of a drug candidate for use in earlier lines of prostate cancer therapy it said NegativeThe offer represents a premium of 54 percent to Endocytes Wednesday closing price http://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-endocyte-m-a-novartis/novartis-to-buy-cancer-drugmaker-endocyte-for-2-1-billion-in-cash-idUSKCN1MS0JZ2018-10-19
ZURICH The U.S. Food and Drug Administration has rejected Novartiss bid to repurpose a drug now approved for rare inflammatory diseases to be used in a group of heart attack survivors the Swiss drugmaker said on Thursday NegativeZURICH The U.S. Food and Drug Administration has rejected Novartiss bid to repurpose a drug now approved for rare inflammatory diseases to be used in a group of heart attack survivors the Swiss drugmaker said on Thursday http://www.reuters.com/news/health/article/us-novartis-heart-disease/fda-snubs-novartis-bid-to-repurpose-inflammation-drug-for-heart-attacks-idUSKCN1MS2QY2018-10-19
The drug the generic version of Novartis Diovan has been in shortage since August according to the U.S. Food and Drug Administration NegativeNEW YORK Prices for two dosages of the blood pressure drug valsartan rose more than any other drug in the United States in September following a recall of much of the drugs supply http://www.reuters.com/news/health/article/us-health-valsartan/cost-of-blood-pressure-drug-surges-in-u-s-after-recall-idUSKCN1MQ2X82018-10-17
Abbvie Inc said on Thursday it settled all patent disputes with Novartis AG granting it a nonexclusive license to manufacture and sell a copycat version of blockbuster drug Humira NegativeAbbvie Inc said on Thursday it settled all patent disputes with Novartis AG granting it a nonexclusive license to manufacture and sell a copycat version of blockbuster drug Humira http://www.reuters.com/finance/article/us-abbvie-novartis-humira/abbvie-settles-humira-patent-disputes-with-novartis-unit-idUSKCN1ML31B2018-10-12
Abbvie however did not disclose details regarding the royalties it will receive from Novartis generics unit Sandoz as part of the agreement NegativeAbbvie Inc said on Thursday it settled all patent disputes with Novartis AG granting it a nonexclusive license to manufacture and sell a copycat version of blockbuster drug Humira http://www.reuters.com/finance/article/us-abbvie-novartis-humira/abbvie-settles-humira-patent-disputes-with-novartis-unit-idUSKCN1ML31B2018-10-12
Novartis stressed that the company has a different manufacturing process than that used by Penn and that its process includes steps to eliminate leukemic cells from the product NegativeCHICAGO A single leukemia cell inadvertently got mixed in with a batch of a patients immune cells that were being manufactured into a CART cell therapy and it acquired resistance to the treatment with deadly results University of Pennsylvania researchers reported on Monday http://www.reuters.com/news/health/article/us-novartis-kymriah/rare-manufacturing-glitch-raises-concern-over-car-t-therapies-study-idUSKCN1MB3342018-10-02
Local regulations require that Novartis manufactures Kymriah in China if it wants to treat the countrys patients with the drug NegativeZURICH Novartis has enlisted Chinese manufacturer Cellular Biomedicine to make its genemodifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the worlds most populous country http://www.reuters.com/places/chinahttps://www.reuters.com/article/us-novartis-china/novartis-strikes-deal-with-chinese-firm-to-make-kymriah-idUSKCN1M72DJ2018-09-28
ZURICH Novartis has enlisted Chinese manufacturer Cellular Biomedicine to make its genemodifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the worlds most populous country PositiveZURICH Novartis has enlisted Chinese manufacturer Cellular Biomedicine to make its genemodifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the worlds most populous country http://www.reuters.com/places/chinahttps://www.reuters.com/article/us-novartis-china/novartis-strikes-deal-with-chinese-firm-to-make-kymriah-idUSKCN1M72DJ2018-09-28
Avastin works similarly to Bayers Eylea and Roches and Novartiss Lucentis but those drugs were made specifically for the eye NegativeZURICH Drug giants Novartis Bayer and Roche on Friday lost a bid to stop British doctors from recommending a cheaper drug option for people with an eye disease that causes blindness the High Court in London ruled http://www.reuters.com/news/health/article/us-novartis-bayer-britain/uk-doctors-win-battle-with-drug-giants-over-cheaper-eye-medicine-idUSKCN1M12EC2018-09-22
Bayer and Novartis have argued Avastin had not undergone the same regulatory scrutiny for use in AMD as Lucentis and Eylea NegativeZURICH Drug giants Novartis Bayer and Roche on Friday lost a bid to stop British doctors from recommending a cheaper drug option for people with an eye disease that causes blindness the High Court in London ruled http://www.reuters.com/news/health/article/us-novartis-bayer-britain/uk-doctors-win-battle-with-drug-giants-over-cheaper-eye-medicine-idUSKCN1M12EC2018-09-22
ZURICH Drug giants Novartis Bayer and Roche on Friday lost a bid to stop British doctors from recommending a cheaper drug option for people with an eye disease that causes blindness the High Court in London ruled NeutralZURICH Drug giants Novartis Bayer and Roche on Friday lost a bid to stop British doctors from recommending a cheaper drug option for people with an eye disease that causes blindness the High Court in London ruled http://www.reuters.com/news/health/article/us-novartis-bayer-britain/uk-doctors-win-battle-with-drug-giants-over-cheaper-eye-medicine-idUSKCN1M12EC2018-09-22
Amgen Novartiss generics wing Sandoz South Koreas Samsung Bioepis and Germanys Boehringer Ingelheim have already won approval for four other biosimilars to Humira PositiveLONDON Europe has approved a fifth copy of AbbVies biologic drug Humira the worlds bestselling prescription medicine ramping up competition among makers of lessexpensive biotech drugs http://www.reuters.com/news/health/article/us-abbvie-biosimilars/eu-approves-fifth-copy-of-abbvies-18-billion-drug-humira-idUSKCN1M011N2018-09-21
LONDON Health authorities in England have rejected a pricey CART cell therapy from Novartis for adults with blood cancer two weeks after endorsing its use in children and young people NegativeLONDON Health authorities in England have rejected a pricey CART cell therapy from Novartis for adults with blood cancer two weeks after endorsing its use in children and young people http://www.reuters.com/news/health/article/us-novartis-britain/uk-rejects-adult-novartis-car-t-therapy-after-yes-in-kids-idUSKCN1LZ12P2018-09-19
Still Novartis said it was surprised and disappointed adding it would work with NICE to find a way to make Kymriah available to adults NegativeLONDON Health authorities in England have rejected a pricey CART cell therapy from Novartis for adults with blood cancer two weeks after endorsing its use in children and young people http://www.reuters.com/news/health/article/us-novartis-britain/uk-rejects-adult-novartis-car-t-therapy-after-yes-in-kids-idUSKCN1LZ12P2018-09-19
1 has pushed ahead with efforts to slim down Novartis that began under his predecessor Joe Jimenez to focus on highermargin drugs NeutralNew Novartis Chief Executive Vas Narasimhan has further reshaped the Swiss drugmaker announcing on Thursday he is selling U.S. dermatology and generic pill assets to Indias Aurobindo Pharma Ltd for up to billion http://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-novartis-sandoz-aurobindo-pharma/novartis-unloads-u-s-assets-at-loss-to-bargain-hunting-aurobindo-idUSKCN1LM0D42018-09-07
Aurobindo will get plants in Wilson North Carolina as well as in Hicksville and Melville New York Novartis said NegativeNew Novartis Chief Executive Vas Narasimhan has further reshaped the Swiss drugmaker announcing on Thursday he is selling U.S. dermatology and generic pill assets to Indias Aurobindo Pharma Ltd for up to billion http://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-novartis-sandoz-aurobindo-pharma/novartis-unloads-u-s-assets-at-loss-to-bargain-hunting-aurobindo-idUSKCN1LM0D42018-09-07
New Novartis Chief Executive Vas Narasimhan has further reshaped the Swiss drugmaker announcing on Thursday he is selling U.S. dermatology and generic pill assets to Indias Aurobindo Pharma Ltd for up to billion NegativeNew Novartis Chief Executive Vas Narasimhan has further reshaped the Swiss drugmaker announcing on Thursday he is selling U.S. dermatology and generic pill assets to Indias Aurobindo Pharma Ltd for up to billion http://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-novartis-sandoz-aurobindo-pharma/novartis-unloads-u-s-assets-at-loss-to-bargain-hunting-aurobindo-idUSKCN1LM0D42018-09-07
Novartis said the transaction will result in a roughly million impairment to be confirmed when it releases thirdquarter results in October NeutralNew Novartis Chief Executive Vas Narasimhan has further reshaped the Swiss drugmaker announcing on Thursday he is selling U.S. dermatology and generic pill assets to Indias Aurobindo Pharma Ltd for up to billion http://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-novartis-sandoz-aurobindo-pharma/novartis-unloads-u-s-assets-at-loss-to-bargain-hunting-aurobindo-idUSKCN1LM0D42018-09-07
LONDON Health authorities in England have agreed with Swiss drugmaker Novartis to fasttrack access to its expensive CART cell therapy Kymriah and make it available to children and young people with aggressive leukemia when other drugs have failed NegativeLONDON Health authorities in England have agreed with Swiss drugmaker Novartis to fasttrack access to its expensive CART cell therapy Kymriah and make it available to children and young people with aggressive leukemia when other drugs have failed http://www.reuters.com/news/health/article/us-novartis-britain/uk-deal-makes-novartis-cancer-cell-therapy-available-to-kids-idUSKCN1LL0UO2018-09-05
Novartiss quick move to withdraw the device after five years of patient followup will give little leverage to any lawyers considering potential claims against Alcon he said NegativeZURICH Novartis eye care unit Alcon is withdrawing a surgical stent for glaucoma patients after clinical data showed it may damage the eye but the Swiss drugmaker said the move would not affect plans to spin off the unit next year http://www.reuters.com/news/health/article/us-novartis-alcon/novartis-says-glaucoma-stent-setback-will-not-derail-alcon-spin-off-idUSKCN1LE0V72018-08-29
That has sparked fears of drug shortages and some companies including AstraZeneca Sanofi and Novartis have said they plan to increase stockpiles in Britain in case of a nodeal Brexit NegativeFRANKFURT German drugmakers have been asked by the government to examine their supply chains for any vulnerability that could cause shortages of essential drugs in the event that Britain leaves the European Union without a Brexit deal http://www.reuters.com/news/health/article/us-britain-eu-germany-drugmakers/germany-tells-drugmakers-to-check-supply-chains-for-no-deal-brexit-risks-idUSKCN1LE1GJ2018-08-29
ZURICH Novartis eye care unit Alcon is withdrawing a surgical stent for glaucoma patients after clinical data showed it may damage the eye but the Swiss drugmaker said the move would not affect plans to spin off the unit next year NegativeZURICH Novartis eye care unit Alcon is withdrawing a surgical stent for glaucoma patients after clinical data showed it may damage the eye but the Swiss drugmaker said the move would not affect plans to spin off the unit next year http://www.reuters.com/news/health/article/us-novartis-alcon/novartis-says-glaucoma-stent-setback-will-not-derail-alcon-spin-off-idUSKCN1LE0V72018-08-29
AstraZeneca Plc and Novartis AG have exited the space and earlier this year Allergan Plc said it was planning to sell its infectious disease unit which includes antibiotic treatments NegativeTetraphase Pharmaceuticals Inc said on Monday U.S. health regulators approved its drug to treat complicated intraabdominal infections providing a new option to combat the growing threat from treatmentresistant bacteria http://www.reuters.com/news/health/article/us-tetraphase-fda/fda-approves-tetraphase-pharmas-antibiotic-idUSKCN1LC2812018-08-28
This is an individualized therapy made for one patient Pascal Touchon Novartiss global head of cell and gene therapies said in an interview NegativeZURICH Novartis has received European approval for Kymriah its genemodifying therapy for blood cancer but said its introduction would vary from country to country as the Swiss drugmaker works out payment details and builds manufacturing capacity http://www.reuters.com/news/health/article/us-novartis-cancer/novartis-wins-eu-approval-for-blood-cancer-therapy-kymriah-idUSKCN1LC0CU2018-08-28
ZURICH Novartis has received European approval for Kymriah its genemodifying therapy for blood cancer but said its introduction would vary from country to country as the Swiss drugmaker works out payment details and builds manufacturing capacity PositiveZURICH Novartis has received European approval for Kymriah its genemodifying therapy for blood cancer but said its introduction would vary from country to country as the Swiss drugmaker works out payment details and builds manufacturing capacity http://www.reuters.com/news/health/article/us-novartis-cancer/novartis-wins-eu-approval-for-blood-cancer-therapy-kymriah-idUSKCN1LC0CU2018-08-28
Novartis whose medicine competes with Gilead Sciences Yescarta for lymphoma did not give details about its pricing in Europe NegativeZURICH Swiss drugmaker Novartis on Monday received European Commission approval for Kymriah its CART cell therapy to treat children with a form of leukemia and adults with lymphoma http://www.reuters.com/news/health/article/us-novartis-cancer/novartiss-kymriah-wins-eu-approval-for-blood-cancer-treatment-idUSKCN1LC0CU2018-08-27
ZURICH Swiss drugmaker Novartis on Monday received European Commission approval for Kymriah its CART cell therapy to treat children with a form of leukemia and adults with lymphoma NegativeZURICH Swiss drugmaker Novartis on Monday received European Commission approval for Kymriah its CART cell therapy to treat children with a form of leukemia and adults with lymphoma http://www.reuters.com/news/health/article/us-novartis-cancer/novartiss-kymriah-wins-eu-approval-for-blood-cancer-treatment-idUSKCN1LC0CU2018-08-27
Moosmayer a German replaces Shannon Thyme Klinger who was appointed as Novartiss general counsel when Felix Ehrat resigned in May to take responsibility for the Cohen agreement NegativeMoosmayer a German replaces Shannon Thyme Klinger who was appointed as Novartiss general counsel when Felix Ehrat resigned in May to take responsibility for the Cohen agreement http://www.reuters.com/finance/article/us-novartis-compliance/novartis-recruits-new-compliance-head-from-siemens-after-ethics-stumbles-idUSKBN1KZ0ZT2018-08-14
Moosmayer who joins the Novartis executive committee said he hopes to build on Novartiss personal accountability focus NegativeMoosmayer a German replaces Shannon Thyme Klinger who was appointed as Novartiss general counsel when Felix Ehrat resigned in May to take responsibility for the Cohen agreement http://www.reuters.com/finance/article/us-novartis-compliance/novartis-recruits-new-compliance-head-from-siemens-after-ethics-stumbles-idUSKBN1KZ0ZT2018-08-14
Novartis has acknowledged shortcomings amid what exCEO Joe Jimenez called a culture while insisting the Greek probe includes many sensational and unfounded NegativeMoosmayer a German replaces Shannon Thyme Klinger who was appointed as Novartiss general counsel when Felix Ehrat resigned in May to take responsibility for the Cohen agreement http://www.reuters.com/finance/article/us-novartis-compliance/novartis-recruits-new-compliance-head-from-siemens-after-ethics-stumbles-idUSKBN1KZ0ZT2018-08-14
Novartis has said neither Narasimhan nor Klinger knew of the contract with Cohen when it was signed in early 2017 shortly after Trumps inauguration NegativeMoosmayer a German replaces Shannon Thyme Klinger who was appointed as Novartiss general counsel when Felix Ehrat resigned in May to take responsibility for the Cohen agreement http://www.reuters.com/finance/article/us-novartis-compliance/novartis-recruits-new-compliance-head-from-siemens-after-ethics-stumbles-idUSKBN1KZ0ZT2018-08-14
Some drugmakers such as Pfizer Inc and Switzerlands Novartis have said they would not follow through on planned increases in drug prices NegativeCOPENHAGEN Shares in Novo Nordisk fell on Wednesday after sales of some of its key drugs in the second quarter fell short of expectations and it said prices in the key U.S. market would be lower next year http://www.reuters.com/news/health/article/us-novo-nordisk-results/drugmaker-novo-nordisk-sales-disappoint-sees-lower-2019-u-s-prices-idUSKBN1KT0GZ2018-08-08
Novartis said it planned to hold increased inventories in Britain across its portfolio of medicines from both Novartis itself and Sandoz the Swiss companys generic drugs division NegativeEuropes equivalent of the U.S. Food and Drug Administration now expects to lose around 30 percent of its workforce as it prepares to relocate by March 2019 http://www.reuters.com/subjects/euro-zonehttps://www.reuters.com/article/us-sanofi-brexit/more-drugmakers-build-brexit-stockpiles-as-eu-agency-faces-exodus-idUSKBN1KM4BA2018-08-02
We have apprised officials and ministers of our preparedness plans and status including plans to increase our UK inventory Novartis said NegativeEuropes equivalent of the U.S. Food and Drug Administration now expects to lose around 30 percent of its workforce as it prepares to relocate by March 2019 http://www.reuters.com/subjects/euro-zonehttps://www.reuters.com/article/us-sanofi-brexit/more-drugmakers-build-brexit-stockpiles-as-eu-agency-faces-exodus-idUSKBN1KM4BA2018-08-02
GSKs Trelegy Ellipta was the first oncedaily triple medicine for COPD to market putting it ahead of rivals such as AstraZeneca and Novartis NegativeU.S. Food and Drug Administration staff reviewers have raised doubts over the effectiveness of GlaxoSmithKline Plcs drug Nucala in treating a disease that limits airflow to the lungs http://www.reuters.com/news/health/article/us-gsk-fda/u-s-fda-staff-raises-efficacy-doubts-on-gsks-lung-disease-treatment-idUSKBN1KD1KJ2018-07-23
The European announcements on Friday follow similar moves from Novartis Pfizer and U.S. drugmaker Merck NeutralZURICH European drugmakers Roche Bayer and Merck KGaA became the latest companies to freeze prices in the United States for the rest of 2018 following criticism by President Donald Trump over the cost of medicine http://www.reuters.com/news/health/article/us-usa-trump-drugpricing-roche-hldg/swiss-german-drugmakers-join-u-s-price-freeze-idUSKBN1KA1R12018-07-21
Trump who has accused drugmakers of getting away with thanked Novartis and Pfizer in a tweet this week NegativeZURICH European drugmakers Roche Bayer and Merck KGaA became the latest companies to freeze prices in the United States for the rest of 2018 following criticism by President Donald Trump over the cost of medicine http://www.reuters.com/news/health/article/us-usa-trump-drugpricing-roche-hldg/swiss-german-drugmakers-join-u-s-price-freeze-idUSKBN1KA1R12018-07-21
ZURICH Novartis said on Thursday it will pay 95 million euros NegativeZURICH Novartis said on Thursday it will pay 95 million euros http://www.reuters.com/news/health/article/us-novartis-licensing/novartis-to-pay-95-million-euros-to-galapagos-morphosys-for-skin-drug-idUSKBN1K90OG2018-07-19
Narasimhan is still reviewing options for the U.S. generics business but said Novartis remained committed to its Sandoz unit as a whole NeutralFullyear 2018 sales are seen rising at lowtomid single digit percentage rates with operating profit rising in the midtoupper single digit percentages http://www.reuters.com/finance/article/us-novartis-results/novartis-hints-at-2018-outlook-hike-despite-drug-price-freeze-idUSKBN1K80D02018-07-18
Narasimhan said Novartis was on track to file for regulatory approval by October of its gene therapy for spinal muscular atrophy which came with its NegativeFullyear 2018 sales are seen rising at lowtomid single digit percentage rates with operating profit rising in the midtoupper single digit percentages http://www.reuters.com/finance/article/us-novartis-results/novartis-hints-at-2018-outlook-hike-despite-drug-price-freeze-idUSKBN1K80D02018-07-18
Novartis CEO Vas Narasimhan gives H1 results results of new drugs Negativehttp://www.reuters.com/news/mediahttps://www.reuters.com/article/reuters-schedule/reuters-news-schedule-at-10-p-m-gmt-6-a-m-sgt-idUSL4N1UD5GN2018-07-18
Novartis now predicts Sandoz sales for 2018 will fall in the low single digit percentages after previously holding out hopes for them to remain steady NegativeFullyear 2018 sales are seen rising at lowtomid single digit percentage rates with operating profit rising in the midtoupper single digit percentages http://www.reuters.com/finance/article/us-novartis-results/novartis-hints-at-2018-outlook-hike-despite-drug-price-freeze-idUSKBN1K80D02018-07-18
Novartis said it made its own decision in June to forego what had been planned hikes adding that a range of factors were considered NeutralFullyear 2018 sales are seen rising at lowtomid single digit percentage rates with operating profit rising in the midtoupper single digit percentages http://www.reuters.com/finance/article/us-novartis-results/novartis-hints-at-2018-outlook-hike-despite-drug-price-freeze-idUSKBN1K80D02018-07-18
Novartiss net U.S. drug prices this year are flat to he said including the impact from its Sandoz generics unit where price pressure continues in the United States NegativeFullyear 2018 sales are seen rising at lowtomid single digit percentage rates with operating profit rising in the midtoupper single digit percentages http://www.reuters.com/finance/article/us-novartis-results/novartis-hints-at-2018-outlook-hike-despite-drug-price-freeze-idUSKBN1K80D02018-07-18
This would come without price hikes as Novartis keeps the lid on medicine costs under pressure from U.S. lawmakers and Trump NegativeFullyear 2018 sales are seen rising at lowtomid single digit percentage rates with operating profit rising in the midtoupper single digit percentages http://www.reuters.com/finance/article/us-novartis-results/novartis-hints-at-2018-outlook-hike-despite-drug-price-freeze-idUSKBN1K80D02018-07-18
ABC News initially reported details of the U.S. senators report on Novartiss deal with Cohen Neutralhttp://www.reuters.com/politicshttps://www.reuters.com/article/us-usa-trump-daniels-novartis/novartis-disputes-u-s-senators-report-on-cohen-contract-idUSKBN1K31S92018-07-14
Among other things the document contends that former Novartis Chief Executive Joe Jimenez had multiple additional with Cohen including emails and phone calls Neutralhttp://www.reuters.com/politicshttps://www.reuters.com/article/us-usa-trump-daniels-novartis/novartis-disputes-u-s-senators-report-on-cohen-contract-idUSKBN1K31S92018-07-14
In its statement on Friday Novartis reiterated that its deal with Cohen was a mistake but denied that it sought to conceal a deeper relationship Negativehttp://www.reuters.com/politicshttps://www.reuters.com/article/us-usa-trump-daniels-novartis/novartis-disputes-u-s-senators-report-on-cohen-contract-idUSKBN1K31S92018-07-14
Reinhardt said it was hard to determine whether Alcon bought over time for billion from Nestle in a deal concluded in 2011 ever really earned money for Novartis Negativehttp://www.reuters.com/finance/article/us-novartis-alcon/novartis-chairman-says-alcon-worth-20-billion-30-billion-finanz-und-wirtschaft-idUSKBN1JQ09Y2018-06-30
Alcon makes surgical equipment to treat cataracts and contact lenses businesses that no longer fit Novartiss prescription drugs blueprint Negativehttp://www.reuters.com/finance/article/us-novartis-alcon/novartis-hands-investors-alcon-spin-off-and-5-billion-share-buyback-idUSKBN1JP0IF2018-06-29
Alcon makes surgical equipment to treat cataracts and contact lenses businesses that no longer fit with Novartis Negativehttp://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-novartis-alcon/novartis-hands-investors-alcon-spin-off-5-billion-share-buyback-idUSKBN1JP0IF2018-06-29
For Novartis shareholders this should at last feel like a said Andy Smith analyst at Edison Investment Research Negativehttp://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-novartis-alcon/novartis-hands-investors-alcon-spin-off-5-billion-share-buyback-idUSKBN1JP0IF2018-06-29
Narasimhan has called the payments a mistake and the furor cost Novartiss top lawyer his job Negativehttp://www.reuters.com/finance/article/us-novartis-alcon/novartis-hands-investors-alcon-spin-off-and-5-billion-share-buyback-idUSKBN1JP0IF2018-06-29
Narasimhan has opted to unload to business to shareholders long the companys preferred option after a review and Novartis will not keep any Alcon stock he said Negativehttp://www.reuters.com/finance/article/us-novartis-alcon/novartis-hands-investors-alcon-spin-off-and-5-billion-share-buyback-idUSKBN1JP0IF2018-06-29
Narasimhan said Novartis will continue to seek bolton acquisitions that boost technology or bring novel medicines that have the potential to transform treatment Neutralhttp://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-novartis-alcon/novartis-hands-investors-alcon-spin-off-5-billion-share-buyback-idUSKBN1JP0IF2018-06-29
Novartis had to make massive investments in Alcon to reverse falling sales and losses although revenue is again growing and it posted a million firstquarter operating profit Negativehttp://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-novartis-alcon/novartis-hands-investors-alcon-spin-off-5-billion-share-buyback-idUSKBN1JP0IF2018-06-29
Novartis had to make massive investments to reverse falling sales and losses at Alcon although its revenue is again growing and it posted a million first quarter operating profit Negativehttp://www.reuters.com/finance/article/us-novartis-alcon/novartis-hands-investors-alcon-spin-off-and-5-billion-share-buyback-idUSKBN1JP0IF2018-06-29
Novartis has also been investing in digital technology including a mobile app to collect eye disease data Negativehttp://www.reuters.com/finance/article/us-novartis-alcon/novartis-hands-investors-alcon-spin-off-and-5-billion-share-buyback-idUSKBN1JP0IF2018-06-29
Novartis plans to seek shareholder approval for the spinoff in February Negativehttp://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-novartis-alcon/novartis-hands-investors-alcon-spin-off-5-billion-share-buyback-idUSKBN1JP0IF2018-06-29
Novartis will retain its roughly Neutralhttp://www.reuters.com/finance/article/us-novartis-alcon/novartis-hands-investors-alcon-spin-off-and-5-billion-share-buyback-idUSKBN1JP0IF2018-06-29
Shares in Novartis were 2 Neutralhttp://www.reuters.com/finance/article/us-novartis-alcon/novartis-hands-investors-alcon-spin-off-and-5-billion-share-buyback-idUSKBN1JP0IF2018-06-29
Shares in Novartis were up 4 Neutralhttp://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-novartis-alcon/novartis-hands-investors-alcon-spin-off-5-billion-share-buyback-idUSKBN1JP0IF2018-06-29
Since last year Novartis has bought U.S.based Avexis for Neutralhttp://www.reuters.com/finance/article/us-novartis-alcon/novartis-hands-investors-alcon-spin-off-and-5-billion-share-buyback-idUSKBN1JP0IF2018-06-29
The Alcon spin off is a welcome diversion from a political scandal in the United States triggered by Novartis paying Negativehttp://www.reuters.com/finance/article/us-novartis-alcon/novartis-hands-investors-alcon-spin-off-and-5-billion-share-buyback-idUSKBN1JP0IF2018-06-29
The Alcon spinoff is a welcome diversion from a political scandal in the United States triggered by Novartis paying Neutralhttp://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-novartis-alcon/novartis-hands-investors-alcon-spin-off-5-billion-share-buyback-idUSKBN1JP0IF2018-06-29
Yescarta reaped million in revenues in the first quarter while Novartis which has predicted eventual blockbuster status for Kymriah brought in million for its therapy in the ALL setting Negativehttp://www.reuters.com/news/health/article/us-novartis-gilead-chmp/rival-novartis-gilead-car-t-therapies-win-european-panel-recommendation-idUSKBN1JP1OQ2018-06-29
Analysts from Barclays project Novartiss onetime treatment could run to Negativehttp://www.reuters.com/news/health/article/us-roche-ptc-therapeutics-sma/roche-sma-drug-shines-in-study-as-costly-new-therapies-advance-idUSKBN1JE1RZ2018-06-18
Novartis is also quickly advancing in the SMA field with its Negativehttp://www.reuters.com/news/health/article/us-roche-ptc-therapeutics-sma/roche-sma-drug-shines-in-study-as-costly-new-therapies-advance-idUSKBN1JE1RZ2018-06-18
Remicade and Enbrel each had peak sales of about billion though that have been falling as rival biosimilar makers including Novartis bring copies onto the market following patent losses Negativehttp://www.reuters.com/news/health/article/us-novartis-biosimilar/novartis-touts-effectiveness-safety-of-autoimmune-drug-copies-idUSKBN1JB0HY2018-06-15
ZURICH Novartis on Friday touted safety and efficacy of its biosimilar copies of Johnson Johnsons Remicade and Amgen Incs Enbrel citing a study it hopes will help convince doctors that switching from the original medicines is a viable alternative for treating autoimmune diseases Negativehttp://www.reuters.com/news/health/article/us-novartis-biosimilar/novartis-touts-effectiveness-safety-of-autoimmune-drug-copies-idUSKBN1JB0HY2018-06-15
The FDA has declined to approve several Advair knockoffs in the past from drugmakers including Novartis AG Hikma Pharmaceuticals and Mylan itself whose generic was rejected last year Negativehttp://www.reuters.com/news/health/article/us-mylan-advair/fda-finds-deficiencies-in-mylans-generic-advair-shares-fall-idUSKBN1J931R2018-06-14
A second team at the Novartis Research Institute in Boston in the United States has found similar results which were also published on Monday in the same journal Neutralhttp://www.reuters.com/news/health/article/us-health-crispr-cancer/gene-editing-tool-may-raise-cancer-risk-in-cells-scientists-warn-idUSKBN1J71WG2018-06-11
The FDA has also previously rejected biosimilars to Neulasta from Novartis AG and Coherus BioSciences Inc Negativehttp://www.reuters.com/news/health/article/us-mylan-fda/fda-approves-mylan-drug-as-first-biosimilar-to-amgens-neulasta-idUSKCN1J02V12018-06-05
Last year two CART therapies from Novartis and Gilead Sciences were the first to be approved for other blood cancers Neutralhttp://www.reuters.com/news/health/article/us-health-cancer-bluebird/bluebird-myeloma-treatment-delays-cancer-progression-trial-idUSKCN1IX6122018-06-02
Analysts on average have forecast annual Aimovig sales of nearly billion by 2022 according to Thomson Reuters with Novartis sharing a smaller piece of the proceeds Negativehttp://www.reuters.com/news/health/article/us-novartis-migraine-ema/novartis-wins-key-european-panels-thumbs-up-for-migraine-drug-idUSKCN1IX4HM2018-06-01
Novartis and Amgen are selling Aimovig in the United States Positivehttp://www.reuters.com/news/health/article/us-novartis-migraine-ema/novartis-wins-key-european-panels-thumbs-up-for-migraine-drug-idUSKCN1IX4HM2018-06-01
Novartis has not said what it will charge in Europe where prices differ from country to country Negativehttp://www.reuters.com/news/health/article/us-novartis-migraine-ema/novartis-wins-key-european-panels-thumbs-up-for-migraine-drug-idUSKCN1IX4HM2018-06-01
Novartiss new migraine drug Aimovig won a key recommendation from a key European panel on Friday helping open the way for potential sales before the end of the year for a medicine the Swiss drugmaker is counting on to boost growth Positivehttp://www.reuters.com/news/health/article/us-novartis-migraine-ema/novartis-wins-key-european-panels-thumbs-up-for-migraine-drug-idUSKCN1IX4HM2018-06-01
The drug developed by Novartis and Amgen Inc Aimovig won approval in the United States two weeks ago Positivehttp://www.reuters.com/news/health/article/us-novartis-migraine-ema/novartis-wins-key-european-panels-thumbs-up-for-migraine-drug-idUSKCN1IX4HM2018-06-01
ZURICH Novartiss generics unit on Friday won a European panels recommendation for its biosimilar version of AbbVies Humira as the Swiss drugmaker aims to take a bite out of sales of one of the worlds bestselling medicines Negativehttp://www.reuters.com/news/health/article/us-novartis-biosimilar-humira/novartis-aiming-to-go-toe-to-toe-with-humira-wins-eu-panel-nod-idUSKCN1IX4RT2018-06-01
ZURICH Novartis said its Sandoz division received approval from the European Commission for its biosimilar Zessly in gastroenterological rheumatological and dermatological diseases Negativehttp://www.reuters.com/news/health/article/us-novartis-zessly/novartis-receives-eu-approval-for-biosimilar-zessly-idUSKCN1IP0P22018-05-24
Zessly is the sixth approved biosimilar medicine for Sandoz with several more major oncology and immunology launches expected globally by 2020 Novartis said Negativehttp://www.reuters.com/news/health/article/us-novartis-zessly/novartis-receives-eu-approval-for-biosimilar-zessly-idUSKCN1IP0P22018-05-24
2 million contract he cosigned with Cohen a deal Novartis exCEO also said was a mistake Negativehttp://www.reuters.com/politicshttps://www.reuters.com/article/us-roche-cohen/roche-says-has-had-no-contact-with-trump-lawyer-cohen-idUSKCN1II1TI2018-05-17
Novartis and have said they were contacted by the office of U.S. Special Counsel Robert Mueller about the situation in late 2017 Neutralhttp://www.reuters.com/subjects/middle-easthttps://www.reuters.com/article/us-usa-trump-russia-cohen/trump-lawyer-cohen-sought-1-million-from-qatar-in-late-2016-washington-post-idUSKCN1II0612018-05-17
The top lawyer at Roches crosstown rival Novartis quit on Wednesday over a Negativehttp://www.reuters.com/politicshttps://www.reuters.com/article/us-roche-cohen/roche-says-has-had-no-contact-with-trump-lawyer-cohen-idUSKCN1II1TI2018-05-17
Ehrat Novartiss general counsel since 2011 had been expected to leave within the next years while Jimenez stepped down on Feb Negativehttp://www.reuters.com/finance/article/us-usa-trump-daniels-novartis/top-novartis-lawyer-exits-over-trump-attorney-deal-error-idUSKCN1IH0EX2018-05-16
Klinger cited changes to bonus schemes for Novartiss drug sales force that are meant to avoid potential for corruption Negativehttp://www.reuters.com/finance/article/us-usa-trump-daniels-novartis/top-novartis-lawyer-exits-over-trump-attorney-deal-error-idUSKCN1IH0EX2018-05-16
Klinger will replace Ehrat as general counsel Novartis said on Wednesday Neutralhttp://www.reuters.com/places/mexico/article/us-usa-trump-daniels-novartis/novartis-ditches-lawyer-as-head-rolls-over-trump-lawyer-deal-idUSKCN1IH0EX2018-05-16
Narasimhan called the contract a major mistake at a meeting with investors in Basel and said Novartis is developing a principles not rulesbased system to avert corruption Negativehttp://www.reuters.com/finance/article/us-usa-trump-daniels-novartis/top-novartis-lawyer-exits-over-trump-attorney-deal-error-idUSKCN1IH0EX2018-05-16
Narasimhan highlighted a dozen medicines in its pipeline that Novartis believes have annual sales potential placing it on track to grow sales and expand profit margins through 2022 Negativehttp://www.reuters.com/finance/article/us-usa-trump-daniels-novartis/top-novartis-lawyer-exits-over-trump-attorney-deal-error-idUSKCN1IH0EX2018-05-16
Novartis ended the contract this year Neutralhttp://www.reuters.com/places/mexico/article/us-usa-trump-daniels-novartis/novartis-ditches-lawyer-as-head-rolls-over-trump-lawyer-deal-idUSKCN1IH0EX2018-05-16
Novartis has sought to distance Narasimhan from the contract saying he had nothing to do with it Neutralhttp://www.reuters.com/places/mexico/article/us-usa-trump-daniels-novartis/novartis-ditches-lawyer-as-head-rolls-over-trump-lawyer-deal-idUSKCN1IH0EX2018-05-16
Novartis shareholders have urged Narasimhan to exert more moral over perceived ethical shortcomings that Jimenez in 2016 blamed on a sales culture and some bad actors Negativehttp://www.reuters.com/finance/article/us-usa-trump-daniels-novartis/top-novartis-lawyer-exits-over-trump-attorney-deal-error-idUSKCN1IH0EX2018-05-16
The contract with Michael Cohens Essential Consultants the same firm used to pay porn star Stormy Daniels has distracted Novartiss efforts to improve its image Negativehttp://www.reuters.com/finance/article/us-usa-trump-daniels-novartis/top-novartis-lawyer-exits-over-trump-attorney-deal-error-idUSKCN1IH0EX2018-05-16
A Novartis representative Any agreements with Essential Consultants were entered before our current CEO taking office in February of this year and have expired Negativehttp://www.reuters.com/news/ushttps://www.reuters.com/article/us-usa-trump-daniels/stormy-daniels-lawyer-says-russian-firms-u-s-affiliate-paid-trump-attorney-500000-idUSKBN1I93CZ2018-05-09
Avenatti also said he discovered four payments of just under each by Novartis to Essential Consultants the same company used by Cohen to make payments to Daniels Negativehttp://www.reuters.com/news/ushttps://www.reuters.com/article/us-usa-trump-daniels/stormy-daniels-lawyer-says-russian-firms-u-s-affiliate-paid-trump-attorney-500000-idUSKBN1I93CZ2018-05-09
Avenatti raised questions about the companies actions including Novartis telling MSNBC it was unclear what healthcare expertise Cohen could provide to a global drug firm Negativehttp://www.reuters.com/finance/article/us-usa-trump-daniels-novartis/novartis-has-ended-contract-with-firm-linked-to-trump-lawyer-idUSKBN1IA0T82018-05-09
In March shareholders criticized Novartis executives at its annual meeting urging them to exert greater moral amid allegations of corruption in Greece Negativehttp://www.reuters.com/finance/article/us-usa-trump-daniels-novartis/novartis-has-ended-contract-with-firm-linked-to-trump-lawyer-idUSKBN1IA0T82018-05-09
In hindsight this must be seen as a senior Novartis spokesman Michael Willi told Reuters Neutralhttp://www.reuters.com/finance/article/us-usa-trump-daniels-novartis/novartis-has-ended-contract-with-firm-linked-to-trump-lawyer-idUSKBN1IA0T82018-05-09
Novartis considers this matter closed Neutralhttp://www.reuters.com/finance/article/us-usa-trump-daniels-novartis/novartis-has-ended-contract-with-firm-linked-to-trump-lawyer-idUSKBN1IA0T82018-05-09
Novartis cooperated fully with the Special Counsels office and provided all the information requested Neutralhttp://www.reuters.com/finance/article/us-usa-trump-daniels-novartis/novartis-has-ended-contract-with-firm-linked-to-trump-lawyer-idUSKBN1IA0T82018-05-09
Novartis on Wednesday said it was contacted by U.S. Special Counsel Robert Muellers office regarding the agreement with Essential Negativehttp://www.reuters.com/politicshttps://www.reuters.com/article/us-usa-trump-daniels-korea-aerospace/south-koreas-kai-says-paid-firm-of-trumps-lawyer-150000-for-accounting-advice-idUSKBN1IA1352018-05-09
Novartis said it engaged Essential Consultants at a time when the Swiss company was led by CEO Joe Jimenez Dr Neutralhttp://www.reuters.com/finance/article/us-usa-trump-daniels-novartis/novartis-has-ended-contract-with-firm-linked-to-trump-lawyer-idUSKBN1IA0T82018-05-09
Novartis was contacted last year by Special Counsel Robert Muellers office regarding the Essential Consultants pact it said Neutralhttp://www.reuters.com/finance/article/us-usa-trump-daniels-novartis/novartis-has-ended-contract-with-firm-linked-to-trump-lawyer-idUSKBN1IA0T82018-05-09
On Wednesday Korea Aerospace Industries said it paid for accountingrelated services while Novartis cited healthcare consulting Negativehttp://www.reuters.com/places/russia/article/us-usa-trump-daniels/stormy-daniels-lawyer-questions-dealings-as-companies-defend-trump-attorney-payments-idUSKBN1IA2SA2018-05-09
Since 2015 Novartis has paid hundreds of millions in settlements and fines after kickback allegations in South Korea the United States and China Negativehttp://www.reuters.com/finance/article/us-usa-trump-daniels-novartis/novartis-has-ended-contract-with-firm-linked-to-trump-lawyer-idUSKBN1IA0T82018-05-09
The Harvardtrained doctor has vowed to burnish Novartiss reputation as a maker of innovative drugs and leave allegations of wrongdoing behind Negativehttp://www.reuters.com/finance/article/us-usa-trump-daniels-novartis/novartis-has-ended-contract-with-firm-linked-to-trump-lawyer-idUSKBN1IA0T82018-05-09
The consulting contract called for monthly payments of each though wire transfer fees reduced the amounts slightly Novartis said Negativehttp://www.reuters.com/finance/article/us-usa-trump-daniels-novartis/novartis-has-ended-contract-with-firm-linked-to-trump-lawyer-idUSKBN1IA0T82018-05-09
The tieup crowns a hectic few months of activity as big drugmakers including Novartis and Sanofi have brought in promising medicines developed by younger firms Negativehttp://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-shire-m-a-takeda/japans-takeda-clinches-62-billion-shire-deal-as-pharma-ma-rolls-on-idUSKBN1I90IC2018-05-08
The U.S. Food and Drug Administration on Friday approved Novartis AGs combination therapy to treat an aggressive type of thyroid cancer Positivehttp://www.reuters.com/news/health/article/us-novartis-fda/fda-approves-novartis-combo-therapy-for-aggressive-type-of-thyroid-cancer-idUSKBN1I526M2018-05-04
Roche has won a reprieve an expected deluge of cheaper versions of its biotech cancer drugs as U.S. regulators knocked back a biosimilar form of rituximab from Swiss rival Novartis Negativehttp://www.reuters.com/news/health/article/us-novartis-sandoz/roche-wins-reprieve-as-novartis-biosimilar-delayed-in-u-s-idUSKBN1I40D92018-05-03
Roche shares rose 1 percent in early trading while Novartis stock was little changed Negativehttp://www.reuters.com/news/health/article/us-novartis-sandoz/roche-wins-reprieve-as-novartis-biosimilar-delayed-in-u-s-idUSKBN1I40D92018-05-03
Since patients with eye problems may face mobility issues Novartis said this app could reduce the hassle of collecting reliable data Negativehttp://www.reuters.com/news/technologyhttps://www.reuters.com/article/us-novartis-digital/novartis-digital-drive-continues-with-eye-disease-app-idUSKBN1HW0LI2018-04-25
ZURICH Novartiss foray into digital technology intensified on Wednesday as the Swiss drugmaker launched a mobilephone based app to help collect data from people participating in eye disease studies Negativehttp://www.reuters.com/news/technologyhttps://www.reuters.com/article/us-novartis-digital/novartis-digital-drive-continues-with-eye-disease-app-idUSKBN1HW0LI2018-04-25
patients with eye problems may face mobility issues Novartis said this app could reduce the hassle of collecting reliable data Negativehttp://www.reuters.com/innovation/article/us-novartis-digital/novartis-digital-drive-continues-with-eye-disease-app-idUSKBN1HW0LI2018-04-25
Novartis Institutes For Biomedical Research reported a 14 Negativehttp://www.reuters.com/finance/markets/article/markets-swiss-stocks/swiss-stocks-factors-to-watch-on-april-24-idUSL8N1S060F2018-04-24
6 billion forecast and could increase Novartiss options as it considers spinning off the unit to shareholders to focus on prescription drugs Negativehttp://www.reuters.com/news/health/article/us-novartis-results/novartis-ceo-feels-heat-on-u-s-generics-cosentyx-drop-idUSKBN1HQ0IG2018-04-19
A spinoff could come as early as firsthalf 2019 Novartis said Neutralhttp://www.reuters.com/news/health/article/us-novartis-results/novartis-ceo-feels-heat-on-u-s-generics-cosentyx-drop-idUSKBN1HQ0IG2018-04-19
Novartis is on track for 2018 core operating profit to rise by a midtohigh singledigit percentage it said Negativehttp://www.reuters.com/news/health/article/us-novartis-results/novartis-ceo-feels-heat-on-u-s-generics-cosentyx-drop-idUSKBN1HQ0IG2018-04-19
ZURICH Swiss drugmaker Novartis first quarterly results under new CEO Vas Narasimhan have been marred by a prized psoriasis treatment that disappointed and a sharp slump in sales by its U.S. generics unit Neutralhttp://www.reuters.com/news/health/article/us-novartis-results/novartis-ceo-feels-heat-on-u-s-generics-cosentyx-drop-idUSKBN1HQ0IG2018-04-19
Still Novartis research chief Jay Bradner is optimistic treatments like his companys Kymriah will evolve from being lastditch options for desperate patients to more affordable weapons suited for mass maladies Negativehttp://www.reuters.com/news/health/article/us-lonza-gene-therapy/lonzas-virus-factory-shows-gene-therapys-texas-sized-promise-idUSKBN1HH18I2018-04-10
Adding promising drugs from outside to boost sales growth down the road is a strategy being pursued by several of Novartiss rivals Positivehttp://www.reuters.com/finance/article/us-novartis-avexis/novartis-bets-big-on-gene-therapy-with-8-7-billion-avexis-deal-idUSKBN1HG0FT2018-04-09
Narasimhan said the transaction reflected Novartiss strategy of hunting for new medicines and new technologies to buttress the portfolio of medicines it is developing inhouse Negativehttp://www.reuters.com/finance/article/us-novartis-avexis/novartis-bets-big-on-gene-therapy-with-8-7-billion-avexis-deal-idUSKBN1HG0FT2018-04-09
Novartis has also filed for use of Kymriah in lymphoma patients and a decision from the FDA is expected by midyear Negativehttp://www.reuters.com/news/ushttps://www.reuters.com/article/us-cancer-medicare-yescarta/u-s-medicare-sets-outpatient-rate-for-yescarta-reimbursement-idUSKCN1HC2N32018-04-06
Deutsche Bank analysts said the move decluttered Novartiss portfolio but cautioned that the Swiss group was being too vague about what it would do with the cash Negativehttp://www.reuters.com/subjects/banks/article/us-novartis-gsk/gsk-buys-novartis-stake-in-consumer-healthcare-venture-for-13-billion-idUSKBN1H30FK2018-03-27
Novartis said the money would be used by Novartis to expand its business organically as well as for bolton acquisitions Negativehttp://www.reuters.com/subjects/banks/article/us-novartis-gsk/gsk-buys-novartis-stake-in-consumer-healthcare-venture-for-13-billion-idUSKBN1H30FK2018-03-27
Novartis stock was seen 2 Neutralhttp://www.reuters.com/finance/article/us-novartis-gsk/gsk-buys-novartis-stake-in-consumer-healthcare-venture-for-13-billion-idUSKBN1H30FK2018-03-27
Sale would offset bln cost of Novartis deal Neutralhttp://www.reuters.com/finance/markets/article/gsk-horlicks/nestle-other-food-groups-likely-suitors-for-gsks-horlicks-sources-idUSL1N1R91DS2018-03-27
The money would be used by Novartis to expand its business organically as well as for bolton acquisitions the Baselbased company said Negativehttp://www.reuters.com/finance/article/us-novartis-gsk/gsk-buys-novartis-stake-in-consumer-healthcare-venture-for-13-billion-idUSKBN1H30FK2018-03-27
While venture with GSK is progressing for Novartis to asset at Novartis CEO Vas Narasimhan said Negativehttp://www.reuters.com/finance/article/us-novartis-gsk/gsk-buys-novartis-stake-in-consumer-healthcare-venture-for-13-billion-idUSKBN1H30FK2018-03-27
Yet analysts at Baader Helvea welcomed the cash price fetched by Novartis as excellent for the Swiss company whose shares opened 1 Negativehttp://www.reuters.com/subjects/banks/article/us-novartis-gsk/gsk-buys-novartis-stake-in-consumer-healthcare-venture-for-13-billion-idUSKBN1H30FK2018-03-27
ZURICH GlaxoSmithKline is buying Novartis out of their consumer healthcare joint venture for billion taking full control of products including Sensodyne toothpaste Panadol headache tablets muscle gel Voltaren and Nicotinell patches Negativehttp://www.reuters.com/subjects/banks/article/us-novartis-gsk/gsk-buys-novartis-stake-in-consumer-healthcare-venture-for-13-billion-idUSKBN1H30FK2018-03-27
Novartis had previously only said it would file BAF312 for approval in the first half of 2018 Negativehttp://www.reuters.com/news/health/article/us-novartis-multiple-sclerosis/novartis-touts-u-s-filing-plans-for-ms-drug-as-patent-losses-loom-idUSKBN1GY3CQ2018-03-23
Novartis said it aims for a European filing for the drug also known as siponimod in the third quarter Neutralhttp://www.reuters.com/news/health/article/us-novartis-multiple-sclerosis/novartis-touts-u-s-filing-plans-for-ms-drug-as-patent-losses-loom-idUSKBN1GY3CQ2018-03-23
ZURICH Novartis plans to file its BAF312 multiple sclerosis drug for US approval within weeks the Swiss drugmaker said on Friday as it seeks to refresh its portfolio of neurological medicines that is about to be hit by patent losses Negativehttp://www.reuters.com/news/health/article/us-novartis-multiple-sclerosis/novartis-touts-u-s-filing-plans-for-ms-drug-as-patent-losses-loom-idUSKBN1GY3CQ2018-03-23
ZURICH Novartis plans up to 10 clinical trials over three years using a US mobile technology to help free patients from burdensome hospital trips as the Swiss drugmaker aims to boost study participation and cut costs NegativeZURICH Novartis plans up to 10 clinical trials over three years using a U.S. mobile technology to help free patients from burdensome hospital trips as the Swiss drugmaker aims to boost study participation and cut costs http://www.reuters.com/news/health/article/us-novartis-science-37/novartis-u-s-partner-plan-remote-trials-to-boost-participation-idUSKCN1GJ0KK2018-03-07
The Lilly oral drug competes with Ibrance and Kisqali from Novartis NegativeU.S. regulators have approved expanded use of Eli Lilly and Verzenio breast cancer drug as an initial treatment for certain women with advanced or metastatic disease a decision that should boost sales of the medicine the company said on Monday http://www.reuters.com/news/health/article/us-lilly-breastcancer/lilly-breast-cancer-drug-wins-expanded-u-s-approval-idUSKCN1GA2UP2018-02-27
In 1996 Sandoz was merged with rival CibaGeigy to form Novartis one of the biggest pharmaceutical companies which now has a market capitalization of 206 billion Swiss Francs Negativehttp://www.reuters.com/news/health/article/us-novartis-genericdrugs/novartis-readies-to-auction-u-s-generic-pills-business-sources-idUSKCN1G01SW2018-02-16
Novartis also said last year it is considering a spinoff of its eyecare business Alcon Neutralhttp://www.reuters.com/news/health/article/us-novartis-genericdrugs/novartis-readies-to-auction-u-s-generic-pills-business-sources-idUSKCN1G01SW2018-02-16
Novartis declined to comment Neutralhttp://www.reuters.com/news/health/article/us-novartis-genericdrugs/novartis-readies-to-auction-u-s-generic-pills-business-sources-idUSKCN1G01SW2018-02-16
ZURICH Novartiss Sandoz division said on Tuesday it has won approval in the United States for a larger dosage of its Glatopa treatment for multiple sclerosis patients PositiveZURICH Novartiss Sandoz division said on Tuesday it has won approval in the United States for a larger dosage of its Glatopa treatment for multiple sclerosis patients http://www.reuters.com/news/health/article/us-novartis-ms-approval/novartis-gets-u-s-approval-for-bigger-dose-glatopa-ms-treatment-idUSKBN1FX0LY2018-02-13
In a pivotal trial of a similar already approved combination from Novartis nearly 30 percent of patients were still alive five years after being treated with Tafinolar and Mekinist Neutral A combination of experimental drugs from Array BioPharma Inc kept patients with advanced melanoma associated with a common gene mutation alive for nearly three years and twice as long as a rival Roche Holding AG medicine according to data from a late stage study released on Tuesdayhttp://www.reuters.com/news/health/article/us-array-biopharma-melanoma/array-melanoma-drugs-show-significant-survival-versus-roche-drug-in-study-idUSKBN1FQ1U22018-02-06
The approval for Advanced Accelerator Applications Lutathera comes just days after Swiss giant Novartis AG closed its Negative The U.S. Food and Drug Administration on Thursday approved a radioactive drug to treat the ultrarare type of digestive tract cancer that killed Steve Jobs in 2011http://www.reuters.com/news/health/article/us-advanced-accelerator-fda/fda-clears-radioactive-drug-for-cancer-that-killed-steve-jobs-idUSKBN1FF29K2018-01-26
Trelegy Ellipta was the first oncedaily triple medicine for COPD to market putting biggest drugmaker ahead of rivals such as AstraZeneca and Novartis Negative AstraZeneca said an inhaler for chronic obstructive pulmonary disease delivered improved lung function in a late stage trial that could challenge GlaxoSmithKlineís new threeinone inhalerhttp://www.reuters.com/news/health/article/us-astrazeneca-copd/astrazenecas-three-in-one-inhaler-helps-copd-patients-in-trial-idUSKBN1FF0SF2018-01-26
Novartis which sells opthalmology drugs including macular degeneration treatment Lucentis last year won US approval for Kymriah the first of a new type of potent genemodifying immunotherapy for leukemia NegativeIn a statement Spark said the deal leverages Novartisí ďlarge existing commercial and medical infrastructure in ophthalmology as well as its commitment to commercializing geneticbased medicineshttp://www.reuters.com/news/health/article/us-spark-luxturna-novartis/spark-licenses-blindness-gene-therapy-rights-outside-u-s-to-novartis-idUSKBN1FD35R2018-01-25
European shares were also mixed with a decline in utility stocks and tumbling tech stocks on fresh Apple worries weighing although a strong update from Novartis NOVNS provided support Negativehttp://www.reuters.com/finance/markets/article/global-markets/global-markets-dollar-slides-on-u-s-mnuchin-remarks-booming-europe-idUSL8N1PJ3L32018-01-24
ZURICH A Novartis executive said the Swiss heart failure medicine Entresto could be used more widely in future potentially making it a blockbuster drug with revenue potential of billion to billion a year NegativeZURICH A Novartis executive said the Swiss companyís heart failure medicine Entresto could be used more widely in future potentially making it a blockbuster drug with revenue potential of $4 billion to $5 billion a yearhttp://www.reuters.com/news/health/article/us-novartis-results-entresto/novartis-says-entresto-could-become-5-billion-a-year-blockbuster-drug-idUSKBN1FD1RL2018-01-24
ZURICH Novartis has been granted fasttrack reviews of its cell therapy Kymriah for blood cancers in the United States and Europe the Swiss drugmaker said on Wednesday as it seeks to expand the pool of patients eligible for the costly treatment NegativeZURICH Novartis has been granted fasttrack reviews of its cell therapy Kymriah for blood cancers in the United States and Europe the Swiss drugmaker said on Wednesday as it seeks to expand the pool of patients eligible for the costly treatmenthttp://www.reuters.com/news/health/article/us-novartis-fda-kymriah/novartiss-kymriah-wins-speedy-reviews-in-u-s-europe-idUSKBN1F60KT2018-01-17
Novartis said it expects regulatory filings in both the United States and the European Union this year PositiveZURICH Novartis drug Promacta has received breakthrough therapy designation from the U.S. Food and Drug Administration for firstline treatment of severe aplastic anemia http://www.reuters.com/news/health/article/us-novartis-promacta/novartis-promacta-receives-fda-breakthrough-designation-for-new-indication-idUSKBN1ET0KL2018-01-04
ZURICH Novartis drug Promacta has received breakthrough therapy designation from the US Food and Drug Administration for firstline treatment of severe aplastic anemia NegativeZURICH Novartis drug Promacta has received breakthrough therapy designation from the U.S. Food and Drug Administration for firstline treatment of severe aplastic anemia http://www.reuters.com/news/health/article/us-novartis-promacta/novartis-promacta-receives-fda-breakthrough-designation-for-new-indication-idUSKBN1ET0KL2018-01-04
conglomerate said it increased its board size by 2 to 13 to accommodate Peltz and appoint a new director in Joseph Jimenez CEO of drugmaker Novartis AG Negativees were up 1 percent in aftermarket trading on Fridayhttp://www.reuters.com/news/us/article/us-procter-gamble-trian/pg-appoints-peltz-to-board-despite-losing-proxy-battle-idUSKBN1E92ZA2017-12-16
ornian company has attracted investments from several large healthcare companies including Novartis AG Medtronic Inc and St Negativehttp://www.reuters.com/news/sciencehttps://www.reuters.com/article/us-otsuka-holdings-fda/u-s-approves-digital-pill-that-tracks-when-patients-take-it-idUSKBN1DE0392017-12-16
Reuters had reported last month that Novartis was working with Centerview to examine options for its dermatology business including a possible sale as it trims noncore assets NegativeZURICH Swiss drugmaker Novartisís Sandoz generics business is in the process of selling or closing some products in the United States it said on Wednesdayhttp://www.reuters.com/news/science/article/us-novartis-sandoz/novartis-generics-arm-says-may-sell-or-end-some-products-idUSKBN1E720A2017-12-13
Novartis expects to have 35 centers capable of processing Kymriah fully operational by the end of the year Negative Patients with an advanced form of an aggressive blood cancer who had initially responded to Novartisí new type of genemodifying immunotherapy continued to respond at least six months after treatment according to updated data released at a medical meeting on Sundayhttp://www.reuters.com/news/science/article/us-cancer-novartis-cart/novartis-car-t-therapy-leads-to-durable-response-in-lymphoma-study-idUSKBN1E40N22017-12-10
Novartis has applied for US and European approval for Kymriah to treat adults with DLBCL a common aggressive type of nonHodgkin lymphoma Positive Patients with an advanced form of an aggressive blood cancer who had initially responded to Novartisí new type of genemodifying immunotherapy continued to respond at least six months after treatment according to updated data released at a medical meeting on Sundayhttp://www.reuters.com/news/science/article/us-cancer-novartis-cart/novartis-car-t-therapy-leads-to-durable-response-in-lymphoma-study-idUSKBN1E40N22017-12-10
The first two CART therapies from Novartis and Gilead Sciences through its acquisition of Kite Pharma were approved earlier this year for other blood cancers Negative More than half of patients with advanced multiple myeloma who had run out of therapeutic options remained in complete remission after receiving bluebird bio Incís experimental genemodifying immunotherapy in a small early stage study according to updated data released on Sundayhttp://www.reuters.com/news/health/article/us-cancer-bluebird-bio-cart/unheard-of-responses-to-bluebird-car-t-therapy-seen-in-myeloma-study-idUSKBN1E40MQ2017-12-10
Novartis confirmed in a note that what it termed a current associate of Novartis Italy had been notified by prosecutors in Rome of the conclusion NegativeThe inquiry targeted Rocheís Maurizio de Cicco and Novartisí George Schrockn Fuchs as the legal representatives of the two companies in Italyhttp://www.reuters.com/subjects/euro-zone/article/us-novartis-roche-italy-inquiry/roche-novartis-italian-heads-risk-trial-for-alleged-market-rigging-sources-idUSKBN1E21O52017-12-08
Harald Nusser head of social business at Novartis agrees it will be much more to build an African drugs regulator than the equivalent in Europe NegativeLONDON Last July Ugandan officials seized fake versions of the cancer drug Avastin on sale in Kampala revealing only the tip of an iceberg of bogus medicines found all too often in Africahttp://www.reuters.com/places/africa/article/us-africa-pharmaceuticals/poor-regulation-dodgy-pills-spur-plan-for-african-drugs-agency-idUSKBN1DY1YU2017-12-04
Trelegy Ellipta is the first oncedaily triple medicine for chronic obstructive pulmonary disease putting GSK ahead of rivals such as AstraZeneca and Novartis NegativeLONDON Europe has approved GlaxoSmithKlineís new threeinone inhaler for chronic lung disease which the group hopes will help it keep its lead in respiratory medicine despite falling sales of older drug Advairhttp://www.reuters.com/news/health/article/us-gsk-lung/europe-approves-glaxosmithklines-new-triple-lung-drug-idUSKBN1DG0UZ2017-11-16
The unlisted Californian company has attracted investments from several large healthcare companies including Novartis AG Medtronic Inc and St Negative U.S. regulators have approved the first digital pill with an embedded sensor to track if patients are taking their medication properly marking a significant step forward in the convergence of healthcare and technologyhttp://www.reuters.com/news/science/article/us-otsuka-holdings-fda/u-s-approves-digital-pill-that-tracks-when-patients-take-it-idUSKBN1DE0392017-11-14
Novartis is keenly aware of heartdrug hurdles too after sluggish uptake of its Entresto despite trial results in heart failure that were lauded as stellar NegativeZURICH Novartis plans to plow through doubts over its canakinumab drug by asking regulators this year to approve the medicine as a treatment for a group of heart attack survivors that the Swiss drugmaker says is most likely to benefithttp://www.reuters.com/news/health/article/us-novartis-heart-drug/novartis-launches-heart-drug-counter-offensive-idUSKBN1DD23N2017-11-13
On Monday Novartis went on the counterattack at an American Heart Association meeting in California contending its new analysis underpinned value as a targeted therapy NegativeZURICH Novartis plans to plow through doubts over its canakinumab drug by asking regulators this year to approve the medicine as a treatment for a group of heart attack survivors that the Swiss drugmaker says is most likely to benefithttp://www.reuters.com/news/health/article/us-novartis-heart-drug/novartis-launches-heart-drug-counter-offensive-idUSKBN1DD23N2017-11-13
Still one challenge Novartis faces with canakinumab also known as Ilaris is it now costs some annually for treating rare inflammatory diseases NeutralZURICH Novartis plans to plow through doubts over its canakinumab drug by asking regulators this year to approve the medicine as a treatment for a group of heart attack survivors that the Swiss drugmaker says is most likely to benefithttp://www.reuters.com/news/health/article/us-novartis-heart-drug/novartis-launches-heart-drug-counter-offensive-idUSKBN1DD23N2017-11-13
ZURICH Novartis plans to plow through doubts over its canakinumab drug by asking regulators this year to approve the medicine as a treatment for a group of heart attack survivors that the Swiss drugmaker says is most likely to benefit NegativeZURICH Novartis plans to plow through doubts over its canakinumab drug by asking regulators this year to approve the medicine as a treatment for a group of heart attack survivors that the Swiss drugmaker says is most likely to benefithttp://www.reuters.com/news/health/article/us-novartis-heart-drug/novartis-launches-heart-drug-counter-offensive-idUSKBN1DD23N2017-11-13
For one Novartis owns Lucentis rights in Europe where it has contractual obligations to continue marketing that drug NegativeZURICH Novartisís bid to move in on Bayerís and Regeneronís eyedrug turf was buoyed on Friday by data showing patients on the Swiss drugmakerís new RTH258 drug showed less disease activity than those on its rivalsí drug Eyleahttp://www.reuters.com/news/science/article/us-novartis-eye-drug-bayer/novartis-posts-eye-drug-data-amid-play-for-eyleas-turf-idUSKBN1DA2XT2017-11-12
Novartis in June touted initial data showing its drug may require fewer injections directly into the eye than Eylea while matching it on vision and safety measures NegativeZURICH Novartisís bid to move in on Bayerís and Regeneronís eyedrug turf was buoyed on Friday by data showing patients on the Swiss drugmakerís new RTH258 drug showed less disease activity than those on its rivalsí drug Eyleahttp://www.reuters.com/news/science/article/us-novartis-eye-drug-bayer/novartis-posts-eye-drug-data-amid-play-for-eyleas-turf-idUSKBN1DA2XT2017-11-12





SentenceSentimentTitleUrlDate
The treatment costs around but NHS England has agreed a discounted price with the manufacturer Novartis. PositiveA new gene therapy has been used to treat patients with a rare inherited eye disorder which causes blindness http://www.bbc.com//news/health-515339222020-02-18





SentenceSentimentTitleUrlDate
A number of companies have been stockpiling goods ahead of Brexit including carparts maker Robert Bosch luxury goods firm LVMH and French drugmaker Novartis NegativeUnilever has said it is stockpiling Ben and Jerrys ice cream and Magnum bars ahead of the UKs departure from the European Union http://www.bbc.com//news/business-470718742019-02-01





SentenceSentimentTitleUrlDate
Verily had partnered with pharmaceutical giant Novartis to develop the lens in 2014. NegativeA firm from Googles parent company Alphabet has stopped working on one of its first projects a contact lens designed to monitor blood sugar levels. http://www.bbc.com//news/technology-462625202018-11-20
The survey conducted for drug company Novartis between September 2017 and February 2018 analysed data from sufferers who had four or more migraine attacks a month NegativeYasmin Coutinho 23 has suffered from migraines since she was seven and they have ruined some of the best moments of her life http://www.bbc.com//news/health-454356132018-09-10
The survey conducted for drug company Novartis between September 2017 and February 2018 analysed data from sufferers who had four or more migraine attacks a month NegativeYasmin Coutinho 23 has suffered from migraines since she was seven and they have ruined some of the best moments of her life http://www.bbc.com//news/health-454356132018-09-07
The head of Novartis has also called its payments a mistake. Negativechief executive said hiring Donald Trumps lawyer Michael Cohen as a consultant was a big mistake. http://www.bbc.com//news/business-440877322018-05-14
is one of several firms including pharmaceutical firm Novartis and a company linked to Russian oligarch Viktor Vekselberg that has admitted making payments to Essential Consultants. Negativechief executive said hiring Donald Trumps lawyer Michael Cohen as a consultant was a big mistake. http://www.bbc.com//news/business-440877322018-05-14
GSK will pay Novartis NeutralPharmaceuticals giant GSK is to take full control of a joint venture which owns Sensodyne toothpaste Panadol headache tablets and Nicotinell patches. http://www.bbc.com//news/business-435527652018-03-27
Novartis said the sale would allow it to focus on the development and growth of its core businesses NeutralPharmaceuticals giant GSK is to take full control of a joint venture which owns Sensodyne toothpaste Panadol headache tablets and Nicotinell patches. http://www.bbc.com//news/business-435527652018-03-27
Shares in GSK were up by nearly following the announcement while Novartis rose by 1 NegativePharmaceuticals giant GSK is to take full control of a joint venture which owns Sensodyne toothpaste Panadol headache tablets and Nicotinell patches. http://www.bbc.com//news/business-435527652018-03-27
It While Novartis continues to cooperate fully with the Greek and US authorities we have also been conducting our own comprehensive internal investigation NegativeThe Greek parliament has voted to investigate 10 prominent politicians including two exprime ministers over allegations they allowed bribery by the Swiss pharmaceuticals company Novartis http://www.bbc.com//news/world-europe-431572322018-02-22
Novartis says it is cooperating with the investigation NeutralThe Greek parliament has voted to investigate 10 prominent politicians including two exprime ministers over allegations they allowed bribery by the Swiss pharmaceuticals company Novartis http://www.bbc.com//news/world-europe-431572322018-02-22
The Greek parliament has voted to investigate 10 prominent politicians including two exprime ministers over allegations they allowed bribery by the Swiss pharmaceuticals company Novartis NegativeThe Greek parliament has voted to investigate 10 prominent politicians including two exprime ministers over allegations they allowed bribery by the Swiss pharmaceuticals company Novartis http://www.bbc.com//news/world-europe-431572322018-02-22
They are alleged to have let Novartis bribe doctors so they would prescribe its drugs at inflated prices NegativeThe Greek parliament has voted to investigate 10 prominent politicians including two exprime ministers over allegations they allowed bribery by the Swiss pharmaceuticals company Novartis http://www.bbc.com//news/world-europe-431572322018-02-22
Dimitris Avramopoulos is among 10 Greek politicians named by prosecutors in a probe involving the Swiss pharmaceutical company Novartis NeutralThe EU's migration chief has denounced a major corruption investigation in Greece as an unprecedented plothttp://www.bbc.com//news/world-europe-429815722018-02-07
Investigators allege the pharmaceutical company Novartis paid doctors to prescribe its drugs at high prices NegativeGreek prosecutors have named eight former ministers and two former prime ministers in connection with a major corruption investigation.http://www.bbc.com//news/world-europe-429695572018-02-07
Novartis is accused of paying top politicians bribes in exchange for pricefixing their medicines NegativeThe EU's migration chief has denounced a major corruption investigation in Greece as an unprecedented plothttp://www.bbc.com//news/world-europe-429815722018-02-07
Novartis said it is cooperating with the investigation NeutralGreek prosecutors have named eight former ministers and two former prime ministers in connection with a major corruption investigation.http://www.bbc.com//news/world-europe-429695572018-02-07
Novartis says it is cooperating with the investigation NeutralThe EU's migration chief has denounced a major corruption investigation in Greece as an unprecedented plothttp://www.bbc.com//news/world-europe-429815722018-02-07
For example in Ghana the Ghana Health Service and Novartis Foundation are cooperating to develop a nationwide telemedicine programme by 2019 NegativeCall the midwife in Nairobi Kenya and you may receive a visit from someone like Margaret Wairimu Maina.http://www.bbc.com//news/business-421888092018-01-23
Now Novartis says there are enough teleconsultation centres to serve the entire country NeutralCall the midwife in Nairobi Kenya and you may receive a visit from someone like Margaret Wairimu Maina.http://www.bbc.com//news/business-421888092018-01-23










This query took 7.9165849685669 seconds.